Plant disease control method

Abstract

The present invention provides a control method effective against plant diseases. The compound represented by formula (I) [wherein n represents 1 or 2, R1 represents a C3–C10 alicyclic hydrocarbon group or the like, Q represents a group or the indicated by Q1, Z represents a C2–C6 chain hydrocarbon group or the like, the group indicated by Q1 represents a group indicated by the formula below (# represents the bond site with R1 and ● represents the bond site with the sulfur atom), and R2 and R3 are the same or different and represent a hydrogen atom or a fluorine atom], or an N-oxide thereof or a salt thereof, can be used for controlling plant diseases.

Description

Plant disease control method

[0001] This application claims priority to and the benefit of Japanese Patent Application No. 2023-164815, filed on September 27, 2023, the entire contents of which are incorporated herein by reference. The present invention relates to a method for controlling plant diseases.

[0002] Patent Document 1 describes an aryl sulfide compound.

[0003] Chinese Patent Application Publication No. 112724092

[0004] An object of the present invention is to provide an excellent method for controlling plant diseases.

[0005] The present inventors have conducted studies to find an excellent method for controlling plant diseases and have found that a compound represented by the following formula (I) has excellent control activity against plant diseases.

[0006] [1] Formula (I) [wherein n represents 1 or 2; R 1represents a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group are optionally substituted with one or more substituents selected from Group A, and any atom constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocyclic ring}, a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B1 (provided that when Q is a group represented by Q6, , 1H-pyrazol-3-yl group) {among the atoms constituting the 5-7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded), any two adjacent atoms not bonded to Q may form another benzene ring, C4-C7 alicyclic hydrocarbon, 4-7-membered non-aromatic heterocycle, or 5-7-membered aromatic heterocycle containing the two adjacent atoms {the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4-7-membered non-aromatic heterocycle, and the 5-7-membered aromatic heterocycle may be substituted with one or more halogen atoms}}, or —C≡CR 13 Q represents a group represented by Q1, a group represented by Q2, a group represented by Q3, a group represented by Q4, a group represented by Q5, or a group represented by Q6, Z represents a C2-C6 chain hydrocarbon group, a methyl group substituted with one or more fluorine atoms, a C1-C2 alkyl group (the C1-C2 alkyl group is substituted with a methoxy group or an ethoxy group), a C3-C8 alicyclic hydrocarbon group, a 3- to 8-membered non-aromatic heterocyclic group (the C3-C8 alicyclic hydrocarbon group and the 3- to 8-membered non-aromatic heterocyclic group are optionally substituted with one or more substituents selected from Group C), a 5- to 10-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D, or NR 14 R 15 The group represented by Q1, the group represented by Q2, the group represented by Q3, the group represented by Q4, the group represented by Q5, and the group represented by Q6 are groups represented by the following formula (# represents R 1 represents the bonding site with the aryl group, and ● represents the bonding site with the sulfur atom), R 2 , R 3 , R 4, R 5 , R 6 , and R 7 are the same or different and represent a hydrogen atom or a fluorine atom; X 1 is CR 12 or a nitrogen atom, X 2 is CR 16 or a nitrogen atom, X 3 is CR 17 or a nitrogen atom, X 4 is CR 18 or a nitrogen atom (provided that X 1 is CR 12 and X 2 is CR 16 and X 3 is CR 17 and X 4 is CR 18 (Except when 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 are the same or different and represent a methyl group optionally substituted with one or more fluorine atoms, a halogen atom, or a hydrogen atom; R 13 represents a C1-C6 chain hydrocarbon group, a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group (the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group E), a phenyl group, or a 5- to 7-membered aromatic heterocyclic group (the phenyl group and the 5- to 7-membered aromatic heterocyclic group may be substituted with one or more substituents selected from Group D), 14 and R 15are the same or different and represent a C1-C6 alkyl group, a methyl group substituted with one or more fluorine atoms, or a C1-C2 alkyl group (the C1-C2 alkyl group is substituted with a methoxy group or an ethoxy group). Group A: a group consisting of a C1-C6 chain hydrocarbon group, a C1-C6 alkoxy group (the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group may be substituted with one or more substituents selected from Group E), a hydroxy group, a halogen atom, and a cyano group. Group B1: the group consisting of a C3-C10 alicyclic hydrocarbon group optionally substituted with one or more substituents selected from Group D, a methyl group optionally substituted with one or more substituents selected from Group F, a C2-C6 open chain hydrocarbon group optionally substituted with one or more substituents selected from Group E, a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group (the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group and the C1-C6 alkylsulfonyl group are optionally substituted with one or more halogen atoms), a hydroxy group, a halogen atom, and a cyano group. Group C: a group consisting of C1-C6 chain hydrocarbon groups, C1-C6 alkoxy groups (the C1-C6 chain hydrocarbon groups and the C1-C6 alkoxy groups may be substituted with one or more substituents selected from Group E), oxo groups, thioxo groups, hydroxy groups, halogen atoms, and cyano groups. Group D: a group consisting of C1-C6 chain hydrocarbon groups, C1-C6 alkoxy groups (the C1-C6 chain hydrocarbon groups and the C1-C6 alkoxy groups may be substituted with one or more substituents selected from Group E), halogen atoms, and cyano groups. Group E: a group consisting of C1-C3 alkoxy groups, halogen atoms, and cyano groups. Group F: a group consisting of a methoxy group, a chlorine atom, and a cyano group. [2] A method for controlling plant diseases, which comprises treating a plant or soil in which a plant is grown with a compound represented by the formula (hereinafter referred to as the present compound Z) or an N-oxide thereof, or a salt thereof (hereinafter the present compound Z, the N-oxide thereof, or a salt thereof will be referred to as the present compound W). 1is a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group (the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group A, and any atom constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocyclic ring), or one or more substituents selected from group B an optionally substituted 5- to 7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) {among the atoms constituting the 5- to 7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded), any two adjacent atoms not bonded to Q may form another C4-C7 alicyclic hydrocarbon, 4- to 7-membered non-aromatic heterocycle, or 5- to 7-membered aromatic heterocycle containing the two adjacent atoms}, or -C≡CR 13 (hereinafter referred to as Compound N), or an N-oxide thereof, or a salt thereof (hereinafter Compound N, its N-oxide, or a salt thereof will be referred to as Compound N), which is: Group B: a group consisting of a methyl group optionally substituted with one or more substituents selected from Group F, a C2-C6 chain hydrocarbon group optionally substituted with one or more substituents selected from Group E, a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group (the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, and the C1-C6 alkylsulfonyl group are optionally substituted with one or more halogen atoms), a hydroxy group, a halogen atom, and a cyano group. [3] In the compound W of [1], Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and R 1a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) are each independently selected from group A, and among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3-10 membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-10 membered non-aromatic heterocyclic group is bonded to the group represented by Q2), any atom not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3-7 membered non-aromatic heterocycle); and a 5- to 7-membered aromatic heterocyclic group optionally bonded to the group represented by Q2 (provided that when Q is a group represented by Q6, excluding a 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2) {the 5- to 7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, excluding a 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2); any two adjacent atoms not bonded to Q among the atoms constituting the group bonded to the group shown in the formula (A), may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the two adjacent atoms {the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4- to 7-membered non-aromatic heterocycle, and the 5- to 7-membered aromatic heterocycle may be substituted with one or more halogen atoms}, or -C≡CR 13 Z represents a C2-C6 chain hydrocarbon group, a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from group D, or NR 14 R 15 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R11 , and R 12 is a hydrogen atom, and X 2 and X 4 is CH, and X 3 is a nitrogen atom, and R 13 is a C1-C6 chain hydrocarbon group or a phenyl group, and R 14 and R 15 are the same or different and are a C1-C6 alkyl group, or an N-oxide thereof, or a salt thereof. [wherein na represents 1 or 2; X 1a represents CH or a nitrogen atom, R 1a represents a C3-C10 alicyclic hydrocarbon group, a 3- to 7-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 7-membered non-aromatic heterocyclic group are selected from Group A a and any atom constituting the C3-C10 alicyclic hydrocarbon group and the 3-7-membered non-aromatic heterocyclic group which is not bonded to pyridine or pyrazine may form a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocyclic ring as a spiro atom}, or a 5-7-membered aromatic heterocyclic group {the 5-7-membered aromatic heterocyclic group is a group selected from group B1 a among the atoms constituting the 5-7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another benzene ring, C4-C7 alicyclic hydrocarbon, 4-7-membered non-aromatic heterocycle, or 5-7-membered aromatic heterocycle containing the adjacent two atoms {the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4-7-membered non-aromatic heterocycle, and the 5-7-membered aromatic heterocycle may be substituted with one or more halogen atoms}; Z a represents a C2-C6 chain hydrocarbon group, group C a a C3-C8 alicyclic hydrocarbon group optionally substituted by one or more substituents selected from the group consisting of a 5- to 10-membered aromatic heterocyclic group (the 5- to 10-membered aromatic heterocyclic group is selected from the group consisting of a 5- to 10-membered aromatic heterocyclic group ... a and the group A may be substituted with one or more substituents selected from the following. aC1-C6 chain hydrocarbon group, C1-C6 alkoxy group {the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group are selected from the group E a Group B1: a group consisting of a hydroxy group, a halogen atom, and a cyano group, each of which may be substituted with one or more substituents selected from the group consisting of a :Group D a a C3-C10 alicyclic hydrocarbon group optionally substituted with one or more substituents selected from group F a a methyl group optionally substituted with one or more substituents selected from Group E a Group C consists of a C2-C6 chain hydrocarbon group optionally substituted by one or more substituents selected from the above, a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group (the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, and the C1-C6 alkylsulfonyl group are optionally substituted by one or more halogen atoms), a hydroxy group, a halogen atom, and a cyano group. a C1-C6 chain hydrocarbon group, C1-C6 alkoxy group {the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group are selected from the group E a Group D: a group consisting of an oxo group, a thioxo group, a hydroxy group, a halogen atom, and a cyano group, each of which may be substituted with one or more substituents selected from the group consisting of: a C1-C6 chain hydrocarbon group, C1-C6 alkoxy group {the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group are selected from the group E a The group consisting of a halogen atom and a cyano group, each of which may be substituted with one or more substituents selected from the group consisting of: a Group F: a group consisting of a C1-C3 alkoxy group, a halogen atom, and a cyano group. a : a group consisting of a methoxy group, a chlorine atom, and a cyano group.] (hereinafter referred to as compound Z of the present invention) or an N-oxide thereof or a salt thereof (hereinafter, compound Z of the present invention or an N-oxide thereof or a salt thereof will be referred to as compound W of the present invention). [5] R 1a is a 3- to 7-membered non-aromatic heterocyclic group {the 3- to 7-membered non-aromatic heterocyclic group is selected from the group A aand any atom constituting the 3-7-membered non-aromatic heterocyclic group that is not bonded to pyridine or pyrazine may form a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocycle as a spiro atom}, or a 5-7-membered aromatic heterocyclic group {the 5-7-membered aromatic heterocyclic group is selected from the group B a and among the atoms constituting the 5-7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another C4-C7 alicyclic hydrocarbon, a 4-7-membered non-aromatic heterocycle, or a 5-7-membered aromatic heterocycle containing the adjacent two atoms (hereinafter referred to as Compound N of the present invention), or an N-oxide or a salt thereof (hereinafter Compound N of the present invention or its N-oxide or a salt thereof will be referred to as Compound of the present invention): Group B a :Group F a a methyl group optionally substituted with one or more substituents selected from Group E a The group consisting of a C2-C6 chain hydrocarbon group optionally substituted by one or more substituents selected from the group consisting of a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group (the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, and the C1-C6 alkylsulfonyl group are optionally substituted by one or more halogen atoms), a hydroxy group, a halogen atom, and a cyano group. [6] R 1a a C3-C10 alicyclic hydrocarbon group optionally substituted with one or more C1-C6 chain hydrocarbon groups, a 3- to 7-membered non-aromatic heterocyclic group {the 3- to 7-membered non-aromatic heterocyclic group is selected from the group A a 2, and any atom constituting the 3-7-membered non-aromatic heterocyclic group that is not bonded to pyridine or pyrazine may form a C3-C7 alicyclic hydrocarbon as a spiro atom}, or a 5-7-membered aromatic heterocyclic group {the 5-7-membered aromatic heterocyclic group is selected from group B2 aand among the atoms constituting the 5- to 7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another benzene ring or a C4-C7 alicyclic hydrocarbon containing the adjacent two atoms; Z a is a C2-C6 chain hydrocarbon group or a 5- to 10-membered aromatic heterocyclic group {the 5- to 10-membered aromatic heterocyclic group is selected from the group D a The compound according to [4], an N-oxide thereof, or a salt thereof, is optionally substituted with one or more substituents selected from the following: a Group B2: A group consisting of C1-C3 alkyl groups and halogen atoms. a

[0023]

[0024]

[0025]

[0026]

[0027]

[0028]

[0029]

[0030]

[0031]

[0032]

[0033]

[0034]

[0035]

[0036]

[0037]

[0038]

[0039]

[0040]

[0041]

[0038]

[0042]

[0039]

[0043]

[0044]

[0045]

[0050]

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

[0057]

[0058]

[0060]

[0061]

[0062]

[0063]

[0064]

[0065]

[0066]

[0067]

[0070]

[0071]

[0072]

[0073]

[0074]

[0075]

[0080]

[0081]

[0082]

[0083]

[0084]

[0085]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[1009]

[110]

[1209]

[1309]

[1409]

[1509]

[1609]

[1709]

[1809]

[1909]

[2109]

[2209]

[2309]

[2409]

[2509]

[2609]

[2709]

[2809]

[2909]

[3109]

[3209] [3

[10] Use of the compound according to any one of [4] to [6], its N-oxide, or a salt thereof, or the composition according to [8] for controlling plant diseases.

[11] A seed or a vegetative reproductive organ bearing an effective amount of the compound according to any one of [4] to [6], its N-oxide, or a salt thereof, or an effective amount of the composition according to [8].

[0007] According to the present invention, plant diseases can be controlled.

[0008] Substituents in the present invention will be explained. A halogen atom means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. When a substituent is substituted with two or more halogen atoms or substituents, these halogen atoms or substituents may be the same or different. In the present specification, the term "optionally substituted with one or more substituents selected from group X" (X is A, B, B1, C, D, E, F, A2, A a , B a , B1 a , B2 a , C a , D a , E a , F a , and A aIn the notation "CX-CY," when two or more substituents selected from group X are present, the substituents may be the same or different. In this specification, the notation "CX-CY" means that the number of carbon atoms is X to Y. For example, the notation "C1-C6" means that the number of carbon atoms is 1 to 6. The chain hydrocarbon group represents an alkyl group, an alkenyl group, or an alkynyl group. Examples of the alkyl group include a methyl group, an ethyl group, a propyl group, an isopropyl group, a 1,1-dimethylpropyl group, a 1,2-dimethylpropyl group, a butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, and a hexyl group. Examples of the alkenyl group include a vinyl group, a 1-propenyl group, a 2-propenyl group, a 1-methyl-1-propenyl group, a 1-methyl-2-propenyl group, a 1,2-dimethyl-1-propenyl group, a 3-butenyl group, a 4-pentenyl group, and a 5-hexenyl group. Examples of alkynyl groups include ethynyl, 1-propynyl, 2-propynyl, 1-methyl-2-propynyl, 1,1-dimethyl-2-propynyl, 2-butynyl, 4-pentynyl, and 5-hexynyl groups. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy groups. Examples of alkylsulfanyl groups include methylsulfanyl, ethylsulfanyl, isopropylsulfanyl, and hexylsulfanyl groups. Examples of alkylsulfinyl groups include methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, and hexylsulfinyl groups. Examples of alkylsulfonyl groups include methanesulfonyl, ethanesulfonyl, isopropanesulfonyl, and hexanesulfonyl groups. Examples of the alicyclic hydrocarbon include a cyclobutene ring, a cyclopentene ring, a cyclopentadiene ring, a cyclohexene ring, a cyclohexadiene ring, and a cycloheptene ring. Examples of the alicyclic hydrocarbon group include a cycloalkyl group or a cycloalkenyl group.Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups. Examples of cycloalkenyl groups include cyclopentenyl and cyclohexenyl groups. Examples of non-aromatic heterocycles include dihydrofuran, dihydrothiophene, dihydropyrrole, 1,3-dioxole, pyran, and dihydropyran rings. Examples of aromatic heterocycles include furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine rings. Examples of aromatic heterocyclic groups include 5-membered aromatic heterocyclic groups such as pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl; and 6-membered aromatic heterocyclic groups such as pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and tetrazinyl. Examples of non-aromatic heterocyclic groups include aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, oxazolinyl, thiazolinyl, oxazolidinyl, thiazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, dioxolanyl, dioxanyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, azepanyl, oxepanyl, and thiepanyl groups.

[0009] The compound W or the compound W of the present invention may exist as one or more stereoisomers. Stereoisomers include enantiomers, diastereomers, atropisomers, and geometric isomers. The present invention includes each stereoisomer and a mixture of stereoisomers in any ratio.

[0010] The N-oxide of the compound represented by formula (I) or formula (II) means a structure in which at least one nitrogen atom contained in the compound represented by formula (I) or formula (II) is substituted with an oxo group.

[0011] The compound represented by formula (I) or formula (II) or an N-oxide thereof may form an acid addition salt such as a hydrochloride, a sulfate, a nitrate, a phosphate, an acetate, or a benzoate when mixed with an acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, or benzoic acid.

[0012] The following compounds are examples of the present compound Z.

[0013] [Aspect Z1] The compound Z, in which Q is a group represented by Q1. [Aspect Z2] The compound Z, in which Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect Z3] A compound of the present compound Z, in which Q is a group represented by Q2. [Aspect Z4] A compound of the present compound Z, in which Q is a group represented by Q2, and R 4 and R 5 is a hydrogen atom. [Aspect Z5] A compound of the present compound Z, in which Q is a group represented by Q3. [Aspect Z6] A compound of the present compound Z, in which Q is a group represented by Q3, and R 6 is a hydrogen atom. [Aspect Z7] A compound of the present compound Z, in which Q is a group represented by Q4. [Aspect Z8] A compound of the present compound Z, in which Q is a group represented by Q4, and R 7 is a hydrogen atom. [Aspect Z9] A compound of the present compound Z, in which Q is a group represented by Q5. [Aspect Z10] A compound of the present compound Z, in which Q is a group represented by Q5, and X 2 is CH and X 4 [Aspect Z11] In the compound Z, Q is a group represented by Q5, and X 1is CH and X 2 is CH and X 3 is a nitrogen atom, and X 4 [Aspect Z12] In the compound Z, Q is a group represented by Q5, and X 1 is a nitrogen atom, and X 2 is CH and X 3 is a nitrogen atom, and X 4 is CH. [Aspect Z13] A compound of the present compound Z, in which Q is a group represented by Q6. [Aspect Z14] A compound of the present compound Z, in which Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect Z15] A compound of the present compound Z, in which Q is a group represented by Q1, Q2, Q5, or Q6. [Aspect Z16] A compound of the present compound Z, in which Q is a group represented by Q1, Q2, Q5, or Q6, and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect Z17] In the compound Z, Q is a group represented by Q1 or Q2, and R 2 , R 3 , R 4 and R 5 is a hydrogen atom. [Aspect Z18] In the compound Z, Q is a group represented by Q5 or Q6, and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect Z19] In the present compound Z or any of Aspects Z1 to Z18, Z is a C2-C6 chain hydrocarbon group, a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D, or NR 14R 15 and R 1 a C3-C10 alicyclic hydrocarbon group optionally substituted by one or more C1-C6 chain hydrocarbon groups, a 3-7 membered non-aromatic heterocyclic group {the 3-7 membered non-aromatic heterocyclic group is optionally substituted by one or more substituents selected from Group A2, and any atom not bonded to Q among the atoms constituting the 3-7 membered non-aromatic heterocyclic group may form a C3-C7 alicyclic hydrocarbon as a spiro atom}, a 5-7 membered aromatic heterocyclic group (excluding 1H-pyrazol-3-yl group when Q is a group represented by Q6) optionally substituted by one or more substituents selected from Group B2 {among the atoms constituting the 5-7 membered aromatic heterocyclic group (excluding 1H-pyrazol-3-yl group when Q is a group represented by Q6), any two adjacent atoms not bonded to Q may form another benzene ring containing the two adjacent atoms or a C4-C7 alicyclic hydrocarbon}, or —C≡CR 13 Group A2: a group consisting of C1-C3 alkyl groups and halogen atoms. Group B2: a group consisting of C3-C6 alicyclic hydrocarbon groups, C1-C6 chain hydrocarbon groups, and halogen atoms. [Aspect Z20] In Compound Z or any of Aspects Z1 to Z18, Z is a compound in which Z is a C2-C6 chain hydrocarbon group, a 5- or 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2, or NR 14 R 15 and R 1a C3-C10 alicyclic hydrocarbon group optionally substituted by one or more C1-C6 chain hydrocarbon groups, a 3-7 membered non-aromatic heterocyclic group {the 3-7 membered non-aromatic heterocyclic group is optionally substituted by one or more substituents selected from Group A2, and any atoms constituting the 3-7 membered non-aromatic heterocyclic group not bonded to Q may form a C3-C7 alicyclic hydrocarbon as a spiro atom}, or a 5-6 membered aromatic heterocyclic group (excluding 1H-pyrazol-3-yl group when Q is a group represented by Q6) optionally substituted by one or more substituents selected from Group B2 {among atoms constituting the 5-6 membered aromatic heterocyclic group (excluding 1H-pyrazol-3-yl group when Q is a group represented by Q6), any two adjacent atoms not bonded to Q may form another benzene ring containing the two adjacent atoms or a C4-C7 alicyclic hydrocarbon}, or —C≡CR 13 and R 14 and R 15 are the same or different and are C1-C6 alkyl groups, and R 13 is a C1-C6 chain hydrocarbon group or a phenyl group. [Aspect Z21] A compound of this compound Z or any of Aspects Z3, Z4, Z15, Z16, and Z17, wherein R 1a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) are each independently selected from group A, and among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3-10 membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-10 membered non-aromatic heterocyclic group is bonded to the group represented by Q2), any atom not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3-7 membered non-aromatic heterocycle); and a 5- to 7-membered aromatic heterocyclic group which may be bonded to the group represented by Q2 (provided that when Q is a group represented by Q6, excluding a 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2) {the 5- to 7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, excluding a 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2); any two adjacent atoms not bonded to Q among the atoms constituting the group bonded to the group shown in the formula (A), may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the two adjacent atoms {the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4- to 7-membered non-aromatic heterocycle, and the 5- to 7-membered aromatic heterocycle may be substituted with one or more halogen atoms}, or -C≡CR 13 [Aspect Z22] In the present compound Z or any of Aspects Z3, Z4, Z15, Z16 and Z17, Z is a compound in which Z is a C2-C6 chain hydrocarbon group, a 5- or 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D, or NR 14 R 15 and R 1a C3-C10 alicyclic hydrocarbon group optionally substituted by one or more C1-C6 chain hydrocarbon groups, a 3-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the 3-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) may be substituted by one or more substituents selected from Group A2, and any atom constituting the 3-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) which is not bonded to Q is a C3-C7 alicyclic hydrocarbon group as a spiro atom; a 5- to 7-membered aromatic heterocyclic group optionally substituted by one or more substituents selected from group B2 (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2) {among the atoms constituting the 5- to 7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2), any two adjacent atoms not bonded to Q may form another benzene ring or a C4-C7 alicyclic hydrocarbon containing the two adjacent atoms}, or -C≡CR 13 [Aspect Z23] In the present compound Z or any of Aspects Z3, Z4, Z15, Z16 and Z17, Z is a compound in which Z is a C2-C6 chain hydrocarbon group, a 5- or 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2, or NR 14 R 15 and R 1a C3-C10 alicyclic hydrocarbon group optionally substituted by one or more C1-C6 chain hydrocarbon groups, a 3-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the 3-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) optionally substituted by one or more substituents selected from Group A2, and any atom constituting the 3-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) which is not bonded to Q is a C3-C7 alicyclic hydrocarbon group as a spiro atom or a 5- to 6-membered aromatic heterocyclic group optionally substituted by one or more substituents selected from group B2 (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 6-membered aromatic heterocyclic group is bonded to the group represented by Q2) {among the atoms constituting the 5- to 6-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 6-membered aromatic heterocyclic group is bonded to the group represented by Q2) any two adjacent atoms not bonded to Q may form another benzene ring containing the two adjacent atoms, or a C4-C7 alicyclic hydrocarbon}, or -C≡CR 13 and R 14 and R 15 are the same or different and are C1-C6 alkyl groups, and R 13 is a C1-C6 chain hydrocarbon group or a phenyl group.

[0014] The following compounds are examples of the present compound N.

[0015] [Aspect 1] A compound of the present compound N, wherein Z is a C2-C6 chain hydrocarbon group. [Aspect 2] A compound of the present compound N, wherein Z is a C2-C6 alkyl group. [Aspect 3] A compound of the present compound N, wherein Z is an ethyl group or a propyl group. [Aspect 4] A compound of the present compound N, wherein Z is a methyl group substituted with one or more fluorine atoms. [Aspect 5] A compound of the present compound N, wherein Z is a trifluoromethyl group. [Aspect 6] A compound of the present compound N, wherein Z is a C1-C2 alkyl group (the C1-C2 alkyl group is substituted with a methoxy group or an ethoxy group). [Aspect 7] A compound of the present compound N, wherein Z is a 2-methoxyethyl group or a 2-ethoxyethyl group. [Aspect 8] A compound of the present compound N, wherein Z is a C3-C8 alicyclic hydrocarbon group. [Aspect 9] A compound of the present compound N, wherein Z is a cyclopropyl group, a cyclopentyl group, or a cyclohexyl group. [Aspect 10] A compound of the present compound N, wherein Z is a 3- to 8-membered non-aromatic heterocyclic group. [Aspect 11] A compound of the present compound N, wherein Z is a 3-tetrahydrofuranyl group or a 3-tetrahydrothienyl group. [Aspect 12] A compound of the present compound N, wherein Z is a 5- to 10-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D. [Aspect 13] A compound of the present compound N, wherein Z is a 5-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D. [Aspect 14] A compound of the present compound N, wherein Z is a 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D. [Aspect 15] A compound of the present compound N, wherein Z is a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, or a 2-pyrazinyl group. [Aspect 16] The compound N, wherein Z is a 2-furyl group, a 3-furyl group, a 2-thienyl group, or a 3-thienyl group. [Aspect 17] The compound N, wherein Z is NR 14 R 15[Aspect 18] A compound of the present compound N, in which Z is a dimethylamino group. [Aspect 19] A compound of the present compound N, in which Z is a 5- or 6-membered aromatic heterocyclic group. [Aspect 20] A compound of the present compound N, in which Z is a C2-C6 open chain hydrocarbon group or a 5- or 6-membered aromatic heterocyclic group. [Aspect 21] A compound of the present compound N, in which Z is a C2-C6 alkyl group or a 5-membered aromatic heterocyclic group. [Aspect 22] A compound of the present compound N, in which Z is a C2-C6 alkyl group or a 6-membered aromatic heterocyclic group. [Aspect 23] A compound of the present compound N, in which Z is an ethyl group, a propyl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 2-pyrazinyl group, a 2-furyl group, a 3-furyl group, a 2-thienyl group, or a 3-thienyl group.

[0016] [Aspect 24] The compound N, wherein Q is a group represented by Q1. [Aspect 25] The compound N, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 26] A compound according to aspect 1, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 27] The compound according to aspect 2, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 28] The compound according to aspect 3, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 29] The compound according to aspect 12, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 30] In aspect 13, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 31] The compound according to aspect 14, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 32] In aspect 15, Q is a group represented by Q1, and R 2 and R 3is a hydrogen atom. [Aspect 33] The compound according to aspect 16, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 34] In aspect 19, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 35] In aspect 20, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 36] The compound according to aspect 21, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 37] The compound according to aspect 22, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 38] The compound according to aspect 23, wherein Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom. [Aspect 39] A compound in which Q is a group represented by Q2 in the compound N. [Aspect 40] A compound in which Q is a group represented by Q2 and R 4 and R 5 is a hydrogen atom. [Aspect 41] A compound of the present compound N, in which Q is a group represented by Q3. [Aspect 42] A compound of the present compound N, in which Q is a group represented by Q3, and R 6 is a hydrogen atom. [Aspect 43] A compound in which Q is a group represented by Q4 in the compound N. [Aspect 44] A compound in which Q is a group represented by Q4 and R 7 A compound in which is a hydrogen atom.

[0017] [Aspect 45] The compound N, wherein Q is a group represented by Q5. [Aspect 46] The compound N, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 [Embodiment 47] In the compound N, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 48] The compound according to aspect 1, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 49] The compound according to aspect 2, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 50] The compound according to aspect 3, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 51] The compound according to aspect 12, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 52] The compound according to aspect 13, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 53] The compound according to aspect 14, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 54] The compound according to aspect 15, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 55] The compound according to aspect 16, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 56] In aspect 19, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 57] The compound according to aspect 20, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 58] The compound according to aspect 21, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 59] The compound according to aspect 22, wherein Q is a group represented by Q5, and X 2 is CR 16and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 60] In aspect 23, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 61] In the compound N, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 62] The compound according to aspect 1, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 63] The compound according to aspect 2, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 64] The compound according to aspect 3, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18is a hydrogen atom. [Aspect 65] The compound according to aspect 12, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 66] The compound according to aspect 13, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 67] The compound according to aspect 14, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 68] The compound according to aspect 15, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 69] The compound according to aspect 16, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 70] In aspect 19, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 71] The compound according to aspect 20, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 72] The compound according to aspect 21, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 73] The compound according to aspect 22, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 74] The compound according to embodiment 23, wherein Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 75] In the compound N, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18is a hydrogen atom. [Aspect 76] The compound according to aspect 1, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 77] The compound according to embodiment 2, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 78] The compound according to embodiment 3, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 79] The compound according to aspect 12, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 80] The compound according to aspect 13, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 81] The compound according to aspect 14, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 82] The compound according to aspect 15, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 83] The compound according to aspect 16, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 84] In aspect 19, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 85] The compound according to aspect 20, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 86] The compound according to aspect 21, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 87] The compound according to aspect 22, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 88] The compound according to aspect 23, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 89] A compound in which Q is a group represented by Q6 in the compound N. [Aspect 90] A compound in which Q is a group represented by Q6 and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 91] The compound according to aspect 1, wherein Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11is a hydrogen atom. [Aspect 92] In aspect 2, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 93] The compound according to aspect 3, wherein Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 94] The compound according to aspect 12, wherein Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 95] The compound according to aspect 13, wherein Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 96] The compound according to aspect 14, wherein Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 97] In aspect 15, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 98] The compound according to aspect 16, wherein Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 99] In aspect 19, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 100] In aspect 20, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 101] In aspect 21, Q is a group represented by Q6, and R 8 , R 9 , R10 , and R 11 is a hydrogen atom. [Aspect 102] In aspect 22, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom. [Aspect 103] In aspect 23, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 A compound in which is a hydrogen atom.

[0018] [Aspect 104] The compound N, wherein Q is a group represented by Q1 or a group represented by Q2. [Aspect 105] The compound N, wherein Q is a group represented by Q1 or a group represented by Q2, and R 2 , R 3 , R 4 and R 5 is a hydrogen atom. [Aspect 106] A compound in which Q in the compound N is a group represented by Q2, a group represented by Q3, or a group represented by Q4. [Aspect 107] A compound in which Q in the compound N is a group represented by Q2, a group represented by Q3, or a group represented by Q4, and R 4 , R 5 , R 6 and R 7 is a hydrogen atom. [Embodiment 108] In the compound N, Q is a group represented by Q3 or a group represented by Q4, and R 6 and R 7 A compound in which is a hydrogen atom.

[0019] [Aspect 109] The compound N, wherein Q is a group represented by Q5 or a group represented by Q6. [Aspect 110] The compound N, wherein Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 [Embodiment 111] In the compound N, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 112] In aspect 1, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 113] In aspect 2, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 114] In embodiment 3, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 115] In aspect 12, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9, R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 116] In aspect 13, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 117] In aspect 14, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 118] In aspect 15, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 119] In aspect 16, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11, R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 120] In aspect 19, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 121] In aspect 20, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 122] In aspect 21, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 123] In aspect 22, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16, R 17 and R 18 is a hydrogen atom. [Aspect 124] In aspect 23, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 125] In the compound N, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 126] In aspect 1, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 127] In aspect 2, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R16 and R 18 is a hydrogen atom. [Aspect 128] In aspect 3, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 129] In aspect 12, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 130] In aspect 13, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 131] In aspect 14, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R16 and R 18 is a hydrogen atom. [Aspect 132] In aspect 15, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 133] In aspect 16, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 134] In embodiment 19, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 135] In aspect 20, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12, R 16 and R 18 is a hydrogen atom. [Aspect 136] In aspect 21, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 137] In embodiment 22, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 138] In embodiment 23, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 139] In the compound N, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 140] In aspect 1, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 141] In aspect 2, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 142] In embodiment 3, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 143] In aspect 12, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 144] In embodiment 13, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 145] In aspect 14, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 146] In aspect 15, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 147] In aspect 16, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 148] In aspect 19, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 149] In aspect 20, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 150] In aspect 21, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 151] In aspect 22, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 152] In embodiment 23, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 A compound in which is a hydrogen atom.

[0020] [Aspect 153] The compound N, wherein Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6. [Aspect 154] The compound N, wherein Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 155] In embodiment 1, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 156] In aspect 2, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 157] In embodiment 3, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 158] In embodiment 12, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 159] In aspect 13, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 160] In aspect 14, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 161] In aspect 15, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 162] In aspect 16, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 163] In aspect 19, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 164] In embodiment 20, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 165] In aspect 21, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 166] In aspect 22, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Aspect 167] In aspect 23, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom. [Embodiment 168] In the compound N, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 169] In aspect 1, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 170] In aspect 2, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 171] In aspect 3, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 172] In aspect 12, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 173] In aspect 13, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 174] In embodiment 14, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18is a hydrogen atom. [Aspect 175] In aspect 15, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 176] In aspect 16, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 177] In embodiment 19, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Embodiment 178] In embodiment 20, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 179] In aspect 21, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 180] In aspect 22, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom. [Aspect 181] In aspect 23, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 A compound in which is a hydrogen atom.

[0021] [Aspect 182] The compound N, wherein n is 1. [Aspect 183] The compound N, wherein n is 2.

[0022] [Embodiment 184] The compound N, wherein Q is a group represented by Q1 and n is 2. [Embodiment 185] The compound N, wherein Q is a group represented by Q1 and R 2 and R 3 is a hydrogen atom and n is 2. [Embodiment 186] In embodiment 1, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Embodiment 187] In embodiment 2, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Embodiment 188] In embodiment 3, Q is a group represented by Q1, and R 2 and R3 is a hydrogen atom and n is 2. [Aspect 189] In aspect 12, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Aspect 190] In aspect 13, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Aspect 191] In aspect 14, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Aspect 192] In aspect 15, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Aspect 193] In aspect 16, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Aspect 194] In aspect 19, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Embodiment 195] In embodiment 20, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Aspect 196] In aspect 21, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Embodiment 197] In embodiment 22, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2. [Embodiment 198] In embodiment 23, Q is a group represented by Q1, and R 2 and R 3 is a hydrogen atom and n is 2.

[0023] [Aspect 199] The compound N, wherein Q is a group represented by Q2 and n is 2. [Aspect 200] The compound N, wherein Q is a group represented by Q2 and R 4 and R 5is a hydrogen atom and n is 2. [Aspect 201] A compound in which Q is a group represented by Q3 and n is 2 in the compound N. [Aspect 202] A compound in which Q is a group represented by Q3 and R 6 is a hydrogen atom and n is 2. [Aspect 203] A compound in which Q is a group represented by Q4 and n is 2 in the compound N. [Aspect 204] A compound in which Q is a group represented by Q4 and R 7 is a hydrogen atom and n is 2.

[0024] [Aspect 205] The compound N, wherein Q is a group represented by Q5 and n is 2. [Aspect 206] The compound N, wherein Q is a group represented by Q5 and X 2 is CR 16 and X 4 is CR 18 and n is 2. [Embodiment 207] In the compound N, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 208] In aspect 1, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 209] In aspect 2, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 210] In aspect 3, Q is a group represented by Q5, and X 2 is CR16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 211] In aspect 12, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 212] In aspect 13, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Embodiment 213] In embodiment 14, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Embodiment 214] In embodiment 15, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 215] In aspect 16, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18is a hydrogen atom and n is 2. [Aspect 216] In aspect 19, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 217] In aspect 20, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 218] In aspect 21, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 219] In aspect 22, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Aspect 220] In aspect 23, Q is a group represented by Q5, and X 2 is CR 16 and X 4 is CR 18 and R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Embodiment 221] In the compound N, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 222] In aspect 1, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 223] In aspect 2, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 224] In embodiment 3, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 225] In embodiment 12, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 226] In embodiment 13, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18is a hydrogen atom and n is 2. [Embodiment 227] In embodiment 14, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 228] In embodiment 15, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 229] In embodiment 16, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 230] In aspect 19, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 231] In embodiment 20, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 232] In aspect 21, Q is a group represented by Q5, and X 2 is CR16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 233] In aspect 22, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 234] In embodiment 23, Q is a group represented by Q5, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 235] In the compound N, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 236] The compound according to embodiment 1, wherein Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 237] In embodiment 2, Q is a group represented by Q5, and X 1 is CR12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 238] In embodiment 3, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 239] In embodiment 12, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 240] In aspect 13, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 241] In aspect 14, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R16 and R 18 is a hydrogen atom and n is 2. [Embodiment 242] In embodiment 15, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 243] In embodiment 16, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 244] In embodiment 19, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 245] In embodiment 20, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 246] In aspect 21, Q is a group represented by Q5, and X 1 is CR 12 and X2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Embodiment 247] In embodiment 22, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 248] In aspect 23, Q is a group represented by Q5, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 12 , R 16 and R 18 is a hydrogen atom and n is 2. [Aspect 249] A compound in which Q is a group represented by Q6 and n is 2 in the compound N. [Aspect 250] A compound in which Q is a group represented by Q6 and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 251] In embodiment 1, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 252] In embodiment 2, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 253] In embodiment 3, Q is a group represented by Q6, and R8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 254] In embodiment 12, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 255] In embodiment 13, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 256] In embodiment 14, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 257] In embodiment 15, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Embodiment 258] In embodiment 16, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Aspect 259] In aspect 19, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Aspect 260] In aspect 20, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Aspect 261] In aspect 21, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Aspect 262] In aspect 22, Q is a group represented by Q6, and R8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2. [Aspect 263] In aspect 23, Q is a group represented by Q6, and R 8 , R 9 , R 10 , and R 11 is a hydrogen atom and n is 2.

[0025] [Embodiment 264] The compound N, wherein Q is a group represented by Q1 or a group represented by Q2, and n is 2. [Embodiment 265] The compound N, wherein Q is a group represented by Q1 or a group represented by Q2, and R 2 , R 3 , R 4 and R 5 is a hydrogen atom, and n is 2. [Aspect 266] A compound in which Q in the compound N is a group represented by Q2, a group represented by Q3, or a group represented by Q4, and n is 2. [Aspect 267] A compound in which Q in the compound N is a group represented by Q2, a group represented by Q3, or a group represented by Q4, and R 4 , R 5 , R 6 and R 7 is a hydrogen atom, and n is 2. [Embodiment 268] In the compound N, Q is a group represented by Q3 or a group represented by Q4, and R 6 and R 7 is a hydrogen atom and n is 2.

[0026] [Aspect 269] The compound N, wherein Q is a group represented by Q5 or a group represented by Q6, and n is 2. [Aspect 270] The compound N, wherein Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and n is 2. [Embodiment 271] In the compound N, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 272] In embodiment 1, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 273] In aspect 2, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom and n is 2. [Embodiment 274] In embodiment 3, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 275] In aspect 12, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 276] In aspect 13, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 277] In embodiment 14, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 278] In aspect 15, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 279] In aspect 16, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 280] In aspect 19, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 281] In aspect 20, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 282] In aspect 21, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 283] In aspect 22, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Aspect 284] In aspect 23, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 285] In the compound N, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 286] In aspect 1, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 287] In aspect 2, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 288] In aspect 3, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 289] In aspect 12, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 290] In aspect 13, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 291] In aspect 14, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 292] In aspect 15, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 293] In aspect 16, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 294] In aspect 19, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18is a hydrogen atom, and n is 2. [Aspect 295] In aspect 20, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 296] In aspect 21, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 297] In aspect 22, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 298] In aspect 23, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12, R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 299] In the compound N, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 300] In aspect 1, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 301] In aspect 2, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 302] In aspect 3, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 303] In aspect 12, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 304] In embodiment 13, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 305] In aspect 14, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9, R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 306] In aspect 15, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 307] In embodiment 16, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 308] In aspect 19, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18is a hydrogen atom, and n is 2. [Aspect 309] In aspect 20, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 310] In aspect 21, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 311] In embodiment 22, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 312] In embodiment 23, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom and n is 2.

[0027] [Embodiment 313] The compound N, wherein Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and n is 2. [Embodiment 314] The compound N, wherein Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 315] In embodiment 1, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 316] In embodiment 2, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 317] In embodiment 3, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 318] In embodiment 12, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 319] In embodiment 13, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 320] In embodiment 14, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 321] In embodiment 15, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 322] In embodiment 16, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 323] In embodiment 19, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 324] In embodiment 20, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 325] In embodiment 21, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 326] In embodiment 22, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 327] In embodiment 23, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 is a hydrogen atom, and n is 2. [Embodiment 328] In the compound N, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 329] In embodiment 1, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Aspect 330] In aspect 2, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18is a hydrogen atom, and n is 2. [Embodiment 331] In embodiment 3, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 332] In embodiment 12, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 333] In embodiment 13, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5, R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 334] In embodiment 14, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 335] In embodiment 15, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 336] In embodiment 16, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 337] In embodiment 19, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 338] In embodiment 20, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18is a hydrogen atom, and n is 2. [Embodiment 339] In embodiment 21, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 340] In embodiment 22, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and n is 2. [Embodiment 341] In embodiment 23, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom and n is 2.

[0028] [Embodiment 342] In the compound N, R 1 is a C3-C10 alicyclic hydrocarbon group {the C3-C10 alicyclic hydrocarbon group may be substituted with one or more substituents selected from Group A2, and any atom constituting the C3-C10 alicyclic hydrocarbon group that is not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle}. Group A2: A group consisting of C1-C3 alkyl groups and halogen atoms. [Embodiment 343] In Compound N, R 1 is a C5-C7 alicyclic hydrocarbon group optionally substituted with one or more substituents selected from Group A2. 1 is a cyclopropyl group, a cyclohexyl group, a 1-cyclopentenyl group, a 1-cyclohexenyl group, or a 4,4-dimethyl-1-cyclohexen-1-yl group. 1 is a 3- to 10-membered non-aromatic heterocyclic group {the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A2, and any atom constituting the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle}. [Embodiment 346] A compound in which R 1 is a 5- to 7-membered non-aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2. 1 is a 1-piperidyl group or a 1-azepanyl group. 1is a C3-C10 alicyclic hydrocarbon group or a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A2, and any atom constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocyclic ring}. [Embodiment 349] A compound in which R 1 is a C5-C7 alicyclic hydrocarbon group or a 5- to 7-membered non-aromatic heterocyclic group (the C5-C7 alicyclic hydrocarbon group and the 5- to 7-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A2). 1 is a 5-7 membered aromatic heterocyclic group (excluding 1H-pyrazol-3-yl group when Q is a group represented by Q6) optionally substituted with one or more substituents selected from Group B {any two adjacent atoms constituting the 5-7 membered aromatic heterocyclic group (excluding 1H-pyrazol-3-yl group when Q is a group represented by Q6) which are not bonded to Q may form another C4-C7 alicyclic hydrocarbon, 4-7 membered non-aromatic heterocycle, or 5-7 membered aromatic heterocycle containing the two adjacent atoms}. [Embodiment 351] A compound in which R 1 is a 5- or 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2. 1 is a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 5-chloro-6-fluoropyridin-3-yl group, a 6-chloro-5-methylpyridin-3-yl group, a 6-chloro-5-fluoropyridin-3-yl group, a 5-fluoro-6-methylpyridin-2-yl group, a 5-fluoro-4-methylpyridin-2-yl group, or a 6-fluoro-5-methylpyridin-3-yl group. 1is a 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, a 1H-pyrazol-4-yl group, a 2-thienyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, the 1H-pyrazol-4-yl group, the 2-thienyl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group may be substituted with one or more substituents selected from Group A2}. [Embodiment 354] A compound of the present invention, wherein R 1 is a 5-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2. 1 is a 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2. 1 But -C≡CR 13 [Embodiment 357] In the compound N, R 1 But -C≡CR 13 and R 13 is a C1-C6 chain hydrocarbon group or a C3-C7 alicyclic hydrocarbon group. 1 is a 3,3-dimethyl-1-butyn-1-yl group, a 1-cyclohexen-1-yl group, or a 1-cyclopenten-1-yl group. 1 a 3- to 10-membered non-aromatic heterocyclic group {the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A2, and any atom constituting the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle}, a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B, or —C≡CR 13 [Embodiment 360] In the compound N, R 1 represents a 5- to 7-membered non-aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2, a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2, or —C≡CR 13 and R13 is a C1-C6 chain hydrocarbon group or a C3-C7 alicyclic hydrocarbon group. 1 is a 1-cyclopenten-1-yl group, a 1-cyclohexen-1-yl group, a 4,4-dimethyl-1-cyclohexen-1-yl group, a 1H-pyrazol-1-yl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group {the 1H-pyrazol-1-yl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group may be substituted with one or more substituents selected from group A2}, or —C≡CR 13 and R 13 is a 3,3-dimethyl-1-butyn-1-yl group, a 1-cyclohexen-1-yl group, or a 1-cyclopenten-1-yl group. [Embodiment 362] In this compound N, Z is a C2-C6 chain hydrocarbon group or a 5- or 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D, Q is a group represented by Q5 or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and R 1 is a 3- to 10-membered non-aromatic heterocyclic group {the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A2, and any atom constituting the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B. [Aspect 363] In Compound N, Z is a C2-C6 alkyl group or a 5- to 6-membered aromatic heterocyclic group, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and R 1 is a 5- to 7-membered non-aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2, or a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2. [Embodiment 364] In Compound N, Z is an ethyl group, a propyl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 2-pyrazinyl group, a 2-furyl group, a 3-furyl group, a 2-thienyl group, or a 3-thienyl group, Q is a group represented by Q5 or Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and R 1 is a 3-bromo-1H-pyrazol-1-yl group, a 4-chloro-3-methyl-1H-pyrazol-1-yl group, a 4-bromo-3-methyl-1H-pyrazol-1-yl group, a 5-chloro-6-fluoropyridin-3-yl group, a 6-chloro-5-methylpyridin-3-yl group, a 6-chloro-5-fluoropyridin-3-yl group, a 5-fluoro-6-methylpyridin-2-yl group, a 5-fluoro-4-methylpyridin-2-yl group, or a 6-fluoro-5-methylpyridin-3-yl group, and n is 2. [Embodiment 365] A compound in which Z is an ethyl group, a propyl group, or a 2-thienyl group, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and R 1 is a 1H-pyrazol-1-yl group, a 2-pyridyl group, or a 3-pyridyl group (the 1H-pyrazol-1-yl group, the 2-pyridyl group, and the 3-pyridyl group may be substituted with one or more substituents selected from Group A2). [Embodiment 366] A compound N, in which Z is an ethyl group, a propyl group, a 2-furyl group, a 3-furyl group, or a 2-thienyl group, Q is a group represented by Q5 or a group represented by Q6, and X 1 is CR 12 and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and R 1is a 1-piperidyl group, a 4-methyl-piperidin-1-yl group, a 4,4-dimethyl-piperidin-1-yl group, a 1-azepanyl group, a 1H-pyrazol-1-yl group, a 2-pyridyl group, or a 3-pyridyl group (the 1H-pyrazol-1-yl group, the 2-pyridyl group, and the 3-pyridyl group may be substituted with one or more substituents selected from Group A2). [Aspect 367] A compound in Aspect 365, wherein n is 2. [Aspect 368] A compound in Aspect 365, wherein Q is a group represented by Q5 and n is 2. [Aspect 369] A compound in Aspect 366, wherein n is 2. [Aspect 370] A compound in Aspect 366, wherein Q is a group represented by Q5 and n is 2. [Embodiment 371] In the present compound N, Z is a C2-C6 chain hydrocarbon group or a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and R 1 is a 3- to 10-membered non-aromatic heterocyclic group {the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A2, and any atom constituting the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocyclic ring as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B. [Embodiment 372] A compound in which R 1wherein any atom constituting the C3-C10 alicyclic hydrocarbon group and the 3-10-membered non-aromatic heterocyclic group (when Q is a group represented by Q2, a carbon atom constituting the 3-10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) is optionally substituted with one or more substituents selected from Group A, and among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3-10-membered non-aromatic heterocyclic group (when Q is a group represented by Q2, a carbon atom constituting the 3-10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2), which is not bonded to Q, is a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocyclic group as a spiro atom a 5-7-membered aromatic heterocyclic group optionally substituted by one or more substituents selected from group B (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5-7-membered aromatic heterocyclic group is bonded to the group represented by Q2) {among the atoms constituting the 5-7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5-7-membered aromatic heterocyclic group is bonded to the group represented by Q2), any two adjacent atoms not bonded to Q may form another C4-C7 alicyclic hydrocarbon, 4-7-membered non-aromatic heterocycle, or 5-7-membered aromatic heterocycle containing the two adjacent atoms}, or -C≡CR 13 [Embodiment 373] In the compound N, R 1is a 3-10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the 3-10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) is optionally substituted with one or more substituents selected from Group A2, and any atom constituting the 3-10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3-10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) that is not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocycle}. [Embodiment 374] A compound in which R 1 is a 5-7 membered non-aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2 (provided that when Q is a group represented by Q2, a carbon atom constituting the 5-7 membered non-aromatic heterocyclic group is bonded to the group represented by Q2). [Embodiment 375] A compound of the present invention, wherein Q is a group represented by Q1, a group represented by Q3, a group represented by Q4, a group represented by Q5, or a group represented by Q6, and R 1 is a 1-piperidyl group or a 1-azepanyl group. 1 is a C3-C10 alicyclic hydrocarbon group or a 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) are optionally substituted with one or more substituents selected from Group A2, and among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2), any atom not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle}. [Embodiment 377] In the compound N, R1 is a C5-C7 alicyclic hydrocarbon group or a 5-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 5-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the C5-C7 alicyclic hydrocarbon group and the 5-7-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 5-7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) may be substituted with one or more substituents selected from Group A2}. [Embodiment 378] A compound in which R 1 is a 5-7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5-7-membered aromatic heterocyclic group is bonded to the group represented by Q2) {among the atoms constituting the 5-7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5-7-membered aromatic heterocyclic group is bonded to the group represented by Q2) any two adjacent atoms not bonded to Q may form another C4-C7 alicyclic hydrocarbon, 4-7-membered non-aromatic heterocycle, or 5-7-membered aromatic heterocycle containing the two adjacent atoms}. [Embodiment 379] A compound of the present invention, １ is a 5- to 6-membered aromatic heterocyclic group optionally substituted by one or more substituents selected from Group A2 (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 6-membered aromatic heterocyclic group is bonded to the group represented by Q2). [Embodiment 380] A compound of the present invention, wherein Q is a group represented by Q1, a group represented by Q3, a group represented by Q4, a group represented by Q5 or a group represented by Q6, and R 1is a 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, a 1H-pyrazol-4-yl group, a 2-thienyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group (the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, the 1H-pyrazol-4-yl group, the 2-thienyl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group may be substituted with one or more substituents selected from Group A2). [Embodiment 381] A compound of the present invention, wherein R 1 is a 5-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2 (provided that when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded, and when Q is a group represented by Q2, a carbon atom constituting the 5-membered aromatic heterocyclic group is bonded to the group represented by Q2). [Embodiment 382] A compound of this compound N, wherein R 1 is a 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group A2 (provided that when Q is a group represented by Q2, a carbon atom constituting the 6-membered aromatic heterocyclic group is bonded to the group represented by Q2). 1 a 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) may be substituted with one or more substituents selected from group A2, and the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) any atom not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3-7 membered non-aromatic heterocycle); a 5-7 membered aromatic heterocyclic group optionally substituted with one or more substituents selected from group B (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5-7 membered aromatic heterocyclic group is bonded to the group represented by Q2), or -C≡CR 13[Embodiment 384] In the compound N, R 1 a 5- to 7-membered non-aromatic heterocyclic group optionally substituted by one or more substituents selected from Group A2 (provided that when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered non-aromatic heterocyclic group is bonded to the group represented by Q2), a 5- to 7-membered aromatic heterocyclic group optionally substituted by one or more substituents selected from Group A2 (provided that when Q is a group represented by Q6, excluding 1H-pyrazol-3-yl group, when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2), or —C≡CR 13 and R 13 is a C1-C6 chain hydrocarbon group or a C3-C7 alicyclic hydrocarbon group. [Embodiment 385] In the compound N, Q is a group represented by Q1, a group represented by Q3, a group represented by Q4, a group represented by Q5, or a group represented by Q6, and R 1 is a 1-cyclopenten-1-yl group, a 1-cyclohexen-1-yl group, a 4,4-dimethyl-1-cyclohexen-1-yl group, a 1H-pyrazol-1-yl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group {the 1H-pyrazol-1-yl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group may be substituted with one or more substituents selected from group A2}, or —C≡CR 13 and R 13 is a 3,3-dimethyl-1-butyn-1-yl group, a 1-cyclohexen-1-yl group, or a 1-cyclopenten-1-yl group. [Embodiment 386] In this compound N, Z is a C2-C6 chain hydrocarbon group or a 5- or 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D, Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6, and X 2 is CR 16 and X 3 is a nitrogen atom, and X 4 is CR 18 and R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R10 , R 11 , R 12 , R 16 and R 18 is a hydrogen atom, and R 1 is a 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) is optionally substituted with one or more substituents selected from Group A2, and among the atoms constituting the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2), any atom not bonded to Q may act as a spiro atom to form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B.

[0029] Examples of the compound Z of the present invention include the following compounds.

[0030] [Aspect CZ1] In the compound Z of the present invention, Z a is a C2-C6 chain hydrocarbon group. [Aspect CZ2] In the compound Z of the present invention, Z a is a C2-C6 alkyl group. [Aspect CZ3] Compound Z of the present invention, a is an ethyl group or a propyl group. [Aspect CZ4] In the compound Z of the present invention, Z a is a C3-C8 alicyclic hydrocarbon group. [Aspect CZ5] Compound Z of the present invention, a is a cyclopropyl group, a cyclopentyl group, or a cyclohexyl group. a But group D a [Aspect CZ7] In the compound Z of the present invention, Z is a 5- to 10-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from the following: a is a 5-membered aromatic heterocyclic group. [Aspect CZ8] In the compound Z of the present invention, Za is a 2-furyl group, a 3-furyl group, a 2-thienyl group, or a 3-thienyl group. [Aspect CZ9] In the compound Z of the present invention, Z a is a 6-membered aromatic heterocyclic group. [Aspect CZ10] In the compound Z of the present invention, Z a is a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, or a 2-pyrazinyl group. [Aspect CZ11] In the compound Z of the present invention, Z a is a 5- or 6-membered aromatic heterocyclic group. [Aspect CZ12] In the compound Z of the present invention, Z a is a C2-C6 alkyl group or a 5- or 6-membered aromatic heterocyclic group. a is an ethyl group, a propyl group, a 2-furyl group, a 3-furyl group, a 2-thienyl group, a 3-thienyl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, or a 2-pyrazinyl group. [Aspect CZ14] In compound Z of the present invention, Z a is an ethyl group, a propyl group, or a 2-thienyl group. [Aspect CZ15] In the compound Z of the present invention, X 1a [Aspect CZ16] In the compound Z of the present invention, X is CH. 1a is a nitrogen atom. [Aspect CZ17] In the compound Z of the present invention, R 1a is a 3- to 7-membered non-aromatic heterocyclic group {the 3- to 7-membered non-aromatic heterocyclic group is selected from the group A a and any atom constituting the 3-7-membered non-aromatic heterocyclic group that is not bonded to pyridine or pyrazine may form a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocyclic ring as a spiro atom. [Aspect CZ18] In Compound Z of the present invention, R 1a But Group A a Compounds which are 5-7 membered non-aromatic heterocyclic groups optionally substituted with one or more substituents selected from Group A. a 2: A group consisting of C1-C3 alkyl groups and halogen atoms. [Aspect CZ19] In the compound Z of the present invention, R 1ais a 1-piperidyl group, a 4-methyl-piperidin-1-yl group, a 4,4-dimethyl-piperidin-1-yl group, or a 1-azepanyl group. [Aspect CZ20] Compound Z of the present invention, wherein R 1a is a 5- to 7-membered aromatic heterocyclic group {the 5- to 7-membered aromatic heterocyclic group is selected from the group B1 a and among the atoms constituting the 5-7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another benzene ring, C4-C7 alicyclic hydrocarbon, 4-7-membered non-aromatic heterocycle, or 5-7-membered aromatic heterocycle containing the adjacent two atoms (the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4-7-membered non-aromatic heterocycle, and the 5-7-membered aromatic heterocycle may be substituted with one or more halogen atoms). [Aspect CZ21] A compound of Compound Z of the present invention, wherein R 1a But Group A a 2 (among the atoms constituting the 5-membered aromatic heterocyclic ring, any two adjacent atoms not bonded to pyridine or pyrazine may form another benzene ring containing the two adjacent atoms, or a C4-C7 alicyclic hydrocarbon (the benzene ring and the C4-C7 alicyclic hydrocarbon may be substituted with one or more halogen atoms)). [Aspect CZ22] In Compound Z of the present invention, R 1a a 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, or a 1H-pyrazol-4-yl group {the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, and the 1H-pyrazol-4-yl group are selected from the group A a and R is a substituted or unsubstituted group, and R is a substituted or unsubstituted group. 1a But Group A a A compound of the present invention, wherein R is a 1H-pyrazol-1-yl group optionally substituted with one or more substituents selected from the group consisting of 1H-pyrazol-1-yl, ... 1a But Group A aA compound of the present invention, wherein R is a 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from the group consisting of 1 and 2. 1a a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are those of Group A a 2.} [Aspect CZ26] In the compound Z of the present invention, R 1a But Group A a 2 {among the atoms constituting the 5-6-membered aromatic heterocyclic ring, any two adjacent atoms not bonded to pyridine or pyrazine may form another benzene ring containing the two adjacent atoms, or a C4-C7 alicyclic hydrocarbon {the benzene ring and the C4-C7 alicyclic hydrocarbon may be substituted with one or more halogen atoms}}. [Aspect CZ27] In Compound Z of the present invention, R 1a a 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, a 1H-pyrazol-4-yl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, the 1H-pyrazol-4-yl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are each selected from Group A a 2}. [Aspect CZ28] A compound of the present invention, in which n a is 1. [Aspect CZ29] A compound of the present invention, in which n a is 2. [Aspect CZ30] A compound of the present invention, in which n a is 1. [Aspect CZ31] A compound of the present invention, in which n a is 1. [Aspect CZ32] A compound of the present invention, in which n a is 2. [Aspect CZ33] A compound of the present invention, in which n a is 2. [Aspect CZ34] A compound of the present invention, in which Z a is a C2-C6 alkyl group or a 5-membered aromatic heterocyclic group, and R 1a a 6- to 7-membered non-aromatic heterocyclic group or a 5- to 6-membered aromatic heterocyclic group {the 6- to 7-membered non-aromatic heterocyclic group and the 5- to 6-membered aromatic heterocyclic group are selected from the group A a[Aspect CZ35] The compound of Aspect CZ34, wherein na is 2 and X 1a [Aspect CZ36] In the compound Z of the present invention, Z a is an ethyl group, a propyl group, or a 2-thienyl group, and R 1a a 1-piperidyl group, a 4-methyl-piperidin-1-yl group, a 4,4-dimethyl-piperidin-1-yl group, a 1-azepanyl group, a 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, a 1H-pyrazol-4-yl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, the 1H-pyrazol-4-yl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are each selected from group A a and X is optionally substituted with one or more substituents selected from 2. [Aspect CZ37] The compound of Aspect CZ36, wherein na is 2 and X 1a [Aspect CZ38] In the compound Z of the present invention, Z a is a C2-C6 alkyl group or a 5-membered aromatic heterocyclic group, and R 1a is a 6- to 7-membered non-aromatic heterocyclic group or a 6-membered aromatic heterocyclic group {the 6- to 7-membered non-aromatic heterocyclic group and the 6-membered aromatic heterocyclic group are selected from the group A a and optionally substituted with one or more substituents selected from the group consisting of 2 and 3. [Aspect CZ39] In the compound Z of the present invention, Z a is an ethyl group, a propyl group, or a 2-thienyl group, and R 1a a 1-piperidyl group, a 4-methyl-piperidin-1-yl group, a 4,4-dimethyl-piperidin-1-yl group, a 1-azepanyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are group A a and optionally substituted with one or more substituents selected from 2. [Aspect CZ40] The compound of Aspect CZ38, wherein na is 2 and X 1a [Aspect CZ41] The compound of Aspect CZ39, wherein na is 2 and X is CH. 1a Compounds in which is CH.

[0031] The following compounds are examples of the compound N of the present invention.

[0032] [Aspect C1] In the compound N of the present invention, Z a is a C2-C6 chain hydrocarbon group. [Aspect C2] Compound N of the present invention, a is a C2-C6 alkyl group. [Aspect C3] Compound N of the present invention, a is an ethyl group or a propyl group. [Aspect C4] In the compound N of the present invention, Z a is a C3-C8 alicyclic hydrocarbon group. [Aspect C5] Compound N of the present invention, a is a cyclopropyl group, a cyclopentyl group, or a cyclohexyl group. a But group D a [Aspect C7] In Compound N of the present invention, Z is a 5- to 10-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from the following. a is a 5-membered aromatic heterocyclic group. [Aspect C8] In the compound N of the present invention, Z a is a 2-furyl group, a 3-furyl group, a 2-thienyl group, or a 3-thienyl group. [Aspect C9] Compound N of the present invention, wherein Z a is a 6-membered aromatic heterocyclic group. [Aspect C10] In the compound N of the present invention, Z a is a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, or a 2-pyrazinyl group. [Aspect C11] In Compound N of the present invention, Z a is a 5- or 6-membered aromatic heterocyclic group. [Aspect C12] In Compound N of the present invention, Z a is a C2-C6 alkyl group or a 5- or 6-membered aromatic heterocyclic group. a is an ethyl group, a propyl group, a 2-furyl group, a 3-furyl group, a 2-thienyl group, a 3-thienyl group, a 2-pyridyl group, a 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, or a 2-pyrazinyl group. [Aspect C14] In Compound N of the present invention, Z ais an ethyl group, a propyl group, or a 2-thienyl group. [Aspect C15] In Compound N of the present invention, X 1a [Aspect C16] In the compound N of the present invention, X is CH. 1a is a nitrogen atom. [Aspect C17] In the compound N of the present invention, R 1a is a 3- to 7-membered non-aromatic heterocyclic group {the 3- to 7-membered non-aromatic heterocyclic group is selected from the group A a and any atom constituting the 3-7-membered non-aromatic heterocyclic group that is not bonded to pyridine or pyrazine may form a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocycle as a spiro atom. [Aspect C18] In Compound N of the present invention, R 1a But Group A a Compounds which are 5-7 membered non-aromatic heterocyclic groups optionally substituted with one or more substituents selected from Group A. a 2: A group consisting of C1-C3 alkyl groups and halogen atoms. [Aspect C19] In the compound N of the present invention, R 1a is a 1-piperidyl group, a 4-methyl-piperidin-1-yl group, a 4,4-dimethyl-piperidin-1-yl group, or a 1-azepanyl group. [Aspect C20] Compound N of the present invention, wherein R 1a is a 5- to 7-membered aromatic heterocyclic group {the 5- to 7-membered aromatic heterocyclic group is selected from the group B a and among the atoms constituting the 5-7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another C4-C7 alicyclic hydrocarbon, a 4-7-membered non-aromatic heterocycle, or a 5-7-membered aromatic heterocycle containing the adjacent two atoms. [Aspect C21] Compound N of the present invention, wherein R 1a But Group A a 2. [Aspect C22] In Compound N of the present invention, R 1aa 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, or a 1H-pyrazol-4-yl group {the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, and the 1H-pyrazol-4-yl group are selected from the group A a and R is an integer of 1 to 2; and R is an integer of 1 to 2; and R is an integer of 1 to 2; and 1a But Group A a [Aspect C24] In Compound N of the present invention, R 1a But Group A a A compound of the present invention wherein R is a 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from the group consisting of 1 and 2. [Aspect C25] In Compound N of the present invention, R 1a a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are those of Group A a [Aspect C26] In Compound N of the present invention, R 1a But Group A a A compound of the present invention wherein R is a 5- or 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from the group consisting of 1 and 2. [Aspect C27] In Compound N of the present invention, R 1a a 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, a 1H-pyrazol-4-yl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, the 1H-pyrazol-4-yl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are each selected from Group A a2}. [Aspect C28] A compound of the present invention, in which n a is 1. [Aspect C29] A compound of the present invention, in which n a is 2. [Aspect C30] A compound of the present invention, in which n a is 1. [Aspect C31] A compound of the present invention, in which n a is 1. [Aspect C32] A compound of the present invention, in which n a is 2. [Aspect C33] A compound of the present invention, in which n a is 2. [Aspect C34] A compound of the present invention, in which Z a is a C2-C6 alkyl group or a 5-membered aromatic heterocyclic group, and R 1a a 6- to 7-membered non-aromatic heterocyclic group or a 5- to 6-membered aromatic heterocyclic group {the 6- to 7-membered non-aromatic heterocyclic group and the 5- to 6-membered aromatic heterocyclic group are selected from the group A a [Aspect C35] The compound according to Aspect C34, wherein na is 2 and X 1a [Aspect C36] In the compound N of the present invention, Z is CH. a is an ethyl group, a propyl group, or a 2-thienyl group, and R 1a a 1-piperidyl group, a 4-methyl-piperidin-1-yl group, a 4,4-dimethyl-piperidin-1-yl group, a 1-azepanyl group, a 1H-pyrazol-1-yl group, a 1H-pyrazol-3-yl group, a 1H-pyrazol-4-yl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 1H-pyrazol-1-yl group, the 1H-pyrazol-3-yl group, the 1H-pyrazol-4-yl group, the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are each selected from group A a [Aspect C37] The compound according to Aspect C36, wherein na is 2 and X 1a [Aspect C38] In the compound N of the present invention, Z is CH. a is a C2-C6 alkyl group or a 5-membered aromatic heterocyclic group, and R 1a is a 6- to 7-membered non-aromatic heterocyclic group or a 6-membered aromatic heterocyclic group {the 6- to 7-membered non-aromatic heterocyclic group and the 6-membered aromatic heterocyclic group are selected from the group A aand optionally substituted with one or more substituents selected from the group consisting of 1 and 2. [Aspect C39] In Compound N of the present invention, Z a is an ethyl group, a propyl group, or a 2-thienyl group, and R 1a a 1-piperidyl group, a 4-methyl-piperidin-1-yl group, a 4,4-dimethyl-piperidin-1-yl group, a 1-azepanyl group, a 2-pyridyl group, a 3-pyridyl group, or a 4-pyridyl group {the 2-pyridyl group, the 3-pyridyl group, and the 4-pyridyl group are group A a [Aspect C40] The compound according to Aspect C38, wherein na is 2 and X 1a [Aspect C41] The compound in Aspect C39, wherein na is 2 and X is CH. 1a Compounds in which is CH.

[0033] [Aspect A1] A method for controlling soybean rust fungi by treating soybeans or the soil in which soybeans are grown with the present compound. [Aspect A2] A method for controlling soybean rust fungi by treating soybeans or the soil in which soybeans are grown with the present compound W. [Aspect AC1] A method for controlling soybean rust fungi by treating soybeans or the soil in which soybeans are grown with the present compound. [Aspect AC2] Seeds or vegetative reproductive organs carrying an effective amount of the present compound. [Aspect AC3] A method for controlling soybean rust fungi by treating soybeans or the soil in which soybeans are grown with the present compound W. [Aspect AC4] Seeds or vegetative reproductive organs carrying an effective amount of the present compound W.

[0034] Next, a method for producing the compound W (including the compound W of the present invention) will be described.

[0035] Production Method A A compound represented by formula (I-b) (hereinafter referred to as compound (I-b)) or a compound represented by formula (I-c) (hereinafter referred to as compound (I-c)) can be produced by reacting a compound represented by formula (I-a) (hereinafter referred to as compound (I-a)) with an oxidizing agent. [wherein QA represents a group represented by Q2, a group represented by Q3, a group represented by Q4, a group represented by Q5, or a group represented by Q6; Z 51represents a C2-C6 open chain hydrocarbon group, a methyl group substituted with one or more fluorine atoms, a C1-C2 alkyl group {the C1-C2 alkyl group is substituted with a methoxy group or an ethoxy group}, a C3-C8 alicyclic hydrocarbon group, a 3- to 8-membered non-aromatic heterocyclic group {the C3-C8 alicyclic hydrocarbon group and the 3- to 8-membered non-aromatic heterocyclic group are optionally substituted with one or more substituents selected from Group C}, or a 5- to 10-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group D, and the other symbols have the same meanings as above.] First, a method for producing compound (I-b) from compound (I-a) will be described. The reaction is usually carried out in a solvent. Examples of solvents used in the reaction include halogenated hydrocarbons such as dichloromethane, chloroform, and chlorobenzene (hereinafter referred to as halogenated hydrocarbons); nitriles such as acetonitrile and propionitrile (hereinafter referred to as nitriles); alcohols such as methanol and ethanol (hereinafter referred to as alcohols); acetic acid; water, and mixtures of two or more of these. Examples of oxidizing agents used in the reaction include sodium periodate, m-chloroperbenzoic acid (hereinafter referred to as mCPBA), and hydrogen peroxide. When hydrogen peroxide is used as the oxidizing agent, a base or catalyst may be added as necessary. Examples of bases used in the reaction include sodium carbonate. When a base is used in the reaction, the base is usually used in a ratio of 0.01 to 1 mole per mole of compound (I-a). Examples of catalysts used in the reaction include sodium tungstate. When a catalyst is used in the reaction, the catalyst is usually used in a ratio of 0.01 to 0.5 moles per mole of compound (I-a). In the reaction, an oxidizing agent is typically used in a ratio of 1 to 1.2 moles per mole of compound (I-a). The reaction temperature is typically within the range of -20 to 80°C. The reaction time is typically within the range of 0.1 to 12 hours. After completion of the reaction, water is added to the reaction mixture, which is then extracted with an organic solvent. The organic layer is washed, as necessary, with an aqueous solution of a reducing agent (e.g., sodium sulfite, sodium thiosulfate) and an aqueous solution of a base (e.g., sodium bicarbonate). Compound (I-b) can be obtained by drying and concentrating the organic layer.

[0036] Next, a method for producing compound (I-c) from compound (I-b) will be described. The reaction is typically carried out in a solvent. Examples of solvents used in the reaction include halogenated hydrocarbons, nitriles, alcohols, acetic acid, water, and mixtures of two or more of these. Examples of oxidizing agents used in the reaction include mCPBA and hydrogen peroxide. When hydrogen peroxide is used as the oxidizing agent, a base or catalyst may be added as necessary. Examples of bases used in the reaction include sodium carbonate. When a base is used in the reaction, the base is typically used in a ratio of 0.01 to 1 mole per mole of compound (I-b). Examples of catalysts used in the reaction include sodium tungstate. When a catalyst is used in the reaction, the catalyst is typically used in a ratio of 0.01 to 0.5 moles per mole of compound (I-b). The oxidizing agent is typically used in a ratio of 1 to 2 moles per mole of compound (I-b). The reaction temperature is typically within the range of -20 to 120°C. The reaction time is usually in the range of 0.1 to 12 hours. After completion of the reaction, water is added to the reaction mixture, which is then extracted with an organic solvent. The organic layer is washed, if necessary, with an aqueous solution of a reducing agent (e.g., sodium sulfite or sodium thiosulfate) and an aqueous solution of a base (e.g., sodium bicarbonate). The organic layer is dried and concentrated to obtain compound (I-c).

[0037] Compound (I-c) can also be produced in a one-step reaction (one-pot) by reacting compound (I-a) with an oxidizing agent. The reaction can be carried out using the oxidizing agent in a proportion of usually 2 to 5 moles per mole of compound (I-a) in accordance with the method for producing compound (I-c) from compound (I-b).

[0038] Production Method B A compound represented by formula (I-d) (hereinafter referred to as compound (I-d)) can be produced by reacting a compound represented by formula (B1) (hereinafter referred to as compound (B1)) with a compound represented by formula (M1) (hereinafter referred to as compound (M1)) in the presence of a base. [In the formula, X 51represents a chlorine atom or OS(O)Z, and other symbols have the same meanings as above.] The reaction is usually carried out in a solvent. Examples of solvents used in the reaction include hydrocarbons such as hexane, toluene, and xylene (hereinafter referred to as hydrocarbons); ethers such as methyl tert-butyl ether (hereinafter referred to as MTBE), tetrahydrofuran (hereinafter referred to as THF), and dimethoxyethane (hereinafter referred to as DME) (hereinafter referred to as ethers); halogenated hydrocarbons; amides such as dimethylformamide (hereinafter referred to as DMF) and N-methylpyrrolidone (hereinafter referred to as amides); esters such as methyl acetate and ethyl acetate (hereinafter referred to as esters); nitriles; water, and mixtures of two or more of these. Examples of the base used in the reaction include organic bases such as triethylamine and pyridine (hereinafter referred to as organic bases); alkali metal carbonates such as sodium carbonate and potassium carbonate (hereinafter referred to as alkali metal carbonates); alkali metal bicarbonates such as sodium bicarbonate and potassium bicarbonate (hereinafter referred to as alkali metal bicarbonates); alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, and cesium hydroxide (hereinafter referred to as alkali metal hydroxides); alkali metal hydrides such as lithium hydride and sodium hydride (hereinafter referred to as alkali metal hydrides); and alkali metal alkoxides such as sodium tert-butoxide and potassium tert-butoxide (hereinafter referred to as alkali metal alkoxides). In the reaction, compound (M1) is typically used in a ratio of 1 to 10 moles, and a base is typically used in a ratio of 1 to 10 moles, relative to 1 mole of compound (B1). The reaction temperature is typically within the range of −20 to 150° C. The reaction time is usually in the range of 0.1 to 120 hours. After completion of the reaction, the reaction mixture is mixed with water and then extracted with an organic solvent. The organic layer is subjected to post-treatments such as drying and concentration to obtain compound (I-d). Compound (M1) is a commercially available compound or can be produced using known methods.

[0039] Production Method B-1 The compound represented by formula (I-d-A) (hereinafter referred to as compound (I-d-A)) can be produced by reacting compound (B1) with a compound represented by formula (M1-A) (hereinafter referred to as compound (M1-A)) in the presence of a base. [In the formula, the symbols have the same meanings as defined above.] The reaction can be carried out using compound (M1-A) instead of compound (M1) in accordance with Production Method B. Compound (M1-A) is a commercially available compound, or can be produced by a known method, for example, the method described in Synthesis, 1987, 1, 72-73.

[0040] Production Method C Compound (I-a) can be produced by reacting a compound represented by formula (B2) (hereinafter referred to as compound (B2)) with a compound represented by formula (M2) (hereinafter referred to as compound (M2)) in the presence of a base. [In the formula, X 52 represents a halogen atom, a mesyloxy group, or a triflyloxy group, and the other symbols have the same meanings as above.] The reaction is usually carried out in a solvent. Examples of the solvent used in the reaction include alcohols, nitriles, ethers, hydrocarbons, amides, water, and mixtures of two or more of these. Examples of the base used in the reaction include alkali metal hydrides, alkali metal carbonates, organic bases, sodium hydride, and tripotassium phosphate. X 52is a bromine atom, an iodine atom, or a triflyloxy group, a metal catalyst and / or a ligand may be added as necessary. Examples of the metal catalyst used in the reaction include palladium catalysts such as palladium(II) acetate and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride; nickel catalysts such as bis(cyclooctadiene)nickel(0) and nickel(II) chloride; and copper catalysts such as copper(I) iodide and copper(I) chloride. When a metal catalyst is used in the reaction, the metal catalyst is usually used in a ratio of 0.01 to 1 mole per mole of compound (B2). Examples of the ligand used in the reaction include triphenylphosphine, xantphos, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 1,1'-bis(diphenylphosphino)ferrocene, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 1,2-bis(diphenylphosphino)ethane, 2,2'-bipyridine, 2-aminoethanol, 8-hydroxyquinoline, and 1,10-phenanthroline. When a ligand is used in the reaction, the ligand is typically used in a ratio of 0.01 to 1 mole per mole of compound (B2). In the reaction, compound (M2) is typically used in a ratio of 1 to 10 moles, and a base is typically used in a ratio of 1 to 10 moles per mole of compound (B2). The reaction temperature is usually in the range of -20°C to 200°C. The reaction time is usually in the range of 0.1 to 72 hours. After completion of the reaction, compound (I-a) can be obtained by post-treatment operations such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer. Compound (M2) is known or can be produced by a method similar to that known.

[0041] Production Method D Compound (Ic) can also be produced by reacting compound (B2) with a compound represented by formula (M3) (hereinafter referred to as compound (M3)). [In the formula, the symbols have the same meanings as defined above.] The reaction is usually carried out in a solvent. Examples of solvents used in the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, nitriles, dimethyl sulfoxide (hereinafter referred to as DMSO), water, and mixtures of two or more of these. In the reaction, compound (M3) is usually used in a ratio of 1 to 3 moles per mole of compound (B2). The reaction temperature is usually in the range of 0 to 150°C. The reaction time is usually in the range of 0.1 to 48 hours. After completion of the reaction, compound (I-c) can be obtained by adding water to the reaction mixture, extracting with an organic solvent, and performing post-treatment operations such as drying and concentrating the organic layer. Compound (M3) is either known or can be produced according to a known method.

[0042] Production Method E Compound (I-a) can also be produced by reacting a compound represented by formula (B3) (hereinafter referred to as compound (B3)) with a compound represented by formula (M4) (hereinafter referred to as compound (M4)) in the presence of a base. [In the formula, X 53represents a chlorine atom, a bromine atom, an iodine atom, a mesyloxy group, or a triflyloxy group, and other symbols have the same meanings as above.] The reaction is usually carried out in a solvent. Examples of solvents used in the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, water, and mixtures of two or more of these. Examples of bases used in the reaction include organic bases, alkali metal carbonates, alkali metal hydrogencarbonates, sodium hydride, and tripotassium phosphate. If necessary, a metal catalyst and / or a ligand may be used in the reaction. Examples of metal catalysts used in the reaction include copper catalysts such as copper(I) iodide, copper(I) bromide, copper(I) chloride, copper(I) oxide, copper(I) trifluoromethanesulfonate benzene complex, tetrakis(acetonitrile)copper(I) hexafluorophosphate, and copper(I) 2-thiophenecarboxylate; nickel catalysts such as bis(cyclooctadiene)nickel(0) and nickel(II) chloride; and palladium catalysts such as palladium acetate, tris(dibenzylideneacetone)dipalladium(0), tetrakis(triphenylphosphine)palladium(0), and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride. When a metal catalyst is used in the reaction, the metal catalyst is usually used in a ratio of 0.01 to 1 mole per mole of compound (B3). Examples of the ligand used in the reaction include triphenylphosphine, xantphos, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 1,1'-bis(diphenylphosphino)ferrocene, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 1,2-bis(diphenylphosphino)ethane, 2,2'-bipyridine, 2-aminoethanol, 8-hydroxyquinoline, 1,10-phenanthroline, trans-1,2-cyclohexanediamine, trans-N,N'-dimethylcyclohexane-1,2-diamine, N,N'-dimethylethylenediamine, and N,N-dimethylglycine hydrochloride.When a ligand is used in the reaction, the ligand is typically used in a ratio of 0.01 to 1 mole per mole of compound (B3). In the reaction, compound (M4) is typically used in a ratio of 1 to 10 moles, and a base is typically used in a ratio of 1 to 10 moles per mole of compound (B3). The reaction temperature is typically in the range of 0 to 150°C. The reaction time is typically in the range of 0.1 to 48 hours. After completion of the reaction, compound (I-a) can be obtained by adding water to the reaction mixture, extracting with an organic solvent, and performing post-treatments such as drying and concentrating the organic layer. Compound (M4) is either known or can be produced according to known methods.

[0043] Production Method F A compound represented by formula (I-e) (hereinafter referred to as compound (I-e)) can be produced by reacting a compound represented by formula (B4) (hereinafter referred to as compound (B4)) with a compound represented by formula (M5) (hereinafter referred to as compound (M5)) in the presence of a base. [In the formula, R 14X and R 15X are the same or different and represent a C1-C6 alkyl group, a methyl group substituted with one or more fluorine atoms, or a C1-C2 alkyl group (the C1-C2 alkyl group is substituted with a methoxy group or an ethoxy group), or R 14X and R 15Xmay, together with the nitrogen atom to which they are bonded, form a 3- to 8-membered non-aromatic heterocycle (the 3- to 8-membered non-aromatic heterocycle may be substituted with one or more substituents selected from Group C) or a 5- to 10-membered aromatic heterocycle optionally substituted with one or more substituents selected from Group D, and other symbols have the same meanings as above.] The reaction is usually carried out in a solvent. Examples of solvents used in the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, water, and mixtures of two or more thereof. Examples of bases used in the reaction include organic bases, alkali metal carbonates, alkali metal hydrogencarbonates, sodium hydride, and tripotassium phosphate. In the reaction, compound (M5) is usually used in a ratio of 1 to 10 moles, and a base is usually used in a ratio of 1 to 10 moles, per mole of compound (B4). The reaction temperature is usually in the range of 0 to 150°C. The reaction time is usually in the range of 0.1 to 48 hours. After the reaction is complete, compound (I-e) can be obtained by post-treatment such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer. Compound (M5) is known or can be produced by a method similar to that known.

[0044] Production Method F-1 The compound represented by formula (I-e-A) (hereinafter referred to as compound (I-e-A)) can be produced by a step (hereinafter referred to as step (1)) of reacting compound (B3) with an oxidizing agent to obtain a compound represented by formula (B3-A) (hereinafter referred to as compound (B3-A)), and a step (hereinafter referred to as step (2)) of reacting compound (B3-A) with compound (M5) in the presence of a base. [In the formula, the symbols have the same meanings as above.] Step (1) can be carried out in accordance with, for example, the method described in WO 2016 / 204096, the method described in Tetrahedron Letters, 2017, 58, 2244-2247, the method described in Synthesis, 1987, 1, 72-73, the method described in Organic Letter, 2019, 21, 1484-1487, or the method described in Bioorganic & Medicinal Chemistry Letter, 2013, 23, 3723-3727. Step (2) can be carried out in accordance with Production Method F using compound (B3-A) instead of compound (B4).

[0045] Production Method G A compound represented by formula (If) (hereinafter referred to as compound (If)) can be produced by reacting a compound represented by formula (B5) (hereinafter referred to as compound (B5)) with a compound represented by formula (M6) (hereinafter referred to as compound (M6)) in the presence of a palladium catalyst and a base. [wherein QB represents a group represented by Q1, a group represented by Q3, a group represented by Q4, a group represented by Q5, or a group represented by Q6; X 54 represents a chlorine atom, a bromine atom, an iodine atom, or a triflyloxy group; Met 1 represents B(OH)2 or a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group, and R 1X represents a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A, and among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group, Met 1or any atom not bonded to QB may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B1 (provided that when QB is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) {among the atoms constituting the 5- to 7-membered aromatic heterocyclic group (provided that when QB is a group represented by Q6, 1H-pyrazol-3-yl group is excluded), Met 1 or any two adjacent atoms not bonded to QB may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the two adjacent atoms} (provided that R 1X In Met 1 or the atom bonded to QB is a carbon atom), and other symbols have the same meanings as above.] The reaction is usually carried out in a solvent. Examples of solvents used in the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, DMSO, water, and mixtures of two or more of these. Examples of palladium catalysts used in the reaction include palladium(II) acetate and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride. Examples of bases used in the reaction include organic bases, alkali metal carbonates, alkali metal bicarbonates, sodium fluoride, and tripotassium phosphate. In the reaction, compound (M6) is usually used in a ratio of 0.5 to 2 moles, palladium catalyst is usually used in a ratio of 0.01 to 0.3 moles, and base is usually used in a ratio of 1 to 10 moles, relative to 1 mole of compound (B5). The reaction temperature is usually in the range of 0 to 150°C. The reaction time is usually in the range of 0.1 to 120 hours. After the reaction is complete, compound (If) can be obtained by post-treatment such as adding water to the reaction mixture, extracting with an organic solvent, and drying and concentrating the organic layer. Compound (M6) is known or can be produced according to known methods.

[0046] Production Method H Compound (If) can also be produced by reacting a compound represented by formula (B6) (hereinafter referred to as compound (B6)) with a compound represented by formula (M7) (hereinafter referred to as compound (M7)) in the presence of a palladium catalyst and a base. [In the formula, R 1Z represents a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group A, and X among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group is 54 or any atom not bonded to QB may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B1 (provided that when QB is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) {among the atoms constituting the 5- to 7-membered aromatic heterocyclic group, X 54 or any two adjacent atoms not bonded to QB may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the two adjacent atoms} (provided that R 1Z In this case, X 54 or the atom bonded to QB is a carbon atom), and other symbols have the same meanings as above.] The reaction can be carried out in accordance with Production Method G, using compound (M7) instead of compound (B5) and compound (B6) instead of compound (M6). Compound (M7) is known or can be produced in accordance with a known method.

[0047] Production Method I A compound represented by formula (I-g) (hereinafter referred to as compound (I-g)) can be produced by reacting a compound represented by formula (B7) (hereinafter referred to as compound (B7)) with a compound represented by formula (M8) (hereinafter referred to as compound (M8)) in the presence of a base. [In the formula, R 1Wrepresents a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group A, and X among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group is 52 or any atom not bonded to the pyrazole represented by compound (I-g) may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from group B1 {X among the atoms constituting the 5- to 7-membered aromatic heterocyclic group 52 or any two adjacent atoms not bonded to the pyrazole represented by compound (I-g) may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the two adjacent atoms (provided that R 1W In this case, X 52 or the atom bonded to the pyrazole in compound (I-g) is a carbon atom), and other symbols have the same meanings as above.] The reaction can be carried out in accordance with Production Method C, using compound (B7) instead of compound (M2) and compound (M8) instead of compound (B2). Compound (M8) is known or can be produced in accordance with a known method.

[0048] Production Method J A compound represented by formula (I-h) (hereinafter referred to as compound (I-h)) can be produced by reacting a compound represented by formula (B8) (hereinafter referred to as compound (B8)) with a compound represented by formula (M9) (hereinafter referred to as compound (M9)) in the presence of a base. [In the formula, R 1Yrepresents a 3- to 10-membered non-aromatic heterocyclic group optionally substituted by one or more substituents selected from Group A {among the atoms constituting the 3- to 10-membered non-aromatic heterocyclic group, any atom not bonded to a hydrogen atom or Q shown in compound (M9) may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted by one or more substituents selected from Group B1 (provided that, when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) {among the atoms constituting the 5- to 7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to a hydrogen atom or Q shown in compound (M9) may form another benzene ring, C4-C7 alicyclic hydrocarbon, 4- to 7-membered non-aromatic heterocycle, or 5- to 7-membered aromatic heterocycle containing the two adjacent atoms} (provided that R 1Y (wherein the hydrogen atom or the atom bonded to QB in compound (M9) is a nitrogen atom), and other symbols have the same meanings as above.) The reaction can be carried out in accordance with Production Method C, using compound (B8) instead of compound (B2) and compound (M9) instead of compound (M2). Compound (M9) is known or can be produced in accordance with a known method.

[0049] Production Method K The compound represented by formula (I-i) (hereinafter referred to as compound (I-i)) can be produced by reacting compound (B5) with a compound represented by formula (M10) (hereinafter referred to as compound (M10)) in the presence of a palladium catalyst and a base. [In the formula, X 55 represents an oxygen atom or a sulfur atom, and RB 1 and R.B. 2 are the same or different and represent one substituent selected from Group B1 or a hydrogen atom; 1 and R.B. 2may, together with the carbon atom to which they are attached, form a benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle, and other symbols have the same meanings as above.] The reaction can be carried out in accordance with Production Method G using Compound (M10) instead of Compound (M6). Compound (M10) is known or can be produced in accordance with a known method.

[0050] Production Method L The compound represented by formula (I-j) (hereinafter referred to as compound (I-j)) can be produced by reacting compound (B5) with a compound represented by formula (M11) (hereinafter referred to as compound (M11)) in the presence of a metal catalyst and a base. [In the formula, the symbols have the same meanings as defined above.] The reaction is usually carried out in a solvent. Examples of solvents used in the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, and mixtures of two or more of these. Examples of metal catalysts used in the reaction include bis(triphenylphosphine)palladium(II) dichloride. If necessary, a metal catalyst such as copper(I) iodide may be additionally used in the reaction. Examples of bases used in the reaction include organic bases. In the reaction, compound (M11) is usually used in a ratio of 1 to 10 moles, a metal catalyst is usually used in a ratio of 0.01 to 1 mole, and a base is usually used in a ratio of 1 to 10 moles, relative to 1 mole of compound (B5). The reaction temperature is usually within the range of 0 to 150°C. The reaction time is usually within the range of 0.1 to 120 hours. After completion of the reaction, compound (I-j) can be obtained by post-treatment such as concentration and drying. The compound (M11) is known or can be produced according to a known method.

[0051] Production Method M The compound represented by formula (B7-2) (hereinafter referred to as compound (B7-2)) can be produced by a step (hereinafter referred to as step (B7-1)) of reacting compound (B7) with hydroxylamine-O-sulfonic acid to obtain a compound represented by formula (B7-1) (hereinafter referred to as compound (B7-1)), and a step (hereinafter referred to as step (B7-2)) of reacting compound (B7-1) with compound (B7-3) in the presence of a base. [In the formula, nx represents an integer of 1 to 8, and the other symbols have the same meanings as above.] Step (B7-1) can be carried out, for example, according to the method described in Journal of Organic Chemistry, 2021, 86(19), 13465-13474, the method described in Organic & Biomolecular Chemistry, 2003, 1(23), 4268-4274, or the method described in Organic Letters, 2018, 20(9), 2628-2631. Step (B7-2) is usually carried out in a solvent. Examples of solvents used in the reaction include hydrocarbons, ethers, halogenated hydrocarbons, amides, esters, nitriles, water, and mixtures of two or more thereof. Examples of bases used in the reaction include organic bases, alkali metal carbonates, alkali metal bicarbonates, sodium hydride, and tripotassium phosphate. In the reaction, compound (B7-3) is typically used in a ratio of 1 to 10 moles, and base is typically used in a ratio of 1 to 10 moles, per mole of compound (B7-1). The reaction temperature is typically in the range of 0 to 150°C. The reaction time is typically in the range of 0.1 to 48 hours. After completion of the reaction, compound (B7-2) can be obtained by adding water to the reaction mixture, extracting with an organic solvent, and performing post-treatment operations such as drying and concentrating the organic layer. Compound (B7-3) is either a commercially available compound or can be produced according to known methods.

[0052] Production Method N The compound represented by formula (B7-4) (hereinafter referred to as compound (B7-4)) can be produced by reacting compound (B7) with a compound represented by formula (B7-5) (hereinafter referred to as compound (B7-5)) in the presence of a metal catalyst and a base. [In the formula, X 56 represents a chlorine atom, a bromine atom, or an iodine atom, and other symbols have the same meanings as above.] The reaction can be carried out, for example, according to the method described in Synthesis, 2011, 5, 816-820 or the method described in Journal of Organic Chemistry, 2010, 75, 3, 980-983.

[0053] Reference Production Method A The compound represented by formula (B1-a) (hereinafter referred to as compound (B1-a)) can be produced by reacting a compound represented by formula (C1) (hereinafter referred to as compound (C1)) with hydrazine. [In the formula, X 61 represents a hydroxy group, a dimethylamino group, or a diethylamino group, and other symbols have the same meanings as above.] The reaction can be carried out, for example, according to the method described in Bioorganic and Medicinal Chemistry, 2014, 22, 4189. or J. Med. Chem., 2003, 46, 5416.

[0054] Reference Production Method B The compound represented by formula (C1-a) (hereinafter referred to as compound (C1-a)) can be produced by reacting a compound represented by formula (C2) (hereinafter referred to as compound (C2)) with a compound represented by formula (M21) (hereinafter referred to as compound (M21)). [In the formula, X 62 and X 63 are the same or different and represent a methyl group or an ethyl group; X 64 and X 65 are the same or different and represent a C1-C4 alkyl group or a benzyl group, and other symbols have the same meanings as above.] The reaction can be carried out, for example, according to the method described in European Journal of Medicinal Chemistry, 2011, 46, 5817. Compound (C2) and compound (M21) are commercially available compounds or can be produced using known methods.

[0055] Reference Production Method C The compound represented by formula (C1-b) (hereinafter referred to as compound (C1-b)) can be produced by reacting compound (C2) with a compound represented by formula (M22) (hereinafter referred to as compound (M22)) in the presence of a base. [In the formula, the symbols have the same meanings as defined above.] The reaction can be carried out in accordance with the method described in, for example, J. Am. Chem. Soc., 2017, 139, 2421. Compound (M22) is a commercially available compound or can be produced using a known method.

[0056] Reference Production Method D The compound represented by formula (B2-a) (hereinafter referred to as compound (B2-a)) can be produced by reacting a compound represented by formula (C3) (hereinafter referred to as compound (C3)) with a compound represented by formula (M23) (hereinafter referred to as compound (M23)) in the presence of a palladium catalyst and a base. [wherein QC represents a group represented by Q3, a group represented by Q4, a group represented by Q5, or a group represented by Q6; R 1XA represents a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from Group A, and among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group, Met 1 or any atom not bonded to QC may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B1 (provided that when QC is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) {among the atoms constituting the 5- to 7-membered aromatic heterocyclic group, Met 1 or any two adjacent atoms not bonded to QC may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the adjacent two atoms} (provided that R 1XA In Met 1or the atom bonded to QC is a carbon atom), and other symbols have the same meanings as above.] The reaction can be carried out in accordance with Production Method G by using compound (C3) instead of compound (B5) and compound (M23) instead of compound (M6). Compound (C3) and compound (M23) are known or can be produced in accordance with known methods.

[0057] Reference Production Method E The compound represented by formula (B2-b) (hereinafter referred to as compound (B2-b)) can be produced by reacting a compound represented by formula (C4) (hereinafter referred to as compound (C4)) with a compound represented by formula (M24) (hereinafter referred to as compound (M24)) in the presence of a palladium catalyst and a base. [In the formula, R 1XB represents a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group A, and X among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group is 54 or any atom not bonded to QC may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, or a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from Group B1 (provided that when QC is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) {among the atoms constituting the 5- to 7-membered aromatic heterocyclic group, X 54 or any two adjacent atoms not bonded to QC may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the adjacent two atoms} (provided that R 1XB In this case, X 54 or the atom bonded to QC is a carbon atom), and other symbols have the same meanings as above.] The reaction can be carried out in accordance with Production Method G, using compound (M24) instead of compound (B5) and compound (C4) instead of compound (M6). Compound (C4) and compound (M24) are known or can be produced in accordance with known methods.

[0058] Reference Production Method E-1 The compound represented by formula (B2-c) (hereinafter referred to as compound (B2-c)) can be produced by reacting a compound represented by formula (C3-A) (hereinafter referred to as compound (C3-A)) with compound (M8) in the presence of a base. [wherein the symbols have the same meanings as defined above.] The reaction can be carried out according to Production Method C, except that compound (C3-A) is used in place of compound (M2) and compound (M8) is used in place of compound (B2).

[0059] Reference Production Method F Compound (B3) can be produced by reacting compound (B2) with a sulfurizing agent in the presence of a base. [wherein the symbols have the same meanings as defined above.] The reaction can be carried out according to Production Method C, except that a sulfurizing agent such as hydrogen sulfide is used in place of Compound (M2).

[0060] Reference Production Method G Compound (B4) can be produced from a compound represented by formula (C5) (hereinafter referred to as compound (C5)). [In the formula, X 64 represents SH or S(O)OH, and other symbols have the same meanings as above.] The reaction can be carried out in accordance with, for example, the method described in WO 2016 / 204096 or the method described in Tetrahedron Letters, 2017, 58, 2244-2247. Compound (C5) is known or can be produced in accordance with a known method.

[0061] Reference Production Method H The compound represented by formula (B8-a) (hereinafter referred to as compound (B8-a)) can be produced by reacting compound (C3) with compound (M2) in the presence of a base. [wherein the symbols have the same meanings as defined above.] The reaction can be carried out according to Production Method C, except that compound (C3) is used in place of compound (B2).

[0062] Reference Production Method I A compound represented by formula (B8-b) (hereinafter referred to as compound (B8-b)) or a compound represented by formula (B8-c) (hereinafter referred to as compound (B8-c)) can be produced by reacting compound (B8-a) with an oxidizing agent. [In the formula, the symbols have the same meanings as defined above.] The reaction can be carried out in accordance with Production Method A, except that compound (B8-a) is used in place of compound (I-a) and compound (B8-b) is used in place of compound (I-b).

[0063] Reference Production Method J The compound represented by formula (B6-a) (hereinafter referred to as compound (B6-a)) can be produced by reacting compound (B5) with bis(pinacolato)diboron in the presence of a base and a palladium catalyst. [wherein the symbols have the same meanings as defined above.] The reaction can be carried out according to Production Method G, except that bis(pinacolato)diboron is used in place of compound (M6).

[0064] Reference Production Method K The compound represented by formula (B7-a) (hereinafter referred to as compound (B7-a)) can be produced by carrying out a first step of reacting a compound represented by formula (C6) (hereinafter referred to as compound (C6)) with butyllithium or isopropylmagnesium chloride, followed by reaction with a disulfide or a thiosulfonic acid ester to obtain a compound represented by formula (C7) (hereinafter referred to as compound (C7)), and a second step of reacting compound (C7) with an acid such as hydrochloric acid, trifluoroacetic acid, etc., or a base such as potassium hydroxide, sodium methoxide, etc. [In the formula, the symbols have the same meanings as defined above.] These reactions can be carried out according to the method described in WO 2008 / 129054 or J. Med. Chem., 2016, 59, 2760. Compound (C6) is a commercially available compound, or can be produced according to the method described in J. Med. Chem., 2016, 59, 2760.

[0065] Reference Production Method M A compound represented by formula (B7-c) (hereinafter referred to as compound (B7-c)) or a compound represented by formula (B7-b) (hereinafter referred to as compound (B7-b)) can be produced by reacting compound (B7-a) with an oxidizing agent. [In the formula, the symbols have the same meanings as defined above.] The reaction can be carried out in accordance with Production Method A, except that compound (B7-a) is used in place of compound (I-a) and compound (B7-b) is used in place of compound (I-b).

[0066] Reference Production Method N The compound represented by formula (B8-A) (hereinafter referred to as compound (B8-A)) can be produced by reacting a compound represented by formula (B1-A) (hereinafter referred to as compound (B1-A)) with a compound represented by formula (M1-A2) (hereinafter referred to as compound (M1-A2)) in the presence of a base. [In the formula, the symbols have the same meanings as defined above.] The reaction can be carried out in accordance with Production Method B, using compound (M1-A2) instead of compound (M1). Compound (M1-A2) is a commercially available compound, or can be produced in accordance with the production method for compound (M1-A). Compound (B1-A) is a commercially available compound, or can be produced using a known method.

[0067] The compound of the present invention or compound W of the present invention can be mixed or used in combination with one or more components selected from the group consisting of Group (a), Group (b), Group (c), and Group (d) below (hereinafter referred to as the present component). The term "mixed or used in combination" means that the compound of the present invention or compound W of the present invention and the present component are used simultaneously, separately, or with a time interval. When the compound of the present invention or compound W of the present invention and the present component are used simultaneously, the compound of the present invention or compound W of the present invention and the present component may be contained in separate preparations or in a single preparation. One aspect of the present invention is a composition containing one or more components selected from the group consisting of Group (a), Group (b), Group (c), and Group (d) (i.e., the present component), and the compound of the present invention. Another aspect of the present invention is a composition (hereinafter referred to as Composition A) containing one or more components selected from the group consisting of Group (a), Group (b), Group (c), and Group (d) (i.e., the present component), and compound W of the present invention.

[0068] Group (a) includes acetylcholinesterase inhibitors (e.g., carbamate insecticides, organophosphate insecticides), GABAergic chloride channel blockers (e.g., phenylpyrazole insecticides), sodium channel modulators (e.g., pyrethroid insecticides), nicotinic acetylcholine receptor competitive modulators (e.g., neonicotinoid insecticides), nicotinic acetylcholine receptor allosteric modulators, glutamate-gated chloride channel allosteric modulators (e.g., macrolide insecticides), juvenile hormone mimics, multisite inhibitors, chordotonal organ TRPV channel modulators, mite growth inhibitors, microbial insect midgut membrane disruptors, mitochondrial ATP synthase inhibitors, oxidative phosphorylation uncouplers, nicotinic acetylcholine receptor channel blockers (e.g., nereistoxin insecticides), chitin biosynthesis inhibitors, molting inhibitors, ecdysone receptor agonists, octopamine receptor agonists, mitochondrial electron transport chain complexes I and II, The group consisting of inhibitors of classes III and IV, voltage-dependent sodium channel blockers, acetyl-CoA carboxylase inhibitors, ryanodine receptor modulators (e.g., diamide insecticides), chordotonal organ modulators, microbial insecticides, and other insecticidal, acaricidal, and nematicidal active ingredients, which are described in the IRAC mechanism-based classification.

[0069] Group (b) consists of nucleic acid synthesis inhibitors (e.g., phenylamide fungicides, acylamino acid fungicides), cell division and cytoskeleton inhibitors (e.g., MBC fungicides), respiratory inhibitors (e.g., QoI fungicides, QiI fungicides), amino acid synthesis and protein synthesis inhibitors (e.g., anilinopyrimidine fungicides), signal transduction inhibitors, lipid synthesis and membrane synthesis inhibitors, sterol biosynthesis inhibitors (e.g., DMI fungicides such as triazoles), cell wall biosynthesis inhibitors, melanin synthesis inhibitors, plant defense inducers, multisite contact-active fungicides, microbial fungicides, and other fungicidal active ingredients. These are listed in the FRAC classification based on the mechanism of action.

[0070] Group (c) is a group of plant growth regulators (including mycorrhizal fungi and rhizobia).

[0071] Group (d) is a group of repellent ingredients.

[0072] Examples of combinations of the present component and compound W of the present invention are described below. For example, alanycarb + SX refers to a combination of alanycarb and SX. The abbreviation SX refers to any one compound W of the present invention selected from the compound group SX1 to SX2159. The present components described below are all known components and can be obtained from commercially available preparations or produced by known methods. When the present component is a microorganism, it can also be obtained from a bacterial depository. The number in parentheses indicates the CAS RN (registered trademark).

[0073] Combinations of the present ingredient of the above group (a) with compound W of the present invention: abamectin + SX, acephate + SX, acequinocyl + SX, acetamiprid + SX, acetoprole + SX, acrinathrin + SX, acinonapyr + SX, afidopyropen + SX, afoxolaner + SX, alanycarb + SX, aldicarb + SX, allethrin + SX, alpha-cypermethrin + SX, alpha-endosulfan + SX, aluminum phosphide + SX, Amitraz + SX, azadirachtin + SX, azamethiphos + SX, azinphos-ethyl + SX, azinphos-methyl + SX, azocyclotin + SX, Celastrus angulatus bark + SX, bendiocarb + SX, benfluthrin + SX, benfuracarb + SX, bensultap + SX, bentiofluormin + SX, benzoximate + SX, benzpyrimoxan + SX, beta-cyfluthrin + SX SX, beta-cypermethrin + SX, bifenazate + SX, bifenthrin + SX,Bioallethrin + SX, bioresmethrin + SX, bistrifluron + SX, bisulfufen + SX, borax + SX, boric acid + SX, broflanilide + SX, bromopropylate + SX, buprofezin + SX, butocarboxim + SX, butoxycarboxim + SX, cadusafos + SX, calcium phosphide + SX, carbaryl + SX, carbofuran + SX, carbosulfan + SX, Cartap hydrochloride + SX, cartap + SX, chinomethionate + SX, chlorantraniliprole + SX, chlordane + SX, chlorethoxyfos + SX, chlorfenapyr + SX, chlorfenvinphos + SX, chlorfluazuron + SX, chlormephos + SX, chloropicrin + SX, chlorpyrifos + SX, chlorpyrifos-methyl + SX, chromafenozide + SX, clofentezine + SX, clothianidin + SX, concanamycin A + SX, coumaphos + SX, cryolite + SX,Cyanophos + SX, cyantraniliprole + SX, cybenzoxasulfyl + SX, cyclaniliprole + SX, cyclobutrifluram + SX, cycloprothrin + SX, cycloxaprid + SX, cyenopyrafen + SX, cyetpyrafen + SX, cyflumetofen + SX, cyfluthrin + SX, cyhalodiamide + SX, cyhalothrin + SX, cyhexatin + SX, cypermethrin + SX, Cyphenothrin + SX, cyproflanilide + SX, cyromazine + SX, dazomet + SX, deltamethrin + SX, demeton-S-methyl + SX, diafenthiuron + SX, diazinon + SX, dichlorvos + SX, dichloromezotiaz + SX, dicofol + SX, dicrotophos + SX, diflovidazin + SX, diflubenzuron + SX, dimefluthrin + SX, Dimethoate + SX, dimethylvinphos + SX, dimpropyridaz + SX, dinotefuran + SX, disodium octaborate + SX,Disulfoton + SX, DNOC (2-methyl-4,6-dinitrophenol) + SX, doramectin + SX, dried leaves of Dryopteris filix (mas) + SX, emamectin benzoate + SX, empenthrin + SX, endosulfan + SX, EPN (O-ethyl O-(4-nitrophenyl) phenylphosphonothioate) + SX, epsilon-metofluthrin + SX, epsilon-momfluorothrin + SX, esfenvalerate + SX, ethiofencarb + SX, ethion + SX, Ethiprole + SX, ethoprophos + SX, etofenprox + SX, etoxazole + SX, Artemisia absinthium extract + SX, Azadirachta indica extract + SX, Cassia nigricans extract + SX, Clitoria ternatea extract + SX, Symphytum officinale extract + SX, Chenopodium ambrosioides extract + SX, Tansy extract + SX, Urtica dioica extract + SX, Mistletoe extract (extract of Viscum album) + SX,Famphur + SX, fenamiphos + SX, fenazaquin + SX, fenbutatin oxide + SX, fenitrothion + SX, fenmezoditiaz + SX, fenobucarb + SX, fenoxycarb + SX, fenpropathrin + SX, fenpyroximate + SX, fenthion + SX, fenvalerate + SX, fipronil + SX, flometoquin + SX, flonicamid + SX, Fluacrypyrim + SX, fluazaindolizine + SX, fluazuron + SX, flubendiamide + SX, fluchlordiniliprole + SX, flucycloxuron + SX, flucythrinate + SX, fluensulfone + SX, flufenprox + SX, flufenoxuron + SX, flufiprole + SX, flumethrin + SX, flupentiofenox + SX, flupyradifurone + SX, flupyrimin + SX, flupyroxystrobin + SX, fluralaner + SX, fluvalinate + SX, fluxametamide + SX,Formetanate + SX, fosthiazate + SX, furamethrin + SX, furathiocarb + SX, gamma-cyhalothrin + SX, GS-omega / kappa HXTX-Hv1a peptide + SX, halfenprox + SX, halofenozide + SX, heptafluthrin + SX, heptenophos + SX, hexaflumuron + SX, hexythiazox + SX, potassium salt of hop beta acid + SX, hydramethylnon + SX, hydroprene + SX, imicyafos + SX, imidacloprid + SX, imidaclothiz + SX, imiprothrin + SX, indazapyroxamet + SX, indoxacarb + SX, isocycloseram + SX, isofenphos + SX, isoflualanam + SX, isoprocarb + SX, isopropyl-O-(methoxyaminothiophosphoryl) salicylate + SX, Isoxathion + SX, Ivermectin + SX, Kadethrin + SX, Kappa-tefluthrin + SX, Kappa-bifenthrin + SX,Kinoprene + SX, lambda-cyhalothrin + SX, ledprona + SX, lenoremycin + SX, lepimectin + SX, lime sulfur + SX, lotilaner + SX, lufenuron + SX, machine oil + SX, malathion + SX, mecarbam + SX, meperfluthrin + SX, metaflumizone + SX, metam + SX, methamidophos + SX, methidathion + SX, Methiocarb + SX, methomyl + SX, methoprene + SX, methoxychlor + SX, methoxyfenozide + SX, methyl bromide + SX, metofluthrin + SX, metolcarb + SX, metoxadiazone + SX, mevinphos + SX, milbemectin + SX, milbemycin oxime + SX, mivorilaner + SX, modoflaner + SX, momfluorothrin + SX, monocrotophos + SX, Moxidectin + SX, Naled + SX, Nicofluprole + SX, Nicotine + SX, Nicotine sulfate + SX, Nitenpyram + SX,Novaluron + SX, Noviflumuron + SX, Chenopodium anthelminticum seed oil + SX, Omethoate + SX, Oxamyl + SX, Oxazosulfyl + SX, Oxydemeton-methyl + SX, Parathion + SX, Parathion-methyl + SX, Permethrin + SX, Phenothrin + SX, Phenthoate + SX, Phorate + SX, Phosalone + SX, Phosmet + SX, Phosphamidon + SX Phosphine + SX, phoxim + SX, pioxaniliprole + SX, piperflanilide + SX, pirimicarb + SX, pirimiphos-methyl + SX, prallethrin + SX, profenofos + SX, profluthrin + SX, propargite + SX, propetamphos + SX, propoxur + SX, propylene glycol alginate + SX, prothiofos + SX, pyflubumide + SX, pymetrozine + SX, Pyraclofos + SX, pyrethrins + SX, pyridaben + SX, pyridalyl + SX,Pyridaphenthion + SX, pyrifluquinazone + SX, pyrimidifen + SX, pyriminostrobin + SX, pyriprole + SX, pyriproxyfen + SX, quinalphos + SX, resmethrin + SX, rotenone + SX, ryanodine + SX, sarolaner + SX, selamectin + SX, sigma-cypermethrin + SX, silafluofen + SX, sodium borate + SX, sodium metaborate metaborate + SX, spidoxamat + SX, spinetoram + SX, spinosad + SX, spirobudifen + SX, spirodiclofen + SX, spiromesifen + SX, spiropidione + SX, spirotetramat + SX, sulfiflumin + SX, sulfluramid + SX, sulfotep + SX, sulfoxaflor + SX, sulfur + SX, sulfuryl fluoride + SX, tartar emetic + SX, tau-fluvalinate + SX, tebufenozide + SX, tebufenpyrad + SX, tebupirimfos + SX,Teflubenzuron + SX, tefluthrin + SX, temephos + SX, terbufos + SX, terpene constituents of the extract of Chenopodium ambrosioides near ambrosioides + SX, tetrachlorantraniliprole + SX, tetrachlorvinphos + SX, tetradifon + SX, tetramethrin + SX, tetramethylfluthrin + SX, tetraniliprole + SX, theta-cypermethrin + SX, thiacloprid + SX, Thiamethoxam + SX, thiocyclam + SX, thiodicarb + SX, thiofanox + SX, thiometon + SX, thiosultap disodium + SX, thiosultap monosodium + SX, tiapyrachlor + SX, tigolaner + SX, thioantraniliprole + SX, tioxazafen + SX, tolfenpyrad + SX, tralomethrin + SX, transfluthrin + SX, triazamate + SX, Triazophos + SX, Trichlorfon + SX,Trifluenfuronate + SX, triflumezopyrim + SX, triflumuron + SX, trimethacarb + SX, tyclopyrazoflor + SX, umifoxolaner + SX, vadescana + SX, vamidothion + SX, Quassia amara wood extract + SX, 3,5-dimethylphenyl N-methylcarbamate (XMC) + SX, xylylcarb + SX, zeta-cypermethrin + SX, zinc phosphide + SX, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-(1-oxothietan-3-yl)benzamide (1241050-20-3) + SX, 3-methoxy-N-(5-{5-(trifluoromethyl)-5-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2-oxazol-3-yl}indan-1-yl)propanamide (1118626-57-5) + SX, N-{4-chloro-3-[(1-cyanocyclopropyl)carbamoyl]phenyl}-1-methyl-4-(methanesulfonyl)-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazole-3-carboxamide (1400768-21-9) + SX, N-[3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl]-2-(methanesulfonyl)propanamide (2396747-83-2) + SX, N-[4-chloro-2-(pyridin-3-yl)-1,3-thiazol-5-yl]-N-ethyl-3-(methanesulfonyl)propanamide + SX, 1,4-dimethyl-2-[2-(pyridin-3-yl)-2H-indazol-5-yl]-1,2,4-triazolidine-3,5-dione (2171099-09-3) + SX, 2-isopropyl-5-[(3,4,4-trifluoro-3-buten-1-yl)sulfonyl]-1,3,4-thiadiazole (2058052-95-0) + SX, N-({2-fluoro-4-[(2S,3S)-2-hydroxy-3-(3,4,5-trichlorophenyl)-3-(trifluoromethyl)pyrrolidin-1-yl]phenyl}methyl)cyclopropanecarboxamide + SX, 7-fluoro-N-[1-(methylsulfanyl)-2-methylpropan-2-yl]-2-(pyridin-3-yl)-2H-indazole-4-carboxamide + SX, 7-fluoro-N-[1-(methanesulfinyl)-2-methylpropan-2-yl]-2-(pyridin-3-yl)-2H-indazole-4-carboxamide + SX, 7-fluoro-N-[1-(methanesulfonyl)-2-methylpropan-2-yl]-2-(pyridin-3-yl)-2H-indazole-4-carboxamide + SX, N-[1-(difluoromethyl)cyclopropyl]-2-(pyridin-3-yl)-2H-indazole-4-carboxamide + SX, 2,9-dihydro-9-(methoxymethyl)-2-(pyridin-3-yl)-10H-pyrazolo[3,4-f]pyrido[2,3-b][1,4]oxazepin-10-one (2607927-97-7) + SX, Bacillus thuringiensis-derived Cry1Ab protein + SX,Cry1Ac protein from Bacillus thuringiensis (Bacillus thuringiensis Cry1Ac protein) + SX, Cry1Fa protein from Bacillus thuringiensis (Bacillus thuringiensis Cry1Fa protein) + SX, Cry1A.105 protein from Bacillus thuringiensis (Bacillus thuringiensis Cry1A.105 protein) + SX, Cry2Ab protein from Bacillus thuringiensis (Bacillus thuringiensis Cry2Ab protein) + SX, Vip3A protein from Bacillus thuringiensis (Bacillus thuringiensis Vip3A protein) + SX, mCry3A protein from Bacillus thuringiensis (Bacillus thuringiensis mCry3A protein) + SX, Cry3Ab protein from Bacillus thuringiensis (Bacillus thuringiensis thuringiensis Cry3Ab protein + SX, Bacillus thuringiensis Cry3Bb protein + SX, Bacillus thuringiensis Cry34Ab1 / Cry35Ab1 protein + SX, Adoxophyes orana GV (granulovirus) strain BV-0001 + SX, Anticarsia gemmatalis MNPV (multiple nucleocapsid nucleopolyhedrovirus) + SX,Autographa californica MNPV + SX, Cydia pomonella GV strain V15 + SX, Cydia pomonella GV strain V22 + SX, Cryptophlebia leucotreta GV + SX, Dendrolimus punctatus cypovirus + SX, Helicoverpa armigera nucleopolyhedrovirus BV-0003 + SX, Helicoverpa zea ... NPV) + SX, Lymantria dispar NPV + SX, Mamestra brassicae NPV + SX, Mamestra configurata NPV + SX, Neodiprion abietis NPV + SX, Neodiprion lecontei NPV + SX, Neodiprion sertifer NPV + SX, Nosema locustae NPV + SX, Orgyia pseudotsugata NPV + SX, Pieris rapae granulosis virus (GV) + SX, Plodia interpunctella granulosis virus (GV) + SX, Spodoptera exigua MNPV + SX,Spodoptera littoralis MNPV + SX, Spinach squid (Spodoptera litura NPV) + SX, Arthrobotrys dactyloides + SX, Bacillus firmus strain GB-126 + SX, Bacillus firmus strain I-1582 + SX, Bacillus firmus strain NCIM2637 + SX, Bacillus megaterium + SX, Bacillus sp. strain AQ175 + SX, Bacillus sp. strain AQ177 + SX, Bacillus sp. strain AQ178 + SX, Bacillus sphaericus strain 2362 serotype H5a5b + SX, Bacillus sphaericus strain ABTS1743 + SX, Bacillus thuringiensis strain AQ52 + SX, Bacillus thuringiensis strain BD#32 + SX, Bacillus thuringiensis strain CR-371 + SX, Bacillus thuringiensis subsp. Aizawai strain ABTS-1857 + SX, Bacillus thuringiensis subsp. Aizawai strain AM65-52 + SX, Bacillus thuringiensis subsp. Aizawai strain GC-91 + SX, Bacillus thuringiensis subsp. Aizawai strain NB200 + SX, Bacillus thuringiensis subsp. Aizawai Serotype strain H-7 + SX, Bacillus thuringiensis subsp. Course strain ABTS351 + SX,Bacillus thuringiensis subsp. Kurstaki strain BMP123 + SX, Bacillus thuringiensis subsp. Kurstaki strain CCT1306 + SX, Bacillus thuringiensis subsp. Kurstaki strain EG2348 + SX, Bacillus thuringiensis subsp. Kurstaki strain EG7841 + SX, Bacillus thuringiensis subsp. Kurstaki strain EVB113-19 + SX, Bacillus thuringiensis subsp. Kurstaki strain F810 + SX, Bacillus thuringiensis subsp. Kurstaki strain HD-1 + SX, Bacillus thuringiensis subsp. Kurstaki strain PB54 + SX, Bacillus thuringiensis subsp. Kurstaki strain SA-11 + SX, Bacillus thuringiensis subsp. Kurstaki strain SA-12 + SX, Bacillus thuringiensis subsp. Tenebriosis strain NB176 + SX, Bacillus thuringiensis subsp. Thuringiensis strain MPPL002 + SX, Bacillus thuringiensis subsp. morrisoni + SX, Bacillus thuringiensis var. colmeri + SX, Bacillus thuringiensis var. darmstadiensis strain 24-91 + SX, Bacillus thuringiensis var. dendrolimus + SX, Bacillus thuringiensis var. galleriae + SX,Bacillus thuringiensis var. israelensis strain BMP144 + SX, Bacillus thuringiensis var. israelensis serotype strain H-14 + SX, Bacillus thuringiensis var. japonensis strain buibui + SX, Bacillus thuringiensis var. san diego strain M-7 + SX, Bacillus thuringiensis var. 7216 + SX, Bacillus thuringiensis var. aegypti + SX, Bacillus thuringiensis var. T36 + SX, Beauveria bassiana strain ANT-03 + SX, Beauveria bassiana strain ATCC74040 + SX, Beauveria bassiana strain GHA + SX, Beauveria brongniartii + SX, Burkholderia rinogensis strain A396 + SX, Chromobacterium subtsugae strain PRAA4-1T + SX, Dactyllela ellipsospora + SX, Dactylaria thaumasia + SX, Hirsutella minnesotensis + SX, Hirsutella rhossiliensis + SX, Hirsutella thompsonii + SX, Lagenidium giganteum + SX, Lecanicillium lecanii strain KV01 + SX, Lecanicillium lecanii conidia of strain DAOM198499 + SX, Lecanicillium lecanii conidia of strain DAOM216596 + SX, Lecanicillium muscarium strain Ve6 + SX,Metarhizium anisopliae strain F52 + SX, Metarhizium anisopliae var. acridum + SX, Metarhizium anisopliae var. anisopliae BIPESCO 5 / F52 + SX, Metarhizium flavoviride + SX, Monacrosporium phymatopagum + SX, Paecilomyces fumosoroseus Apopka strain 97 + SX, Paecilomyces lilacinus strain 251 + SX, Paecilomyces tenuipes strain T1 + SX, Paenibacillus popilliae + SX, Pasteuria nishizawae strain Pn1 + SX, Pasteuria penetrans + SX, Pasteuria usgae + SX, Pasteuria thornei + SX, Serratia entomophila + SX, Verticillium chlamydosporium + SX, Verticillium lecani strain NCIM1312 + SX, Wolbachia pipientis + SX。,

[0074] Combinations of the present ingredient of the above group (b) with the compound W of the present invention: acibenzolar-S-methyl + SX, aldimorph + SX, ametoctradin + SX, aminopyrifen + SX, amisulbrom + SX, anilazine + SX, azaconazole + SX, azoxystrobin + SX, basic copper sulfate + SX, benalaxyl + SX, benalaxyl-M + SX, benodanil + SX, benomyl + SX, benthiavalicarb + SX, Benthiavalicarb-isopropyl + SX, benzovindiflupyr + SX, binapacryl + SX, biphenyl + SX, bitertanol + SX, bixafen + SX, blasticidin S + SX, Bordeaux mixture + SX, boscalid + SX, bromothalonil + SX, bromuconazole + SX, bupirimate + SX, captafol + SX, captan + SX, carbendazim + SX, carboxin + SX, carpropamid + SX, chinomethionate + SX, chitin + SX, chloroinconazide + SX, chloroneb + ​​SX,Chlorothalonil + SX, chlozolinate + SX, colletochlorin B + SX, copper(II) acetate + SX, copper(II) hydroxide + SX, copper oxychloride + SX, copper(II) sulfate + SX, coumoxystrobin + SX, cyazofamid + SX, cyflufenamid + SX, cymoxanil + SX, cyproconazole + SX, cyprodinil + SX, dichlobentiazox + SX, Dichlofluanid + SX, diclocymet + SX, diclomezine + SX, dicloran + SX, diethofencarb + SX, difenoconazole + SX, diflumetorim + SX, dimethachlone + SX, dimethirimol + SX, dimethomorph + SX, dimoxystrobin + SX, diniconazole + SX, diniconazole-M + SX, dinocap + SX, dipotassium hydrogenphosphite + SX, dipymetitrone + SX, dithianon + SX,Dodecylbenzenesulphonic acid bisethylenediamine copper(II) salt + SX, dodemorph + SX, dodine + SX, edifenphos + SX, enoxastrobin + SX, epoxiconazole + SX, etaconazole + SX, ethaboxam + SX, ethirimol + SX, etridiazole + SX, garlic extract (Allium sativum) + SX, extract of the cotyledons of lupine plantlets (BLAD) + SX, horsetail extract (Equisetum arvense) + SX SX, tea tree extract (Melaleuca alternifolia) + SX, giant knotweed extract (Reynoutria sachalinensis) + SX, nasturtium extract (Tropaeolus majus) + SX, famoxadone + SX, fenamidone + SX, fenaminstrobin + SX, fenarimol + SX, fenbuconazole + SX, feneptamidoquin + SX, fenfuram + SX, fenhexamid + SX, fenopyramide + SX, fenoxanil + SX Fenpiclonil + SX, fenpicoxamid + SX,Fenpropidin + SX, fenpropimorph + SX, fenpyrazamine + SX, triphenyltin acetate + SX, triphenyltin chloride + SX, fentin hydroxide + SX, ferbam + SX, ferimzone + SX, florylpicoxamid + SX, fluazinam + SX, flubeneteram + SX, fludioxonil + SX, flufenoxadiazam + SX, flufenoxystrobin + SX, fluindapyr + SX, flumetylsulforim + SX, flumorph + SX, fluopicolide + SX, fluopyram + SX, fluopimomide + SX, fluoroimide + SX, fluoxapiprolin + SX, fluoxastrobin + SX, fluoxytioconazole + SX, fluquinconazole + SX, flusilazole + SX, flusulfamide + SX, flutianil + SX, flutolanil + SX, flutriafol + SX, Fluxapyroxad + SX, Folpet + SX, Fosetyl + SX, Fosetyl-aluminum + SX,Fuberidazole + SX, furalaxyl + SX, furametpyr + SX, galquin + SX, guazatine + SX, hexaconazole + SX, hymexazole + SX, imazalil + SX, imibenconazole + SX, iminoctadine + SX, iminoctadine triacetate + SX, inpyrfluxam + SX, iodocarb + SX, ipconazole + SX, ipfentrifluconazole + SX Ipflufenoquin + SX, iprobenfos + SX, iprodione + SX, iprovalicarb + SX, isofetamide + SX, isofleucine + SX, isoflucipram + SX, isoprothiolane + SX, isopyrazam + SX, isotianil + SX, kasugamycin + SX, kresoxim-methyl + SX, laminarin + SX, oak leaves and bark of quercus + SX, mancozeb + SX, mandestrobin + SX, Mandipropamid + SX, maneb + ​​SX, mefentrifluconazole + SX, mepanipyrim + SX, mepronil + SX,Meptyldinocap + SX, metalaxyl + SX, metalaxyl-M + SX, metarylpicoxamid + SX, metconazole + SX, methasulfocarb + SX, metiram + SX, metominostrobin + SX, metrafenone + SX, metyltetraprole + SX, myclobutanil + SX, naftifine + SX, nuarimol + SX, octhilinone + SX, ofurace + SX Orysastrobin + SX, oxadixyl + SX, oxathiapiprolin + SX, oxine-copper + SX, oxolinic acid + SX, oxpoconazole + SX, oxpoconazole fumarate + SX, oxycarboxin + SX, oxytetracycline + SX, pefurazoate + SX, penconazole + SX, pencycuron + SX, penflufen + SX, penthiopyrad + SX, phenamacril + SX, phosphorous acid + SX, Phthalide + SX, picarbutrazox + SX, picoxystrobin + SX, piperalin + SX,Polyoxins + SX, potassium hydrogencarbonate + SX, potassium dihydrogenphosphite + SX, probenazole + SX, prochloraz + SX, procymidone + SX, propamidine + SX, propamocarb + SX, propiconazole + SX, propineb + ​​SX, proquinazid + SX, prothiocarb + SX, prothioconazole + SX, pydiflumetofen + SX, pyraclostrobin + SX, pyrametostrobin + SX, Pyraoxystrobin + SX, pyrapropoyne + SX, pyraziflumid + SX, pyrazophos + SX, pyribencarb + SX, pyributicarb + SX, pyridaclomethyl + SX, pyrifenox + SX, pyrimethanil + SX, pyrimorph + SX, pyriophenone + SX, pyrisoxazole + SX, pyroquilon + SX, Quillaja extract + SX, quinconazole + SX, Quinofumelin + SX, quinoxyfen + SX, quintozene + SX,Quinoa saponins (Chenopodiaceae) + SX, seboctylamine + SX, sedaxane + SX, silthiofam + SX, simeconazole + SX, sodium hydrogencarbonate + SX, spiroxamine + SX, streptomycin + SX, sulfur + SX, tebuconazole + SX, tebufloquin + SX, teclofthalam + SX, tecnazene + SX, terbinafine + SX, tetraconazole + SX Thiabendazole + SX, thifluzamide + SX, thiophanate + SX, thiophanate-methyl + SX, thiram + SX, thymol + SX, tiadinil + SX, tolclofos-methyl + SX, tolfenpyrad + SX, tolprocarb + SX, tolylfluanid + SX, triadimefon + SX, triadimenol + SX, triazoxide + SX, triclopyricarb + SX, tricyclazole + SX, Tridemorph + SX, trifloxystrobin + SX, triflumizole + SX, triforine + SX,トリチコナゾール(triticonazole) + SX, バリダマイシン(validamycin) + SX, バリフェナレート(valifenalate) + SX, ビンクロゾリン(vinclozolin) + SX, マスタードパウダー(yellow mustard powder) + SX, zinc thiazole + SX, ジネブ(zineb) + SX, ジラム(ziram) + SX, ゾキサミド(zoxamide) + SX, N'-[4-({3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl}oxy)-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide (1202781-91-6) + SX, N'-{4-[(4,5-dichlorothiazol-2-yl)oxy]-2,5-dimethylphenyl}-N-ethyl-N-methylmethanimidamide (929908- 57-6) + SX, N'-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylmethanimidamide (1052688-31-9) + SX, N'-[5-chloro-4-(2-fluorophenoxy)-2-methylphenyl]-N-ethyl-N-methylmethanimidamide (2055589-28-9) + SX, N'-[2-chloro-4-(2-fluorophenoxy)-5-methylphenyl]-N-ethyl-N-methylmethanimidamide (2055756-21-1) + SX, N'-(2-chloro-4-phenoxy-5-methylphenyl)-N-ethyl-N-methylmethanimidamide (2062599-39-5) + SX, N'-[4-(1-hydroxy-1-phenyl-2,2,2-trifluoroethyl)-2-methyl-5-methoxyphenyl]-N-isopropyl-N-methylmethanimidamide (2101814-55-3) + SX,N'-[5-bromo-6-(1-methyl-2-propoxyethoxy)-2-methylpyridin-3-yl]-N-ethyl-N-methylmethanimidamide (1817828-69-5) + SX, 4-(2-bromo-4-fluorophenyl)-N-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine (1362477-26-6) + SX, 2-[6-(3-fluoro-4-methoxyphenyl)-5-methylpyridin-2-yl]quinazoline (1257056-97-5) + SX, ethyl (2Z)-3-amino-2-cyano-3-phenylacrylate (39491-78-6) + SX, N-[(2-chlorothiazol-5-yl)methyl]-N-ethyl-6-methoxy-3-nitropyridin-2-amine (1446247-98-8) + SX, 5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentan-1-ol (1394057-11-4) + SX, (1R, 2S, 5S)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentan-1-ol (1801930-06-2) + SX, (1S, 2R, 5R)-5-(4-chlorobenzyl)-2-(chloromethyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentan-1-ol (1801930-07-3) + SX, 2-(chloromethyl)-5-(4-fluorobenzyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentan-1-ol (1394057-13-6) + SX, (1R, 2S,5S)-2-(chloromethyl)-5-(4-fluorobenzyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentan-1-ol (1801930-08-4) + SX, (1S, 2R, 5R)-2-(chloromethyl)-5-(4-fluorobenzyl)-2-methyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentan-1-ol (1801930-09-5) + SX, methyl 3-[(4-chlorophenyl)methyl]-2-hydroxy-1-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)cyclopentan-1-carboxylate (1791398-02-1) + SX, 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-[1-(4-bromo-2,6-difluorophenoxy)cyclopropyl]ethanol (2019215-86-0) + SX, 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)-1-[1-(4-chloro-2,6-difluorophenoxy)cyclopropyl]ethanol (2019215-84-8) + SX, 1-[2-(1-chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxypropyl]-1H-imidazole-5-carbonitrile (2018316-13-5) + SX, 1-[2-(1-chlorocyclopropyl)-3-(2,3-difluorophenyl)-2-hydroxypropyl]-1H-imidazole-5-carbonitrile (2018317-25-2) + SX, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)pyridin-3-yl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol (2082661-43-4) + SX,2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)pyridin-3-yl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol (2082660-27-1) + SX, methyl ({2-methyl-5-[1-(4-methoxy-2-methylphenyl)-1H-pyrazol-3-yl]phenyl}methyl)carbamate (1605879-98-8) + SX, 2-(difluoromethyl)-N-[1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]pyridine-3-carboxamide (1616239-21-4) + SX, 2-(difluoromethyl)-N-[3-ethyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl]pyridine-3-carboxamide (1847460-02-9) + SX, 2-(difluoromethyl)-N-[3-propyl-1,1-dimethyl-2,3-dihydro-1H-inden-4-yl]pyridine-3-carboxamide (1847460-05-2) + SX, (2E,3Z)-5-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide (1445331-27-0) + SX, (2E,3Z)-5-{[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy}-2-(methoxyimino)-N,3-dimethylpent-3-enamide (1445331-54-3) + SX, 5-chloro-4-({2-[6-(4-chlorophenoxy)pyridin-3-yl]ethyl}amino)-6-methylpyrimidine (1605340-92-8) + SX, 4,4-dimethyl-2-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)isoxazolidin-3-one (2098918-25-1) + SX, 5,5-dimethyl-2-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)isoxazolidin-3-one (2098918-26-2) + SX, N-ethyl-2-methyl-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)propanamide + SX, N,2-dimethoxy-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)propanamide + SX, N-methoxy-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)cyclopropanecarboxamide + SX, N-methoxy-N'-methyl-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)urea + SX, N'-ethyl-N-methoxy-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)urea + SX, N,N'-dimethoxy-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)urea + SX, N-acetyl-2-(ethanesulfonyl)-N-[2-(methoxycarbonyl)-4-(trifluoromethoxy)phenyl]-4-(trifluoromethyl)benzamide (2043675-28-9) + SX, 3-(4-bromo-7-fluoroindol-1-yl)butan-2-yl N-[(3-hydroxy-4-methoxypyridin-2-yl)carbonyl]-L-alaninate + SX,3-(7-bromoindol-1-yl)butan-2-yl N-[(3-hydroxy-4-methoxypyridin-2-yl)carbonyl]-L-alaninate + SX, 3-(7-bromo-4-fluoroindol-1-yl)butan-2-yl N-[(3-hydroxy-4-methoxypyridin-2-yl)carbonyl]-L-alaninate + SX, 3-(3,5-dichloropyridin-2-yl)butan-2-yl N-[(3-hydroxy-4-methoxypyridin-2-yl)carbonyl]-L-alaninate + SX, 3-(3,5-dichloropyridin-2-yl)butan-2-yl N-{[3-(acetoxymethoxy)-4-methoxypyridin-2-yl]carbonyl}-L-alaninate + SX, (1S)-1-[1-(naphthalen-1-yl)cyclopropyl]ethyl N-[(3-hydroxy-4-methoxypyridin-2-yl)carbonyl]-L-alaninate + SX, (1S)-1-[1-(naphthalen-1-yl)cyclopropyl]ethyl N-[(3-acetoxy-4-methoxypyridin-2-yl)carbonyl]-L-alaninate + SX, (1S)-1-[1-(naphthalen-1-yl)cyclopropyl]ethyl N-{[3-(acetoxymethoxy)-4-methoxypyridin-2-yl]carbonyl}-L-alaninate + SX, N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)cyclopropanecarboxamide + SX, N-allyl-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)acetamide + SX, N-allyl-N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)propanamide + SX, N-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)propanamide + SX, 3,3,3-trifluoro-N-({2-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)propanamide + SX, 3,3,3-trifluoro-N-({3-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)propanamide + SX, 3,3,3-trifluoro-N-({2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)propanamide + SX, N-({2,3-difluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)butanamide + SX, N-methoxy-N-methyl-N'-({ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)urea + SX, N,N-diethyl-N'-({ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)urea + SX, N-methyl-N'-({ 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)urea + SX, 1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)pyrrolidin-2-one + SX, 1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)piperidin-2-one + SX,4-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)morpholin-3-one + SX, 2-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)isoxazolidin-3-one + SX, 3,3-dimethyl-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)piperidin-2-one + SX, 2-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-1,2-oxazinan-3-one + SX, 1-({3-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)azepan-2-one + SX, 4,4-dimethyl-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)pyrrolidin-2-one + SX, 5-methyl-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)pyrrolidin-2-one + SX, ethyl 1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-1H-pyrazole-4-carboxylate + SX, N-methyl-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-1H-pyrazole-4-carboxamide + SX, N-propyl-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-1H-pyrazole-4-carboxamide + SX, N-methoxy-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-1H-pyrazole-4-carboxamide + SX, N-methoxy-N-methyl-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-1H-pyrazole-4-carboxamide + SX, N,N-dimethyl-1-({4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl}methyl)-1H-1,2,4-triazol-3-amine + SX, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + SX, methyl 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propanoate + SX, ethyl 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propanoate + SX, methyl 2-[2-(trifluoromethyl)-4-(4-chlorophenoxy)phenyl]-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propanoate + SX, 1-(2,3-dimethylpyridin-5-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline + SX, 1-[2-(difluoromethyl)-3-methylpyridin-5-yl]-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline + SX, 2,2-difluoro-N-[6-({[1-(1-methyl-1H-tetrazol-5-yl)benzimidazol-2-yl]oxy}methyl)pyridin-2-yl]-2-phenoxyacetamide + SX,1-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluorophenyl)-2-hydroxypropyl]-1H-imidazole-5-carbonitrile + SX, ethyl 1-[(4-{[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy}phenyl)methyl]-1H-pyrazole-4-carboxylate + SX, ethyl 1-[(4-{[(1Z)-2-ethoxy-3,3,3-trifluoro-1-propen-1-yl]oxy}phenyl)methyl]-1H-pyrazole-4-carboxylate + SX, 6-chloro-3-(3-cyclopropyl-2-fluorophenoxy)-N-[2-(2,4-dimethylphenyl)-2,2-difluoroethyl]-5-methylpyridazine-4-carboxamide + SX, 6-chloro-3-(3-cyclopropyl-2-fluorophenoxy)-N-[2-(3,4-dimethylphenyl)-2,2-difluoroethyl]-5-methylpyridazine-4-carboxamide + SX, 6-chloro-N-[2-(2-chloro-4-methylphenyl)-2,2-difluoroethyl]-3-(3-cyclopropyl-2-fluorophenoxy)-5-methylpyridazine-4-carboxamide + SX, 2-[cyano(2,6-difluoropyridin-4-yl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 2-[cyano(2,6-difluoropyridin-4-yl)amino]-N-(spiro[3.4]octan-1-yl)-5-methylthiazole-4-carboxamide + SX, 2-[cyano(2,6-difluoropyridin-4-yl)amino]-N-hexyl-5-methylthiazole-4-carboxamide + SX, 2-[acetyl(2,6-difluoropyridin-4-yl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 2-[(2-methoxyacetyl)(2,6-difluoropyridin-4-yl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 2-[(2-methylpropanoyl)(2,6-difluoropyridin-4-yl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 2-[(2,6-difluoropyridin-4-yl)amino]-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 2-{[(oxetan-3-yl)carbonyl](2,6-difluoropyridin-4-yl)amino}-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 2-{[(oxolan-3-yl)carbonyl](2,6-difluoropyridin-4-yl)amino}-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 2-{[(oxan-4-yl)carbonyl](2,6-difluoropyridin-4-yl)amino}-N-(2,2-dimethylcyclobutyl)-5-methylthiazole-4-carboxamide + SX, 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-fluorophenyl)ethyl]pyrimidin-2-amine + SX,5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,6-difluorop henyl)ethyl]pyrimidin-2-amine + SX, 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(3,5-difluorophenyl)ethyl]pyrimidin-2-amine + SX, 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(6-chloropyridin-3-yl)ethyl]pyrimidin-2-amine + SX, 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-fluorophenyl)cyclopropyl]pyrimidin-2-amine + SX, 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2,6-difluorophenyl)cyclopropyl]pyrimidin-2-amine + SX, 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-N-[1-(2-fluoro-3-methoxyphenyl)cyclopropyl]pyrimidin-2-amine + SX, 5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-2-{[1-(2,6-difluorophenyl)cyclopropyl]oxy}pyrimidine + SX, 3-[3-(3-cyclopropyl-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(2,4-dimethylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine + SX, (5S)-3-[3-(3-cyclopropyl-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(2,4-dimethylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine + SX,3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(4-bromo-2-methylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine + SX, 3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(2-chloro-4-methylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine + SX, (5S)-3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(2-chloro-4-methylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine + SX, (5R)-3-[3-(3-chloro-2-fluorophenoxy)-6-methylpyridazin-4-yl]-5-[(2-chloro-4-methylphenyl)methyl]-5,6-dihydro-4H-1,2,4-oxadiazine + SX, N-((2S)-1-{3-[2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl]-5-[(E)-1-(isopropoxyimino)ethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl}-3-methylbutan-2-yl)-2-methylpropanamide + SX, N-((2S)-1-{3-[2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl]-5-[(E)-1-(isopropoxyimino)ethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl}-3-methylbutan-2-yl)-2,2-dimethylpropanamide + SX, N-((2S)-1-{3-[2-(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl]-5-[(E)-1-(isopropoxyimino)ethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl}propan-2-yl)-2-methylpropanamide + SX, N-((2S)-1-{3-[2-(2-methoxyphenyl)-2-hydroxyethyl]-5-[(E)-1-(isopropoxyimino)ethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl}propan-2-yl)-2-methylpropanamide + SX, N-((2S)-1-{3-[2-(5-fluoro-2-methoxyphenyl)-2-(2-cyanoethoxy)ethyl]-5-[1-(isopropoxyimino)ethyl]-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl}propan-2-yl)-2-methylpropanamide + SX, methyl ({5-[1-(2,6-difluoro-4-isopropylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl}methyl)carbamate + SX, methyl ({5-[1-(2,6-difluoro-4-cyclopropylphenyl)-1H-pyrazol-3-yl]-2-methylphenyl}methyl)carbamate + SX, methyl ({5-[1-(2,6-difluoro-4-methoxyphenyl)-1H-pyrazol-3-yl]-2-methylphenyl}methyl)carbamate + SX, methyl (Z)-2-(5-cyclopentyl-2-methylphenoxy)-3-methoxyprop-2-enoate + SX, methyl (Z)-2-(5-cyclohexyl-2-methylphenoxy)-3-methoxyprop-2-enoate + SX, methyl (Z)-2-[(3-isopropyl-1H-pyrazol-1-yl)-2-methylphenoxy]-3-methoxyprop-2-enoate + SX, 1-(4,5-dimethyl-1H-benzimidazol-1-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline + SX, 1-(4,5-dimethyl-1H-benzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinoline + SX, 1-(pyrazolo[1,5-a]pyridin-3-yl)-4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinoline + SX, 1-(6,7-dimethylpyrazolo[1,5-a]pyridin-3-yl)-6-fluoro-3,3-dimethylisoquinolin-4(3H)-one + SX, methyl (2Z)-3-methoxy-2-[(4-methyl[1,1'-biphenyl]-3-yl)oxy]prop-2-enoate + SX, Agrobacterium radiobactor strain K1026 + SX, Agrobacterium radiobactor strain K84 + SX, Bacillus amyloliquefaciens strain PTA-4838 (Aveo™ EZ Nematicide) + SX, Bacillus amyloliquefaciens strain AT332 + SX, Bacillus amyloliquefaciens strain B3 + SX, Bacillus amyloliquefaciens strain D747 + SX, Bacillus amyloliquefaciens strain DB101 + SX, Bacillus amyloliquefaciens strain DB102 + SX, Bacillus amyloliquefaciens strain GB03 + SX, Bacillus amyloliquefaciens strain FZB24 + SX, Bacillus amyloliquefaciens strain FZB42 + SX, Bacillus amyloliquefaciens strain IN937a + SX,Bacillus amyloliquefaciens strain MBI600 + SX, Bacillus amyloliquefaciens strain QST713 + SX, Bacillus amyloliquefaciens isolate strain B246 + SX, Bacillus amyloliquefaciens strain F727 + SX, Bacillus amyloliquefaciens subsp. plantarum strain D747 + SX, Bacillus licheniformis strain HB-2 + SX, Bacillus licheniformis strain SB3086 + SX, Bacillus pumilus strain AQ717 + SX, Bacillus pumilus strain BUF-33 + SX, Bacillus pumilus strain GB34 + SX, Bacillus pumilus strain QST2808 + SX, Bacillus simplex strain CGF2856 + SX, Bacillus subtilis strain AQ153 + SX, Bacillus subtilis strain AQ743 + SX, Bacillus subtilis strain BU1814 + SX, Bacillus subtilis strain D747 + SX, Bacillus subtilis strain DB101 + SX, Bacillus subtilis strain FZB24 + SX, Bacillus subtilis strain GB03 + SX, Bacillus subtilis strain HAI0404 + SX, Bacillus subtilis strain IAB / BS03 + SX, Bacillus subtilis strain MBI600 + SX, Bacillus subtilis strain QST30002 / AQ30002 + SX, Bacillus subtilis strain QST30004 / AQ30004 + SX,Bacillus subtilis strain QST713 + SX, Bacillus subtilis strain QST714 + SX, Bacillus subtilis var. Amyloliquefaciens strain FZB24 + SX, Bacillus subtilis strain Y1336 + SX, Burkholderia cepacia + SX, Burkholderia cepacia type Wisconsin strain J82 + SX, Burkholderia cepacia type Wisconsin strain M54 + SX, Candida oleophila strain O + SX, Candida saitoana + SX, Chaetomium cupreum + SX, Clonostachys rosea + SX, Coniothyrium minitans strain CGMCC8325 + SX, Coniothyrium minitans strain CON / M / 91-8 + SX, cryptococcus albidus + SX, Erwinia carotovora subsp. carotovora strain CGE234M403 + SX, Fusarium oxysporum strain Fo47 + SX, Gliocladium catenulatum strain J1446 + SX, Paenibacillus polymyxa strain AC-1 + SX, Paenibacillus polymyxa strain BS-0105 + SX, Pantoea agglomerans strain E325 + SX, Phlebiopsis gigantea strain VRA1992 + SX, Pseudomonas aureofaciens strain TX-1 + SX, Pseudomonas chlororaphis strain 63-28 + SX, Pseudomonas chlororaphis strain AFS009 + SX,Pseudomonas chlororaphis strain MA342 + SX, Pseudomonas fluorescens strain 1629RS + SX, Pseudomonas fluorescens strain A506 + SX, Pseudomonas fluorescens strain CL145A + SX, Pseudomonas fluorescens strain G7090 + SX, Pseudomonas sp. strain CAB-02 + SX, Pseudomonas syringae strain 742RS + SX, Pseudomonas syringae strain MA-4 + SX, Pseudozyma flocculosa strain PF-A22UL + SX, Pseudomonas rhodesiae strain HAI-0804 + SX, Pythium oligandrum strain DV74 + SX, Pythium oligandrum strain M1 + SX, Streptomyces griseoviridis strain K61 + SX, Streptomyces lydicus strain WYCD108US + SX, Streptomyces lydicus strain WYEC108 + SX, Talaromyces flavus strain SAY-Y-94-01 + SX, Talaromyces flavus strain V117b + SX, Trichoderma asperellum strain ICC012 + SX, Trichoderma asperellum SKT-1 + SX, Trichoderma asperellum strain T25 + SX, Trichoderma asperellum strain T34 + SX, Trichoderma asperellum strain TV1 + SX, Trichoderma atroviride strain CNCM 1-1237 + SX, Trichoderma atroviride strain LC52 + SX,Trichoderma atroviride strain IMI 206040 + SX, Trichoderma atroviride strain SC1 + SX, Trichoderma atroviride strain SKT-1 + SX, Trichoderma atroviride strain T11 + SX, Trichoderma gamsii strain ICC080 + SX, Trichoderma harzianum strain 21 + SX, Trichoderma harzianum strain DB104 + SX, Trichoderma harzianum strain DSM 14944 + SX, Trichoderma harzianum strain ESALQ-1303 + SX, Trichoderma harzianum strain ESALQ-1306 + SX, Trichoderma harzianum strain IIHR-Th-2 + SX, Trichoderma harzianum strain ITEM908 + SX, Trichoderma harzianum strain kd + SX, Trichoderma harzianum strain MO1 + SX, Trichoderma harzianum strain SF + SX, Trichoderma harzianum strain T22 + SX, Trichoderma harzianum strain T39 + SX, Trichoderma harzianum strain T78 + SX, Trichoderma harzianum strain TH35 + SX, Trichoderma polysporum strain IMI206039 + SX, trichoderma stromaticum + SX, Trichoderma virens strain G-41 + SX, Trichoderma virens strain GL-21 + SX, Trichoderma viride + SX,Variovorax paradoxus strain CGF4526 + SX, Harpin protein + SX。,

[0075] Combination of the present component of the above group (c) with compound W of the present invention: 1-methylcyclopropene + SX, 1,3-diphenylurea + SX, 2,3,5-triiodobenzoic acid + SX, (1H-indol-3-yl)acetic acid (IAA) + SX, 4-(1H-indol-3-yl)butyric acid (IBA) + SX, 2-(4-chloro-2-methylphenoxy)acetic acid (MCPA) + SX, 4-(4-chloro-2-methylphenoxy)butyric acid (MCPB) + SX, 4-chlorophenoxyacetic acid (4-CPA) + SX, 5-aminolevulinic acid hydrochloride + SX, 6-benzylaminopurine + SX, abscisic acid + SX, AVG (aminoethoxyvinylglycine) + SX, anisiflupurin + SX, ancymidol + SX, butralin + SX, calcium carbonate + SX, calcium chloride + SX, calcium formate + SX, calcium peroxide + SX, calcium polysulfide + SX, calcium sulfate + SX, chlormequat chloride + SX, chlorpropham + SX, choline chloride + SX, cloprop + SX, cyanamide + SX, Cyclanilide + SX,Daminozide + SX, decan-1-ol + SX, dichlorprop + SX, dikegulac + SX, dimethipin + SX, diquat + SX, ethephon + SX, ethychlozate + SX, flumetralin + SX, flurprimidol + SX, forchlorfenuron + SX, formononetin + SX, gibberellin A + SX, gibberellin A3 + SX, inabenfide + SX, Kinetin + SX, lipochitooligosaccharide SP104 + SX, maleic hydrazide + SX, mefluidide + SX, mepiquat chloride + SX, oxidized glutathione + SX, paclobutrazol + SX, pendimethalin + SX, prohexadione calcium + SX, prohydrojasmon + SX, pyraflufen-ethyl + SX, sintophen + SX, sodium 1-naphthaleneacetate + SX, sodium cyanate + SX, Thidiazuron + SX, triapenthenol + SX, tribufos + SX, trinexapac-ethyl + SX,Uniconazole-P + SX, 2-(naphthalen-1-yl)acetamide + SX, [4-oxo-4-(2-phenylethyl)amino]butyric acid + SX, Methyl 5-(trifluoromethyl)benzo[b]thiophene-2-carboxylate + SX, 3-[(6-chloro-4-phenylquinazolin-2-yl)amino]propan-1-ol + SX, Claroideoglomus etunicatum + SX, Claroideoglomus claroideum + SX, Funneliformis mosseae + SX, Gigaspora margarita + SX, Gigaspora rosea + SX, Glomus aggregatum + SX, Glomus deserticola + SX, Glomus monosporum + SX, Paraglomus brasillianum + SX, Rhizophagus clarus + SX, Rhizophagus intraradices RTI-801 + SX, Rhizophagus irregularis DAOM 197198 + SX, Azorhizobium caulinodans + SX, Azospirillum amazonense + SX, Azospirillum brasilense XOH + SX, Azospirillum brasilense Ab-V5 + SX, Azospirillum brasilense Ab-V6 + SX, Azospirillum caulinodans + SX, Azospirillum halopraeferens + SX, Azospirillum irakense + SX, Azospirillum lipoferum + SX, Bradyrhizobium elkanii SEMIA 587 + SX, Bradyrhizobium elkanii SEMIA 5019 + SX, Bradyrhizobium japonicum TA-11 + SX,Bradyrhizobium japonicum USDA 110 + SX, Bradyrhizobium liaoningense + SX, Bradyrhizobium lupini + SX, Delftia acidovorans RAY209 + SX, Mesorhizobium ciceri + SX, Mesorhizobium huakii + SX, Mesorhizobium loti + SX, Rhizobium etli + SX, Rhizobium galegae + SX, Rhizobium leguminosarum bv. Phaseoli + SX, Rhizobium leguminosarum bv. Trifolii + SX, Rhizobium leguminosarum bv. Viciae + SX, Rhizobium trifolii + SX, Rhizobium tropici + SX, Sinorhizobium fredii + SX, Sinorhizobium meliloti + SX, Zucchini Yellow Mosaik Virus weak strain + SX. ,

[0076] Combinations of the present component of the above group (d) with compound W of the present invention: anthraquinone + SX, deet + SX, icaridin + SX.

[0077] The ratio of compound W of the present invention to this component is not particularly limited, and examples thereof include a weight ratio (compound W of the present invention:this component) of 1000:1 to 1:1000, 500:1 to 1:500, 100:1 to 1:100, 50:1, 20:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:20, 1:50, and the like.

[0078] This compound W, the compound W of the present invention, or composition A can control plant diseases caused by plant pathogenic microorganisms such as fungi, oomycetes, Phytomyxea, and bacteria. Examples of fungi include Ascomycota, Basidiomycota, Blastocladiomycota, Chytridiomycota, Mucoromycota, and Olpidiomycota. Specific examples include the following: The scientific name of the plant pathogenic microorganism that causes each disease is shown in parentheses.

[0079] Diseases of rice: blast (Pyricularia oryzae), sesame leaf blight (Cochliobolus miyabeanus), sheath blight (Rhizoctonia solani), bakanae disease (Gibberella fujikuroi), yellowing and wilting disease (Sclerophthora macrospora), false blast and panicle blight (Epicoccum nigrum), seedling blight (Trichoderma viride, Rhizopus oryzae), suspected sheath blight (red sclerotium pathogen (Waitea circinata), brown sclerotium pathogen (Ceratobasidium setariae), brown sheath blight pathogen (Thanatephorus cucumeris)), false smut (Ustilaginoidea virens), black kernel smut (Tilletia horrida, Tilletia barclayana);Wheat diseases: Powdery mildew (Blumeria graminis), head blight (Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Microdochium nivale), yellow rust (Puccinia striiformis), black rust (Puccinia graminis), red rust (Puccinia recondita), pink snow blight (Microdochium nivale, Microdochium majus), small snow blight (Typhula incarnata, Typhula ishikariensis), large snow blight (Sclerotinia borealis), brown snow blight (Pythium spp.), naked smut (Ustilago tritici), grass smut (Tilletia caries, Tilletia controversa), eyespot (Pseudocercosporella herpotrichoides), leaf blight (Septoria tritici), rotten blight (Stagonospora nodorum), yellow spot (Pyrenophora tritici-repentis), seedling damping off caused by Rhizoctonia fungi (Rhizoctonia solani), damping off (Gaeumannomyces graminis), rice blast (Pyricularia graminis-tritici);Barley diseases: powdery mildew (Blumeria graminis), head blight (Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Microdochium nivale), yellow rust (Puccinia striiformis), black rust (Puccinia graminis), small rust (Puccinia hordei), ear bunt (Ustilago nuda), scald (Rhynchosporium secalis), net blotch (Pyrenophora teres), leaf spot (Cochliobolus sativus), leaf spot (Pyrenophora graminea), leaf spot (Ramularia collo-cygni), seedling damping-off (Rhizoctonia solani); corn diseases: rust (Puccinia sorghi), southern rust (Puccinia polysora), sooty blight (Setosphaeria turcica), tropical rust (Physopella zeae), southern leaf blight (Cochliobolus heterostrophus), anthracnose (Colletotrichum graminicola), gray leaf spot (Cercospora zeae-maydis), brown spot (Kabatiella zeae), Phaeosphaeria leaf spot (Phaeosphaeria maydis), Diplodia disease (Stenocarpella maydis, Stenocarpella macrospora), stalk rot (Fusarium graminearum, Fusarium verticilioides, Colletotrichum graminicola), smut (Ustilago maydis), Physoderma maydis, tar spot (Phyllachora maydis);Cotton diseases: anthracnose (Colletotrichum gossypii), white mold (Ramularia areola), black spot (Alternaria macrospora, Alternaria gossypii), black root rot (Thielaviopsis basicola); coffee diseases: rust (Hemileia vastatrix), leaf spot (Cercospora coffeicola); rapeseed diseases: sclerotinia sclerotiorum, black spot (Alternaria brassicae), root rot (Phoma lingam), light leaf spot (Pyrenopeziza brassicae); sugarcane diseases: rust (Puccinia melanocephela, Puccinia kuehnii), smut (Ustilago scitaminea); sunflower diseases: rust (Puccinia helianthi), downy mildew (Plasmopara Citrus diseases: black spot (Diaporthe citri), scab (Elsinoe fawcetti), green mold (Penicillium digitatum), blue mold (Penicillium italicum), late blight (Phytophthora parasitica, Phytophthora citrophthora), aspergillus niger, white mold (Geotrichum candidum var. citri-aurantii), sooty spot (Cladosporium cladosporioides);Apple diseases: Monilinia mali, canker (Valsa ceratosperma), powdery mildew (Podosphaera leucotricha), leaf spot (Alternaria alternata apple pathotype), black spot (Venturia inaequalis), anthracnose (Glomerella cingulata, Colletotrichum acutatum), brown spot (Diplocarpon mali), ring spot (Botryosphaeria berengeriana), late blight (Phytophtora cactorum), red spot (Gymnosporangium juniperi-virginianae, Gymnosporangium yamadae); Pear diseases: black spot (Venturia nashicola, Venturia pirina), black spot (Alternaria alternata Japanese pear pathotype), red spot (Gymnosporangium haraeanum); Peach diseases: brown rot (Monilinia fructicola), black scab (Cladosporium carpophilum), phomopsis rot (Phomopsis sp.), leaf crinkle (Taphrina deformans), powdery mildew (Podosphaera leucotricha); grape diseases: black rot (Elsinoe ampelina), late rot (Glomerella cingulata, Colletotrichum acutatum), powdery mildew (Uncinula necator), rust (Neophysopella sp.), black rot (Guignardia bidwellii), downy mildew (Plasmopara viticola), brown spot (Pseudocercospora vitis), white rot (Coniella castaneicola); persimmon diseases: anthracnose (Gloeosporium kaki, Colletotrichum acutatum), leaf drop (Cercospora kaki, Mycosphaerella nawae), powdery mildew (Phyllactinia kakicola);Fig diseases: Rust (Phakopsora nishidana); Cucurbit diseases: Anthracnose (Colletotrichum lagenarium), Powdery mildew (Sphaerotheca fuliginea), Blight (Didymella bryoniae), Brown spot (Corynespora cassiicola), Blight (Fusarium oxysporum), Downy mildew (Pseudoperonospora cubensis), Late blight (Phytophthora capsici), Damping-off (Pythium sp.), Root rot (Phomopsis sp.); Tomato diseases: Ring spot (Alternaria solani), Leaf mold (Cladosporium fulvum), Leaf mold (Pseudocercospora fuligena), Late blight (Phytophthora infestans), Powdery mildew (Leveillula taurica); Diseases of eggplant: brown spot (Phomopsis vexans), powdery mildew (Erysiphe cichoracearum), black blight (Corynespora melongenae), sooty mold (Mycovellosiella nattrassii), brown spot (Thanatephorus cucumeris); diseases of cruciferous vegetables: black spot (Alternaria japonica), white spot (Cercosporella brassicae), clubroot (Plasmodiophora brassicae), downy mildew (Peronospora parasitica), white rust (Albugo candida), sooty mold (Alternaria brassicicola); diseases of leeks: rust (Puccinia allii), black spot (Alternaria porri), black rot (Sclerotium cepivorum), small sclerotial rot (Botrytis squamosa), leaf blight (Stemphylium vesicarium, Stempphylium botryosum), white silk disease (Sclerotium rolfsii), white spot leaf blight (Botrytis squamosa);Soybean diseases: Purple spot (Cercospora kikuchii), black rot (Elsinoe glycines), black spot (Diaporthe phaseolorum var. sojae), rust (Phakopsora pachyrhizi), brown ring spot (Corynespora cassiicola), anthracnose (Colletotrichum glycines, Colletotrichum truncatum), leaf rot (Rhizoctonia solani), brown spot (Septoria glycines), leaf spot (Cercospora sojina), sclerotinia sclerotiorum, powdery mildew (Microsphaera diffusa), stem rot (Phytophthora sojae), downy mildew (Peronospora manshurica), sudden death (Fusarium virguliforme), black root rot (Calonectria ilicicola), Diaporthe / Phomopsis Diseases of soybeans include: complex (Diaporthe longicolla, Diaporthe phaseolorum, Phomopsis longicolla), pod anomalies of soybeans caused by various pathogenic fungi; diseases of common beans: Sclerotinia sclerotiorum, rust (Uromyces appendiculatus), angular spot (Phaeoisariopsis griseola), anthracnose (Colletotrichum lindemuthianum), root rot (Fusarium solani); diseases of peanuts: black spot (Cercospora personata), brown spot (Cercospora arachidicola), southern blight (Sclerotium rolfsii), black root rot (Calonectria ilicicola); diseases of peas: powdery mildew (Erysiphe pisi), root rot (Fusarium solani);Potato diseases: summer blight (Alternaria solani), late blight (Phytophthora infestans), scarlet rot (Phytophthora erythroseptica), powdery scab (Spongospora subterranea f. sp. subterranea), verticillium wilt (Verticillium albo-atrum, Verticillium dahliae, Verticillium nigrescens), dry rot (Fusarium solani), canker (Synchytrium endobioticum); strawberry diseases: powdery mildew (Sphaerotheca humuli), anthracnose (Glomerella cingulata, Colletotrichum acutatum); tea diseases: net blight (Exobasidium reticulatum), white spot (Elsinoe leucospila), ring spot (Pestalotiopsis Diseases of tobacco: red spot (Alternaria longipes), anthracnose (Colletotrichum tabacum), downy mildew (Peronospora tabacina), late blight (Phytophthora nicotianae); Diseases of sugar beet: brown spot (Cercospora beticola), leaf rot (Thanatephorus cucumeris), root rot (Thanatephorus cucumeris), black root rot (Aphanomyces cochlioides), rust (Uromyces betae); Diseases of rose: black spot (Diplocarpon rosae), powdery mildew (Sphaerotheca pannosa); Diseases of chrysanthemum: brown spot (Septoria chrysanthemi indici), white rust (Puccinia horiana); Onion diseases: white spotted leaf blight (Botrytis cinerea, Botrytis byssoidea, Botrytis squamosa), gray rot (Botrytis allii), small sclerotial rot (Botrytis squamosa);Diseases of various crops: gray mold (Botrytis cinerea), sclerotinia sclerotiorum, black rot (Sclerotium cepivorum), southern blight (Sclerotium rolfsii), damping-off (Pythium aphanidermatum, Pythium irregulare, Pythium ultimum); diseases of radish: black spot (Alternaria brassicicola); diseases of sweet potato: fusarium wilt (Fusarium oxysporum f. sp. batatas), root rot (Diaporthe destruens), black spot (Ceratocystis fimbriata); diseases of turfgrass: dollar spot (Sclerotinia homoeocarpa), brown patch, large patch (Rhizoctonia solani), red blight (Pythium aphanidermatum), anthracnose (Colletotrichum caudatum); Banana diseases: Sigatoka (Mycosphaerella fijiensis, Mycosphaerella musicola); Lentil diseases: Ascochyta (Ascochyta lentis); Chickpea diseases: Ascochyta (Ascochyta rabiei); Bell pepper diseases: Anthracnose (Colletotrichum scovillei), Powdery mildew (Leveillula taurica), Southern blight (Sclerotium rolfsii); Mango diseases: Anthracnose (Colletotrichum acutatum); Cocoa diseases: Witches' broom (Moniliophthora perniciosa), Frosty pod rot (Moniliophthora roreri); Pecan diseases: Black spot (Venturia effusa); Diseases of lychee: downy mildew (Peronophythora litchii), anthracnose (Colletotrichum siemense); Diseases of fruit trees: white root rot (Rosellinia necatrix), purple root rot (Helicobasidium mompa);Diseases of fruits such as apples and pears after harvest: Mucorrot (Mucor piriformis); seed diseases or diseases in the early stages of growth caused by species of the genera Aspergillus, Penicillium, Fusarium, Gibberella, Tricoderma, Thielaviopsis, Rhizopus, Mucor, Corticium, Phoma, Rhizoctonia, Diplodia, etc.; viral diseases: big vein disease of lettuce transmitted by Olpidium brassicae, viral diseases of various crops transmitted by species of the Polymyxa genus (e.g., Polymyxa betae and Polymyxa graminis); diseases caused by bacteria: bacterial seedling blight of rice (Burkholderia plantarii), brown leach disease of rice (Pantoea ananatis), bacterial leaf blight of rice (Xanthomonas oryzae pv. oryzae.), cucumber bacterial spot (Pseudomonas syringae pv. lachrymans), eggplant bacterial wilt (Ralstonia solanacearum), citrus canker (Xanthomonas citri), Chinese cabbage soft rot (Erwinia carotovora), potato scab (Streptomyces scabiei), potato black leg (Pectobacterium carotovorum, Dickeia sp.), peach bacterial bore (Pseudomona syringae, Erwinia nigrifluens, Xanthomonas campestris), plum canker (Pseudomonas syringae pv. morsprunorum, Erwinia sp.), corn Goss's wilt (Clavibacter michiganensis), and grape, olive, and peach Pierce's disease (Xylella fastidiosa), and crown gall of Rosaceae plants such as apples, peaches, and cherries (Agrobacterium tumefaciens);

[0080] The soybean rust fungus with the F129L amino acid substitution in the mitochondrial cytochrome b protein is a soybean rust fungus (scientific name: Phakopsora pachyrhizi) that has a mutation in the mitochondrial cytochrome b gene that encodes the mitochondrial cytochrome protein, resulting in the F129L amino acid substitution, and is therefore resistant to QoI fungicides.

[0081] The method for controlling plant diseases of the present invention is carried out by applying an effective amount of the present compound, the present compound W, the compound of the present invention, the present compound W, or composition A to plants or the soil in which plants are grown. Examples of the treatment method include foliage treatment, soil treatment, and seed treatment.

[0082] This compound, this compound W, the compound of the present invention, compound W of the present invention, or composition A is typically mixed with an inert carrier such as a solid carrier or a liquid carrier and a surfactant, and formulation adjuvants such as binders, dispersants, and stabilizers are added as needed to formulate it into an aqueous suspension, oil suspension, oil solution, emulsifiable concentrate, emulsion, microemulsion, microcapsule formulation, wettable powder, water dispersible granule, dust, granule, or the like. In addition to these formulations, the compound can also be formulated into the dosage forms described in "Manual on development and use of FAO and WHO Specifications for pesticides," FAO Plant Production and Protection Papers-271 to 276, prepared by the FAO / WHO Joint Meeting on Pesticide Specifications, 2016, ISSN:0259-2517. These formulations typically contain 0.0001% to 99% by weight of this compound, this compound W, the compound of the present invention, compound W of the present invention, or composition A.

[0083] Examples of solid carriers include clay (pyrophyllite clay, kaolin clay, etc.), talc, calcium carbonate, diatomaceous earth, zeolite, bentonite, acid clay, attapulgite, white carbon, ammonium sulfate, vermiculite, perlite, pumice, silica sand, fine powder and granular chemical fertilizers (ammonium sulfate, ammonium phosphate, ammonium nitrate, urea, ammonium chloride, etc.), and resins (polyethylene, polypropylene, polyester, polyurethane, polyamide, polyvinyl chloride, etc.).

[0084] Examples of liquid carriers include water, alcohols (ethanol, cyclohexanol, benzyl alcohol, propylene glycol, polyethylene glycol, etc.), ketones (acetone, cyclohexanone, etc.), aromatic hydrocarbons (xylene, phenylxylylethane, methylnaphthalene, etc.), aliphatic hydrocarbons (hexane, cyclohexane, etc.), esters (ethyl acetate, methyl oleate, propylene carbonate, etc.), nitriles (acetonitrile, etc.), ethers (ethylene glycol dimethyl ether, etc.), amides (N,N-dimethylformamide, N,N-dimethyloctanamide, etc.), sulfoxides (dimethyl sulfoxide, etc.), lactams (N-methylpyrrolidone, N-octylpyrrolidone, etc.), fatty acids (oleic acid, etc.), and vegetable oils (soybean oil, etc.).

[0085] Examples of surfactants include nonionic surfactants (polyoxyethylene alkyl ethers, polyoxyethylene alkylaryl ethers, polyethylene glycol fatty acid esters, etc.) and anionic surfactants (alkyl sulfonates, alkylaryl sulfonates, alkyl sulfates, etc.).

[0086] Other formulation adjuvants include, for example, binders, dispersants, colorants, and stabilizers, and specific examples thereof include polysaccharides (starch, gum arabic, cellulose derivatives, alginic acid, etc.), lignin derivatives, synthetic water-soluble polymers (polyvinyl alcohol, polyvinylpyrrolidone, polyacrylic acids, etc.), acid isopropyl phosphate, and dibutylhydroxytoluene.

[0087] Furthermore, an adjuvant can be used as a component that enhances or supports the efficacy of the present compound, the present compound W, the compound of the present invention, the compound W of the present invention, or composition A. Specific examples include Nimbus (registered trademark), Assist (registered trademark), Aureo (registered trademark), Iharol (registered trademark), Silwet L-77 (registered trademark), BreakThru (registered trademark), Sundance II (registered trademark), Induce (registered trademark), Penetrator (registered trademark), AgriDex (registered trademark), Lutensol A8 (registered trademark), NP-7 (registered trademark), Triton (registered trademark), Nufilm (registered trademark), Emulgator NP7 (registered trademark), Emulad (registered trademark), TRITON X 45 (registered trademark), AGRAL 90 (registered trademark), AGROTIN (registered trademark), ARPON (registered trademark), EnSpray N (registered trademark), and BANOLE (registered trademark).

[0088] In the present invention, plants include whole plants and specific parts of plants, such as stems, leaves, flowers, spikes, fruits, trunks, branches, crowns, seeds, vegetative reproductive organs, and seedlings.

[0089] Vegetative reproductive organs refer to plant roots, stems, leaves, and other parts that can grow when separated from the main body and placed in soil. Examples of vegetative reproductive organs include tuberous roots, creeping roots, bulbs, corms (or solid bulbs), tubers, rhizomes, stolons, rhizophores, cane cuttings, propagules, and vine cuttings. Stolons are sometimes called runners, and propagules are also called bulbils and are divided into broad buds and bulbils. Vines refer to shoots (a collective term for leaves and stems) of plants such as sweet potatoes and Japanese yams. Bulbs, corms, tubers, rhizomes, stem fragments, rhizophores, and tuberous roots are collectively called bulbils. Potato cultivation begins by planting tubers in the soil, and the tubers used are generally called seed potatoes.

[0090] Seedlings include seedlings and saplings.

[0091] Examples of methods for controlling plant diseases by applying an effective amount of the present compound, the present compound W, the compound of the present invention, the compound W of the present invention or composition A to soil include methods of applying an effective amount of the present compound, the present compound W, the compound of the present invention, the compound W of the present invention or composition A to soil before or after planting a plant. More specifically, for example, planting hole treatment (spraying in planting holes, mixing in planting hole treatment soil), plant base treatment (spraying in planting holes, mixing in plant base soil, plant base irrigation, plant base treatment in the latter half of the seedling raising period), planting furrow treatment (spraying in planting furrows, mixing in planting furrow soil), row treatment (row spraying, row soil mixing, row spraying in the growing season), row treatment at sowing (row spraying at sowing, mixing in row soil at sowing), overall treatment (overall soil spraying, overall soil mixing), side row treatment, water surface treatment (water surface application, water surface application after flooding), other soil spray treatments (foliar spraying of granules during the growing season, spraying under the crown or around the main trunk, soil surface spraying, soil surface mixing, seeding hole spraying, furrow surface spraying, spraying between plants), and others. Other irrigation treatments include soil irrigation, seedling irrigation, chemical injection treatment, ground level irrigation, chemical drip irrigation, chemigation), seedling tray treatments (seedling tray spraying, seedling tray irrigation, seedling tray flooding), seedling tray treatments (seedling tray spraying, seedling tray irrigation, seedling tray flooding), seedling bed treatments (seedling bed spraying, seedling bed irrigation, water seedling bed spraying, seedling immersion), bed soil mixing treatments (bed soil mixing, bed soil mixing before sowing, spraying before soil covering at sowing, spraying after soil covering at sowing, covering soil mixing), and other treatments (hilling soil mixing, plowing in, topsoil mixing, rain-drop soil mixing, planting position treatment, granular inflorescence spraying, paste fertilizer mixing).

[0092] Seed treatments include, for example, treatment of seeds or vegetative reproductive organs with the present compound, Compound W, the compound of the present invention, Compound W, or Composition A. More specifically, examples include spray treatments in which a suspension of the present compound, Compound W, the compound of the present invention, Compound W, or Composition A is sprayed onto the surface of seeds or vegetative reproductive organs; smear treatments in which the present compound, Compound W, the compound of the present invention, Compound W, or Composition A is applied to seeds or vegetative reproductive organs; immersion treatments in which seeds or vegetative reproductive organs are immersed in a solution of the present compound, Compound W, the compound of the present invention, Compound W, or Composition A for a certain period of time; and methods of coating seeds or vegetative reproductive organs with a carrier containing the present compound, Compound W, the compound of the present invention, Compound W, or Composition A (film coating treatment, pellet coating treatment, etc.). Seed potatoes are particularly examples of the above-mentioned vegetative reproductive organs. In the present invention, seeds or vegetative reproductive organs bearing the present compound, Compound W, the compound of the present invention, Compound W, or Composition A refer to seeds or vegetative reproductive organs to which the present compound, Compound W, the compound of the present invention, Compound W, or Composition A is attached. The seeds or vegetative reproductive organs carrying the present compound, the present compound W, the compound of the present invention, the compound W of the present invention, or Composition A may have materials other than the present compound, the present compound W, the compound of the present invention, the compound W of the present invention, or Composition A applied to them before or after the application of the present compound, the present compound W, the compound of the present invention, the compound W of the present invention, or Composition A to the seeds or vegetative reproductive organs. Furthermore, when Composition A is applied to the surface of the seeds or vegetative reproductive organs as a layer, the layer may consist of one layer or multiple layers. Furthermore, when multiple layers are used, each layer may contain one or more active ingredients, or may consist of a layer containing one or more active ingredients and a layer containing no active ingredients. The seeds or vegetative reproductive organs carrying the present compound, the present compound W, the compound of the present invention, the compound W of the present invention, or Composition A can be obtained, for example, by applying a formulation containing the present compound, the present compound W, the compound of the present invention, the compound W of the present invention, or Composition A to the seeds or vegetative reproductive organs by the seed treatment method described above.

[0093] The application rate of the present compound, the present compound W, the compound of the present invention, the compound W of the present invention or composition A varies depending on weather conditions, formulation type, application time, application method, application location, target disease, target crop, etc., but in the case of foliar application or soil application, it is 2 In the case of seed treatment, the amount of the present compound, the present compound W, the compound of the present invention, the compound W of the present invention or composition A is usually 0.001 g to 100 g per kg of seeds. When the present compound, the present compound W, the compound of the present invention, the compound W of the present invention or composition A is formulated as an emulsifiable concentrate, a wettable powder, a flowable concentrate or the like, it is usually applied after being diluted with water so that the active ingredient concentration is 0.01 ppm to 10,000 ppm, and dusts, granules and the like are usually applied as they are.

[0094] The present compound, the present compound W, the compound of the present invention, the compound W of the present invention or composition A can be used as an agent for controlling plant diseases in agricultural lands such as fields, paddy fields, lawns, orchards, etc. Examples of plants include the following.

[0095] Corn (horse-tooth, hard grain, soft grain, explosive, glutinous, sweet, field corn), rice (long grain, short grain, medium grain, japonica, tropical japonica, indica, javanica, paddy rice, upland rice, floating rice, direct-seeded rice, transplanted rice, glutinous rice), wheat (bread wheat (hard, soft, medium, red wheat, white wheat), durum wheat, spelt wheat, club wheat, each winter wheat type, spring wheat type), barley (two-row barley (= beer barley), six-row barley, naked barley, waxy barley, each winter barley type, spring barley type), rye (winter rye type, spring rye type), triticale (winter triticale type, spring triticale type), oats (winter oat type, spring oat type), sorghum, cotton (upland type, pima type), soybean (fully harvested seed varieties, edamame varieties, green-harvested varieties, indeterminate, determinate, semi-determinate types), peanuts, buckwheat, sugar beet (sugar production, animal feed, root vegetable, leafy vegetable, fuel), rapeseed (winter rapeseed type, spring rapeseed type), canola (winter canola type, spring canola type), sunflower (oil production, food, ornamental), sugarcane, tobacco, tea plant, mulberry, solanaceous vegetables (eggplant, tomato, bell pepper, chili pepper) , potatoes, etc.), Cucurbitaceae vegetables (cucumber, pumpkin, zucchini, watermelon, melon, etc.), Cruciferous vegetables (radish, turnip, horseradish, kohlrabi, Chinese cabbage, cabbage, mustard greens, broccoli, cauliflower, etc.), Asteraceae vegetables (burdock, garland chrysanthemum, artichoke, lettuce, etc.), Liliaceae vegetables (leeks, onions, garlic, asparagus, etc.), Umbelliferae vegetables (carrots, parsley, celery, parsley, etc.), Chenopodiaceae vegetables (spinach, Swiss chard, etc.), Lamiaceae vegetables (perilla, mint, basil, etc.), strawberries, sweet potatoes, yams, scallions, Sweet potatoes, pome fruits (apples, European pears, Japanese pears, Chinese pears, quince, quince, etc.), stone fruits (peaches, plums, nectarines, plums, cherries, apricots, prunes, etc.), citrus fruits (Satsuma mandarins, oranges, lemons, limes, grapefruits, etc.), nuts (chestnuts, walnuts, hazelnuts, almonds, pistachios, cashew nuts, macadamia nuts, etc.), berries (blueberries, cranberries, blackberries, raspberries, etc.), grapes, persimmons, figs, olives, loquats, bananas, coffee, dates, coconuts, ornamental plants, forest plants,Turfgrass, pasture grass,

[0096] The above-mentioned plants are not particularly limited as long as they are varieties that are commonly cultivated, and include plants that can be produced by natural crossbreeding, plants that can be generated by mutation, F1 hybrid plants, and genetically modified crops. Examples of genetically modified crops include plants that have been conferred resistance to herbicides such as HPPD (4-hydroxyphenylpyruvate dioxygenase enzyme) inhibitors such as isoxaflutole, ALS (acetolactate synthase) inhibitors such as imazethapyr and thifensulfuron methyl, EPSP (5-enolpyruvylshikimate-3-phosphate synthase) inhibitors, glutamine synthetase inhibitors, PPO (protoporphyrinogen oxidase) inhibitors, bromoxynil, or dicamba; plants that are capable of synthesizing selective toxins known to be found in the genus Bacillus, such as Bacillus thuringiensis; and plants that can be conferred specific insecticidal activity by synthesizing gene fragments that partially match endogenous genes derived from harmful insects and inducing gene silencing (RNAi; RNA interference) in the target harmful insect.

[0097] The present invention will be explained in more detail below by showing Production Examples, Reference Production Examples, Formulation Examples and Test Examples, but the present invention is not limited to these examples.

[0098] In this specification, Me represents a methyl group, Et represents an ethyl group, Pr represents a propyl group, i-Pr represents an isopropyl group, c-Pr represents a cyclopropyl group, Bu represents a butyl group, t-Bu represents a tert-butyl group, 2-Thie represents a 2-thienyl group, 3-Thie represents a 3-thienyl group, 2-Fura represents a 2-furanyl group, 3-Fura represents a 3-furanyl group, 2-Py represents a 2-pyridyl group, 3-Py represents a 3-pyridyl group, and 4-Py represents a 4-pyridyl group. groups, where 1-Pyrazol-1-yl group, 3-Pyrazol-3-yl group, 4-Pyrazol-4-yl group, 5-Pyrazol-5-yl group, 2-Thiazol-2-yl group, 5-Thiazol-5-yl group, 2-Imidazol-2-yl group, 4-Imidazol-4-yl group, and 2-Pyrazin-2-yl group. When these groups have a substituent, the substituent is written in front of the symbol of these groups together with the substitution position. For example, 5-OMe-2-Pyrazin represents a 5-methoxypyrazin-2-yl group, 5-Br-2-Py represents a 5-bromo-2-pyridyl group, and 1,5-Me2-3-Pyraz represents a 1,5-dimethylpyrazol-3-yl group.

[0099] When the physical properties of a compound are measured by liquid chromatography / mass spectrometry (hereinafter referred to as LC / MS), the measured molecular ion value [M+H] + or [M-H] - The time and retention time (hereinafter referred to as RT) are also recorded. The conditions for liquid chromatography (hereinafter referred to as LC) and mass spectrometry (hereinafter referred to as MS) are as follows. [LC conditions] Column: InertSustain C18, inner diameter 2.1 mm, length 50 mm, particle size 2 μm (GL Sciences) Mobile phase: Solution A: 5 mM ammonium acetate aqueous solution, Solution B: methanol Flow rate: 0.3 mL / min Pump: Two LC-30AD pumps (Shimadzu Corporation) (high pressure gradient) Gradient conditions: Solution was delivered at the concentration gradient shown in [Table LC1].

[0100]

[0101] [MS conditions] Detector: LCMS-8030 (manufactured by Shimadzu Corporation) Ionization method: ESI method

[0102] First, examples of the preparation of the present compounds (including the compounds of the present invention) will be shown.

[0103] Preparation Example 1: Under a nitrogen atmosphere, 0.12 mL of ethanesulfonic acid chloride was added to a mixture of 0.14 g of Intermediate 1, 0.17 mL of triethylamine, and 2 mL of THF, and the mixture was stirred at room temperature for 2 hours. The resulting mixture was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain 0.23 g of Compound 1 represented by the following formula. Compound 1: LC / MS [M+H] + = 241, RT= 3.31min

[0104] Preparation Example 1-1 The compound prepared in accordance with Preparation Example 1 and its physical properties are shown below. Formula (IA-1) In the compound represented by the formula (hereinafter referred to as compound (IA-1)), Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-1].

[0105]

[0106] Preparation Example 2 A mixture of 0.17 g of 3-pyridylboronic acid, 0.30 g of 3-bromo-5-(ethylsulfonyl)pyridine, 0.04 g of {1,1'-bis(diphenylphosphino)ferrocene}dichloropalladium(II), 0.51 g of tripotassium phosphate, 4 mL of DME, and 0.04 mL of water was stirred under reflux for 5 hours. Water was added to the resulting mixture, and the mixture was extracted with ethyl acetate. The resulting organic layer was concentrated under reduced pressure, and the resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:9) to obtain 0.17 g of Compound 17 represented by the following formula: Compound 17: LC / MS [M+H] + = 249, RT= 3.07min

[0107] Preparation Example 2-1 Compounds prepared according to Preparation Example 2 and their physical properties are shown below. b and R1b A compound in which the combination is any of the combinations described in [Table A-2].

[0108] Compound 18: LC / MS [M+H] + = 268, RT= 3.96min Compound 19: LC / MS [M+H] + = 268, RT= 3.73min Compound 20: 1 H-NMR (CDCl3) δ: 8.14 (1H, d), 7.91 (1H, dd), 7.84-7.82 (1H, m), 7.79-7.77 (1H, m), 7.74 (1H, dd), 7.67 (1H, d), 7.38-7.33 (2H, m), 7.13 (1H, dd), 6.73 (1H, d). Compound 21: 1 H-NMR (CDCl3) δ: 8.14 (1H, d), 7.92-7.91 (1H, m), 7.77-7.73 (2H, m), 7.61 (1H, s), 7.43 (1H, dd), 7.15-7.11 (2H, m), 6.72 (1H, d). This compound 22: 1 H-NMR (CDCl3) δ: 8.69 (1H, t), 8.18 (1H, d), 7.91 (1H, dd), 7.76 (1H, dd), 7.64 (4H, dt), 7.15 (1H, dd), 6.71 (1H, d). Compound 23: 1 H-NMR (CDCl3) δ: 8.39 (1H, s), 8.16 (1H, d), 8.14-8.11 (1H, m), 7.90 (1H, dd), 7.76 (1H, dd), 7.14 (1H, dd), 6.72 (1H, d), 2.34 (3H, s).

[0109] Preparation Example 2-2 The compound prepared in accordance with Preparation Example 2 and its physical properties are shown below. Formula (IA-2) In the compound represented by the formula (hereinafter referred to as compound (IA-2)), nb, Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-3].

[0110] This compound 106: 1 H-NMR (CDCl3) δ: 9.45 (1H, d), 9.28 (1H, d), 8.89-8.87 (1H, m), 7.82-7.81 (1H, m), 7.74 (1H, dd), 7.16-7.14 (1H, m), 2.71 (3H, d). Compound 107: 1 H-NMR (CDCl3) δ: 9.51 (1H, d), 9.31 (1H, d), 8.94 (1H, t), 8.88 (1H, s), 7.83 (1H, dd), 7.75 (1H, dd), 7.16 (1H, dd). Compound 108: 1 H-NMR (CDCl3) δ: 9.54 (1H, d), 9.22 (1H, d), 8.84 (1H, t), 3.19-3.15 (2H, m), 2.72 (3H, s), 1.87-1.77 (2H, m), 1.05 (3H, t). Compound 109: 1 H-NMR (CDCl3) δ: 9.41 (1H, d), 8.92 (1H, d), 8.64 (1H, t), 2.97-2.85 (2H, m), 2.71 (3H, s), 1.95-1.86 (1H, m), 1.78-1.66 (1H, m), 1.10 (3H, t). This compound 110: 1 H-NMR (CDCl3) δ: 9.60 (1H, d), 9.25 (1H, d), 8.90-8.89 (2H, m), 3.20-3.16 (2H, m), 1.88-1.78 (2H, m), 1.06 (3H, t). This compound 111: 1 H-NMR (CDCl3) δ: 9.46 (1H, d), 8.93 (1H, d), 8.87 (1H, s), 8.70 (1H, dd), 2.98-2.85 (2H, m), 1.97-1.84 (1H, m), 1.80-1.69 (1H, m), 1.10 (3H, t).

[0111] Preparation Example 2-3 The compound prepared in accordance with Preparation Example 2 and its physical properties are shown below. Formula (IA-6) In the compound represented by the formula (hereinafter referred to as compound (IA-6)), Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-15].

[0112] This compound 112: 1 H-NMR (CDCl3) δ: 8.92 (1H, t), 8.76 (1H, t), 8.35 (1H, t), 7.84-7.80 (2H, m), 7.19 (1H, dd), 2.70 (3H, s). Compound 113: 1 H-NMR (CDCl3) δ: 8.98 (1H, t), 8.89 (1H, s), 8.79 (1H, t), 8.40 (1H, t), 7.83 (2H, ddd), 7.20 (1H, dd).

[0113] Formula (IA-7) In the compound represented by the formula (hereinafter referred to as compound (IA-7)), Z b and R 1b The combination is any of the combinations described in [Table A-16].

[0114] This compound 115: 1 H-NMR (CDCl3) δ: 9.27 (2H, d), 8.72 (1H, d), 8.35-8.32 (1H, m), 3.45-3.41 (2H, m), 2.43 (3H, s), 1.93-1.83 (2H, m), 1.09 (3H, t). This compound 116: 1 H-NMR (CDCl3) δ: 9.48 (1H, s), 9.12 (1H, s), 7.47 (1H, d), 7.00 (1H, d), 4.03 (3H, s), 3.44-3.40 (2H, m), 1.92-1.81 (2H, m), 1.07 (3H, t).

[0115] This compound 119: 1H-NMR (CDCl3) δ: 7.89 (1H, s), 7.71-7.68 (2H, m), 7.56 (1H, t), 7.17 (1H, d), 6.94 (1H, d), 2.75 (6H, s).

[0116] This compound 120: 1 H-NMR (CDCl3) δ: 7.95 (1H, t), 7.75-7.72 (1H, m), 7.70-7.68 (1H, m), 7.54 (1H, t), 7.18 (1H, d), 6.94 (1H, d), 3.30-3.26 (4H, m), 1.80-1.78 (4H, m).

[0117] Preparation Example 3: To a mixture of 0.32 g of Intermediate 2 and 15 mL of chloroform, 0.46 g of mCPBA (75% purity, 25% water content) was added at 0°C and stirred at room temperature for 2 hours. To the resulting mixture, 10 mL of saturated aqueous sodium thiosulfate solution and 10 mL of saturated aqueous sodium bicarbonate solution were added, and the mixture was stirred for 1 hour and then extracted with chloroform. The resulting organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain 0.19 g of Compound 39 represented by the following formula and 0.13 g of Compound 40. Compound 39: LC / MS [M+H] + = 265, RT= 4.03min

[0118] Compound 40: LC / MS [M+H] + = 249, RT= 4.01min

[0119] Preparation Example 3-1 The compound prepared in accordance with Preparation Example 3 and its physical properties are shown below. Formula (IA-3) In the compound represented by the formula (hereinafter referred to as compound (IA-3)), Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-4].

[0120]

[0121] Preparation Example 3-2 The compound prepared in accordance with Preparation Example 3 and its physical properties are shown below. Formula (IA-5) In the compound represented by the formula (hereinafter referred to as compound (IA-5)), X b , Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-5].

[0122]

[0123] Formula (IA-8) In the compound represented by the formula (hereinafter referred to as compound (IA-8)), n, Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-17].

[0124] [Table A-17] Present compound 117: 1 H-NMR (CDCl3) δ: 8.30 (1H, s), 8.05 (1H, dd), 7.92 (1H, d), 7.86 (1H, dd), 7.72 (1H, dd), 7.14 (1H, dd), 7.03 (1H, d), 2.38 (3H, d). This compound 118: 1 H-NMR (CDCl3) δ: 8.31 (1H, t), 8.02 (1H, ddd), 7.97 (1H, d), 7.68 (1H, dd), 7.65 (1H, dd), 7.13 (1H, dd), 6.96 (1H, d), 2.37 (3H, s).

[0125] Preparation Example 4: To a mixture of 0.20 g of the present compound 87 and 5 mL of acetonitrile, 0.16 g of N-chlorosuccinimide was added at room temperature and stirred at 50°C for 4 hours. The resulting mixture was allowed to cool to room temperature, and 5 mL of saturated aqueous sodium thiosulfate and 5 mL of saturated aqueous sodium bicarbonate were added. The mixture was stirred at room temperature for 1 hour and then extracted with ethyl acetate. The resulting organic layer was washed with saturated brine and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain 0.18 g of the present compound 58 represented by the following formula. Compound 58: LC / MS [M+H] + =314, RT= 4.57min

[0126] Preparation Example 4-1 Compounds prepared according to Preparation Example 4 and their physical properties are shown below. b , Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-6].

[0127]

[0128] Preparation Example 5: To a mixture of 0.25 g of the present compound 39 and 5 mL of chloroform, 0.22 g of N-bromosuccinimide was added and stirred at room temperature for 1 hour. 5 mL of saturated aqueous sodium thiosulfate solution and 5 mL of saturated aqueous sodium bicarbonate solution were added to the resulting mixture, which was stirred for 1 hour and then extracted with ethyl acetate. The resulting organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain 0.28 g of the present compound 62 represented by the following formula: Compound 62: LC / MS [M+H] + = 343, RT= 4.53min

[0129] Preparation Example 5-1 Compounds prepared according to Preparation Example 5 and their physical properties are shown below. In compound (IA-2), nb, Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-7].

[0130]

[0131] Preparation Example 5-2 Compounds prepared according to Preparation Example 5 and their physical properties are shown below. b and R 1b A compound in which the combination is any of the combinations described in [Table A-8].

[0132]

[0133] Preparation Example 6: To a mixture of 0.25 g of the present compound 39 and 5 mL of acetonitrile, 0.32 g of N-iodosuccinimide was added and stirred at 60°C for 4 hours. The resulting mixture was allowed to cool to room temperature, and 5 mL of saturated aqueous sodium thiosulfate and 5 mL of saturated aqueous sodium bicarbonate were added. The mixture was stirred for 1 hour and then extracted with ethyl acetate. The resulting organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain 0.26 g of the present compound 70 represented by the following formula. Compound 70: LC / MS [M+H] + = 391, RT= 4.55min

[0134] Preparation Example 6-1 Compounds prepared according to Preparation Example 6 and their physical properties are shown below. In compound (IA-2), nb, Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-9].

[0135]

[0136] Preparation Example 7: Under a nitrogen atmosphere, a mixture of 0.40 g of 3-bromo-5-(propylsulfonyl)pyridine, 0.11 g of bis(triphenylphosphine)palladium(II) dichloride, 0.56 mL of tert-butylacetylene, 4.5 mL of tetrabutylammonium fluoride (1 mol / L THF solution), and 4 mL of THF was stirred at 70°C for 7 hours. The resulting mixture was allowed to cool to room temperature, and then saturated aqueous sodium bicarbonate solution was added and extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (ethyl acetate:hexane = 1:2) to obtain 0.34 g of Compound 73 represented by the following formula. Compound 73: LC / MS [M+H] + = 266, RT= 4.63min

[0137] Preparation Example 7-1 Compounds prepared according to Preparation Example 7 and their physical properties are shown below. In compound (IA-2), nb, Z b and R1b A compound in which the combination is any of the combinations described in [Table A-10].

[0138]

[0139] Preparation Example 8: Under a nitrogen atmosphere, a mixture of 0.30 g of 3-bromo-5-(ethylsulfonyl)pyridine, 0.17 mL of 4-methylpiperidine, 0.054 g of tris(dibenzylideneacetone)dipalladium(0), 0.030 g of 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl, 0.23 g of sodium tert-butoxide, and 3 mL of toluene was stirred under reflux for 4 hours. The resulting mixture was allowed to cool to room temperature, and then water was added and extracted with ethyl acetate. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain 0.13 g of Compound 76, which is represented by the following formula: Compound 76: LC / MS [M+H] + = 269, RT= 4.14min

[0140] Preparation Example 8-1 Compounds prepared according to Preparation Example 8 and their physical properties are shown below. In compound (IA-2), nb, Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-11].

[0141]

[0142] Preparation Example 9: Under a nitrogen atmosphere, a mixture of 0.16 g of benzoxazole, 0.30 g of 3-bromo-5-(propylsulfonyl)pyridine, 0.017 g of palladium(II) acetate, 0.046 g of copper(II) acetate monohydrate, 0.15 g of triphenylphosphine, 0.32 g of potassium carbonate, and 5 mL of toluene was stirred under reflux for 3 hours. The resulting mixture was allowed to cool to room temperature, and then ethyl acetate was added and the mixture was filtered through Celite (trademark). The resulting filtrate was washed with water and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting solid was washed with methanol and hexane to obtain 0.20 g of Compound 83, which is represented by the following formula: Compound 83: LC / MS [M+H]+ = 303, RT= 4.36min

[0143] Preparation Example 9-1 Compounds prepared according to Preparation Example 9 and their physical properties are shown below. In compound (IA-2), nb, Z b and R 1b A compound in which the combination is any of the combinations described in [Table A-12].

[0144]

[0145] Production Example 10 A mixture of 0.30 g of 3-bromo-5-(propylsulfonyl)pyridine, 0.13 g of 3,4-dimethylpyrazole, 0.11 g of copper(I) iodide, 0.1 mL of N,N'-dimethylcyclohexane-1,2-diamine, 0.32 g of potassium carbonate, and 5 mL of DMF was stirred at 100°C for 6 hours. The resulting mixture was allowed to cool to room temperature, and then water was added and extracted with ethyl acetate. The resulting organic layer was washed with saturated brine and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=1:1) to obtain 0.16 g of Compound 86 represented by the following formula. Compound 86: LC / MS [M+H] + = 280, RT= 4.09min

[0146] Preparation Example 10-1 Compounds prepared according to Preparation Example 10 and their physical properties are shown below. In compound (IA-2), nb, Z b and R 1b The combination is any of the combinations described in [Table A-13].

[0147]

[0148] Preparation Example 10-2 The compound prepared in accordance with Preparation Example 10 and its physical properties are shown below. Formula (IA-4) In the compound represented by the formula (hereinafter referred to as compound (IA-4)), Z b and R 1b The combination is any of the combinations described in [Table A-14].

[0149]

[0150] Reference Production Example 1 A mixture of 1.1 g of 1-(1-methyl-1H-pyrazol-3-yl)ethanone, 5.9 mL of N,N-dimethylformamide dimethyl acetal, and 3 mL of DMF was stirred under reflux for 6 hours. The resulting mixture was allowed to cool to room temperature, and then water was added and extracted with chloroform. The resulting organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. To the resulting solid were successively added 2 mL of ethanol and 0.12 mL of hydrazine monohydrate, and the mixture was stirred at room temperature for 8 hours. The resulting mixture was concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography to obtain 0.14 g of intermediate 1 represented by the following formula: Intermediate 1: 1 H-NMR (CDCl3) δ: 7.60 (1H, d), 7.38 (1H, d), 6.59 (1H, d), 6.53 (1H, d), 3.95 (3H, s).

[0151] Reference Production Example 1-1 The compound produced in accordance with Reference Production Example 1 and its physical properties are shown below. Formula (IB-1) In the compound represented by the formula (hereinafter referred to as compound (IB-1)), R 1b A compound in which any of the compounds listed in [Table B-1] is

[0152] Intermediate 4: 1 H-NMR (CDCl3) δ: 7.58 (1H, d), 6.53 (1H, d), 6.30 (1H, s), 3.81 (3H, s), 2.31 (3H, s). Intermediate 5: 1 H-NMR (CDCl3) δ: 7.60 (1H, d), 7.34 (1H, dd), 7.27 (1H, dd), 7.07 (1H, dd), 6.54 (1H, d). Intermediate 6: 1 H-NMR (CDCl3) δ: 7.60 (1H, d), 7.46 (1H, dd), 6.66 (1H, d), 6.55 (1H, d), 6.48 (1H, dd). Intermediate 7: 1H-NMR (CDCl3) δ: 10.34 (1H, br s), 7.58 (1H, d), 7.20 (1H, d), 7.00 (1H, d), 6.49 (1H, d). Intermediate 8: 1 H-NMR (CDCl3) δ: 8.92 (1H, s), 8.03 (1H, br s), 7.98 (1H, dd), 7.65 (1H, d), 7.21 (1H, d), 6.65 (1H, d), 2.60 (3H, s). Intermediate 9: 1 H-NMR (CDCl3) δ: 8.66 (1H, d), 7.88-7.85 (1H, m), 7.69-7.65 (2H, m), 6.82 (1H, d). Intermediate 10: 1 H-NMR (CDCl3) δ: 10.32 (1H, br s), 8.79 (1H, d), 7.99 (1H, dd), 7.67 (1H, d), 7.53 (1H, d), 6.68 (1H, d). Intermediate 11: 1 H-NMR (CDCl3) δ: 10.33 (1H, br s), 8.81 (1H, d), 8.09 (1H, dd), 7.67 (1H, d), 7.38 (1H, d), 6.68 (1H, d). Intermediate 12: 1 H-NMR (CDCl3) δ: 8.59 (1H, s), 8.23 ​​(1H, t), 7.66 (1H, d), 6.77 (1H, s), 4.01 (3H, s). Intermediate 13: 1 H-NMR (CDCl3) δ: 7.81-7.75 (2H, m), 7.63-7.60 (1H, m), 7.40-7.36 (2H, m), 7.11 (1H, d).

[0153] Reference Production Example 2 A mixture of 2.0 g of 1-bromo-3-(propylthio)benzene, 0.84 mL of 3-methylpyrazole, 0.84 g of copper(I) iodide, 0.8 mL of N,N'-dimethylcyclohexane-1,2-diamine, 2.4 g of potassium carbonate, and 40 mL of DMF was stirred at 120°C for 8 hours. Water was added to the resulting mixture, and the mixture was extracted with ethyl acetate. The resulting organic layer was washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=2:1) ​​to obtain 1.43 g of Intermediate 2 represented by the following formula and 0.29 g of Intermediate 3. Intermediate 2: LC / MS [M+H] + = 233, RT= 4.96min

[0154] Intermediate 3: LC / MS [M+H] + = 233, RT= 4.78min

[0155] Reference Production Example 2-1 Compounds produced according to Reference Production Example 2 and their physical properties are shown below. Intermediate 14: LC / MS [M+H] + = 255, RT= 4.30min

[0156] Intermediate 15: LC / MS [M+H] + = 261, RT= 5.28min

[0157] Reference Production Example 3 The compound produced in accordance with Production Example 2 and its physical properties are shown below. Formula (IB-2) In the compound represented by the formula (hereinafter referred to as compound (IB-2)), Z b and R 1b A compound in which the combination is any of the combinations described in [Table B-2].

[0158]

[0159] Reference Production Example 4 Under an argon atmosphere, a mixture of 10.0 g of 1-bromo-3-(propylsulfanyl)benzene, 1.6 g of [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, 13.2 g of bis(pinacolato)diboron, 8.5 g of potassium acetate, and 100 mL of DMSO was stirred at 90°C for 8 hours. The resulting mixture was cooled to room temperature, and water was added thereto, followed by filtration. MTBE was added to the resulting filtrate, and the mixture was washed successively with water and saturated brine. The resulting organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (hexane:ethyl acetate=20:1) to obtain 10.2 g of intermediate 16 represented by the following formula: Intermediate 16: 1 H-NMR (CDCl3) δ: 7.77 (1H, br s), 7.60 (1H, ddd), 7.42 (1H, ddd), 7.29 (1H, dd), 2.92 (2H, t), 1.66 (2H, td), 1.34 (12H, s), 1.02 (3H, t).

[0160] Examples of the present compound W and the present compound W produced according to the above-mentioned production method and production examples are shown below. In the compound represented by the formula (hereinafter referred to as compound (A-1)), Z is an ethyl group, and G A and the group represented by G A The substituent R in the group represented by X7 , R X8 , R X9 and R X10 is any of the combinations described in Combination A (hereinafter referred to as compound group SX1).

[0161] G1 to G40 represent groups represented by the following formulae G1 to G40, respectively.

[0162] G41 to G74 each mean a group defined below. For example, G43 represents a cyclopentyl group. G41: cyclopropyl, G42: cyclobutyl, G43: cyclopentyl, G44: cyclohexyl, G45: cycloheptyl, G46: cyclophenten-1-yl, G47: cyclohexen-1-yl, G48: cyclohepten-1-yl, G49: pyrrolidin-1-yl, G50: piperidin-1-yl, G51: 4-methylpiperidin-1-yl, G52: 4,4-dimethylpiperidin-1-yl, G53: 4,4-dimethyl-1,4-azasilinan-1-yl, G54: azepan-4-yl, G55: morpholin-4-yl, G56: 1,3-dioxolan-2-yl, G57: tetrahydrofuran-2-yl, G58: tetrahydrofuran-3-yl, G59: prop-1-yn-1-yl, G60: but-1-yn-1-yl, G61: pent-1-yn-1-yl, G62: 3-methylbut-1-yn-1-yl, G63: hex-1-yn-1-yl, G64: 4-methylpent-1-yn-1-yl, G65: 3-methylpent-1-yn-1-yl, G66: 3,3-dimethylbut-1-yn-1-yl, G67: hept-1-yn-1-yl, G68: oct-1-yn-1-yl, G69: cyclopropylethynyl, G70: cyclobutylethynyl, G71: cyclopentylethynyl, G72: cyclohexylethynyl, G73: cycloheptylethynyl, G74: phenylethynyl

[0163] Combination A consists of substituent numbers A1 to A1035. Substituent numbers A1 to A1035 refer to G in compound (A-1), compounds represented by formula (A-3), compounds represented by formula (A-4), compounds represented by formula (A-5), compounds represented by formula (A-6), compounds represented by formula (A-7), compounds represented by formula (A-8), compounds represented by formula (A-9), and compounds represented by formula (A-10). A and the group represented by G A The substituent R in the group represented by X7 , R X8 , R X9 , and R X10 The following represents a combination of [Substituent Number; G A , R X7 , R X8 , R X9 , R X10 For example, the substituent number A5 is G A is G1 and R X7 , R X8 , and R X9 are each a hydrogen atom, and R X10 represents a combination in which each of the groups is a fluorine atom.

[0164] Combination A: [A1; G1, H, H, H, H], [A2; G1, F, H, H, H], [A3; G1, H, F, H, H], [A4; G1, H, H, F, H], [A5; G1, H, H, H, F], [A6; G1, Cl, H, H, H], [A7; G1, H, Cl, H, H], [A8; G1, H, H, Cl, H], [A9; G1, H, H, H, Cl], [A10; G1, Me, H, H, H], [A11; G1, H, Me, H, H], [A12; G1, H, H, Me, H], [A13; G1, H, H, H, Me], [A14; G1, F, F, H, H], [A15; G1, F, H, F, H], [A16; G1, F, H, H, F], [A17; G1, F, Cl, H, H], [A18; G1, F, H, Cl, H], [A19; G1, F, H, H, Cl], [A20; G1, F, Me, H, H], [A21; G1, F, H, Me, H], [A22; G1, F, H, H, Me], [A`23; G1, Cl, F, H, H], [A24; G1, Cl, H, F, H], [A25; G1, Cl, H, H, F], [A26; G1, Cl, Cl, H, H], [A27; G1, Cl, H, Cl, H], [A28; G1, Cl, H, H, Cl], [A29; G1, Cl, Me, H, H], [A30; G1, Cl, H, Me, H], [A31; G1, Cl, H, H, Me], [A32; G1, Me, F, H, H], [A33; G1, Me, H, F, H], [A34; G1, Me, H, H, F], [A35; G1, Me, Cl, H, H], [A36; G1, Me, H, Cl, H], [A37; G1, Me, H, H, Cl], [A38; G1, Me, Me, H, H], [A39; G1, Me, H, Me, H], [A40; G1, Me, H, H, Me], [A41; G1, H, F, F, H], [A42; G1, H, Cl, F, H], [A43; G1, H, Me, F, H], [A44; G1, H, F, Cl, H], [A45; G1, H, Cl, Cl, H], [A46; G1, H, Me, Cl, H], [A47; G1, H, F, Me, H], [A48; G1, H, Cl, Me, H], [A49; G1, H, Me, Me, H], [A50; G2, H, H, H, H], [A51; G2, F, H, H, H], [A52; G2, H, F, H, H], [A53; G2, H, H, F, H], [A54; G2, H, H, H, F], [A55; G2, Cl, H, H, H], [A56;G2,H,Cl,H,H]、[A57;G2,H,H,Cl,H]、[A58;G2,H,H,H,Cl]、[A59;G2,Me,H,H,H]、[A60;G2,H,Me,H,H]、[A61;G2,H,H,Me,H]、[A62;G2,H,H,H,Me]、[A63;G2,F,F,H,H]、[A64;G2,F,H,F,H]、[A65;G2,F,H,H,F]、[A66;G2,F,Cl,H,H]、[A67;G2,F,H,Cl,H]、[A68;G2,F,H,H,Cl]、[A69;G2,F,Me,H,H]、[A70;G2,F,H,Me,H]、[A71;G2,F,H,H,Me]、[A72;G2,Cl,F,H,H]、[A73;G2,Cl,H,F,H]、[A74;G2,Cl,H,H,F]、[A75;G2,Cl,Cl,H,H]、[A76;G2,Cl,H,Cl,H]、[A77;G2,Cl,H,H,Cl]、[A78;G2,Cl,Me,H,H]、[A79;G2,Cl,H,Me,H]、[A80;G2,Cl,H,H,Me]、[A81;G2,Me,F,H,H]、[A82;G2,Me,H,F,H]、[A83;G2,Me,H,H,F]、[A84;G2,Me,Cl,H,H]、[A85;G2,Me,H,Cl,H]、[A86;G2,Me,H,H,Cl]、[A87;G2,Me,Me,H,H]、[A88;G2,Me,H,Me,H]、[A89;G2,Me,H,H,Me]、[A90;G2,H,F,F,H]、[A91;G2,H,Cl,F,H]、[A92;G2,H,Me,F,H]、[A93;G2,H,F,Cl,H]、[A94;G2,H,Cl,Cl,H]、[A95;G2,H,Me,Cl,H]、[A96;G2,H,F,Me,H]、[A97;G2,H,Cl,Me,H]、[A98;G2,H,Me,Me,H]、[A99;G3,H,H,H,H]、[A100;G3,F,H,H,H]、[A101;G3,H,F,H,H]、[A102;G3,H,H,F,H]、[A103;G3,H,H,H,F]、[A104;G3,Cl,H,H,H]、[A105;G3,H,Cl,H,H]、[A106;G3,H,H,Cl,H]、[A107;G3,H,H,H,Cl]、[A108;G3,Me,H,H,H]、[A109;G3,H,Me,H,H]、[A110;G3,H,H,Me,H]、[A111;G3,H,H,H,Me]、[A112;G3,F,F,H,H]、[A113;G3,F,H ,F,H]、[A114;G3,F,H,H,F]、[A115;G3,F,Cl,H,H]、[A116;G3,F,H,Cl,H]、 [A117;G3,F,H,H,Cl]、[A118;G3,F,Me,H,H]、[A119;G3,F,H,Me,H]、[A120 ;G3,F,H,H,Me]、[A121;G3,Cl,F,H,H]、[A122;G3,Cl,H,F,H]、[A123;G3,C l,H,H,F]、[A124;G3,Cl,Cl,H,H]、[A125;G3,Cl,H,Cl,H]、[A126;G3,Cl,H ,H,Cl]、[A127;G3,Cl,Me,H,H]、[A128;G3,Cl,H,Me,H]、[A129;G3,Cl,H,H ,Me]、[A130;G3,Me,F,H,H]、[A131;G3,Me,H,F,H]、[A132;G3,Me,H,H,F]、 [A133;G3,Me,Cl,H,H]、[A134;G3,Me,H,Cl,H]、[A135;G3,Me,H,H,Cl]、[A1 36;G3,Me,Me,H,H]、[A137;G3,Me,H,Me,H]、[A138;G3,Me,H,H,Me]、[A139 ;G3,H,F,F,H]、[A140;G3,H,Cl,F,H]、[A141;G3,H,Me,F,H]、[A142;G3,H, F,Cl,H]、[A143;G3,H,Cl,Cl,H]、[A144;G3,H,Me,Cl,H]、[A145;G3,H,F,M e,H]、[A146;G3,H,Cl,Me,H]、[A147;G3,H,Me,Me,H]、[A148;G4,H,H,H,-] 、[A149;G4,F,H,H,-]、[A150;G4,H,F,H,-]、[A151;G4,H,H,F,-]、[A152;G 4,Cl,H,H,-]、[A153;G4,H,Cl,H,-]、[A154;G4,H,H,Cl,-]、[A155;G4,Me, H,H,-]、[A156;G4,H,Me,H,-]、[A157;G4,H,H,Me,-]、[A158;G4,F,F,H,-] 、[A159;G4,F,H,F,-]、[A160;G4,F,Cl,H,-]、[A161;G4,F,H,Cl,-]、[A162;G4,F,Me,H,-]、[A163;G4,F,H,Me,-]、[A164;G4,Cl,F,H,-]、[A165;G4,Cl,H,F,-]、[A166;G4,Cl,Cl,H,-]、[A167;G4,Cl,H,Cl,-]、[A168;G4,Cl,Me,H,-]、[A169;G4,Cl,H,Me,-]、[A170;G4,Me,F,H,-]、[A171;G4,Me,H,F,-]、[A172;G4,Me,Cl,H,-]、[A173;G4,Me,H,Cl,-]、[A174;G4,Me,Me,H,-]、[A175;G4,Me,H,Me,-]、[A176;G4,H,F,F,-]、[A177;G4,H,Cl,F,-]、[A178;G4,H,Me,F,-]、[A179;G4,H,F,Cl,-]、[A180;G4,H,Cl,Cl,-]、[A181;G4,H,Me,Cl,-]、[A182;G4,H,F,Me,-]、[A183;G4,H,Cl,Me,-]、[A184;G4,H,Me,Me,-]、[A185;G5,H,H,H,-]、[A186;G5,F,H,H,-]、[A187;G5,H,F,H,-]、[A188;G5,H,H,F,-]、[A189;G5,Cl,H,H,-]、[A190;G5,H,Cl,H,-]、[A191;G5,H,H,Cl,-]、[A192;G5,Me,H,H,-]、[A193;G5,H,Me,H,-]、[A194;G5,H,H,Me,-]、[A195;G5,F,F,H,-]、[A196;G5,F,H,F,-]、[A197;G5,F,Cl,H,-]、[A198;G5,F,H,Cl,-]、[A199;G5,F,Me,H,-]、[A200;G5,F,H,Me,-]、[A201;G5,Cl,F,H,-]、[A202;G5,Cl,H,F,-]、[A203;G5,Cl,Cl,H,-]、[A204;G5,Cl,H,Cl,-]、[A205;G5,Cl,Me,H,-]、[A206;G5,Cl,H,Me,-]、[A207;G5,Me,F,H,-]、[A208;G5,Me,H,F,-]、[A209;G5,Me,Cl,H,-]、[A210;G5,Me,H,Cl,-]、[A211;G5,Me,Me,H,-]、[A212;G5,Me,H,Me,-]、[A213;G5,H,F,F,-]、[A214;G5,H,Cl,F,-]、[A215;G5,H,Me,F,-]、[A216;G5,H,F,Cl,-]、[A217;G5,H,Cl,Cl,-]、[A218;G5,H,Me,Cl,-]、[A219;G5,H,F,Me,-]、[A220;G5,H,Cl,Me,-]、[A221;G5,H,Me,Me,-]、[A222;G6,H,H,H,-]、[A223;G6,F,H,H,-]、[A224;G6,H,F,H,-]、[A225;G6,H,H,F,-]、[A226;G6,Cl,H,H,-]、[A227;G6,H,Cl,H,-]、[A228;G6,H,H,Cl,-]、[A229;G6,Me,H,H,-]、[A230;G6,H,Me,H,-]、[A231;G6,H,H,Me,-]、[A232;G6,F,F,H,-]、[A233;G6,F,H,F,-]、[A234;G6,F,Cl,H,-]、[A235;G6,F,H,Cl,-]、[A236;G6,F,Me,H,-]、[A237;G6,F,H,Me,-]、[A238;G6,Cl,F,H,-]、[A239;G6,Cl,H,F,-]、[A240;G6,Cl,Cl,H,-]、[A241;G6,Cl,H,Cl,-]、[A242;G6,Cl,Me,H,-]、[A243;G6,Cl,H,Me,-]、[A244;G6,Me,F,H,-]、[A245;G6,Me,H,F,-]、[A246;G6,Me,Cl,H,-]、[A247;G6,Me,H,Cl,-]、[A248;G6,Me,Me,H,-]、[A249;G6,Me,H,Me,-]、[A250;G6,H,F,F,-]、[A251;G6,H,Cl,F,-]、[A252;G6,H,Me,F,-]、[A253;G6,H,F,Cl,-]、[A254;G6,H,Cl,Cl,-]、[A255;G6,H,Me,Cl,-]、[A256;G6,H,F,Me,-]、[A257;G6,H,Cl,Me,-]、[A258;G6,H,Me,Me,-]、[A259;G7,H,H,H,-]、[A260;G7,F,H,H,-]、[A261;G7,H,F,H,-]、[A262;G7,H,H,F,-]、[A263;G7,Cl,H,H,-]、[A264;G7,H,Cl,H,-]、[A265;G7,H,H,Cl,-]、[A266;G7,Me,H,H,-]、[A267;G7,H,Me,H,-]、[A268;G7,H,H,Me,-]、[A269;G7,F,F,H,-]、[A270;G7,F,H,F,-]、[A271;G7,F,Cl,H,-]、[A272;G7,F,H,Cl,-]、[A273;G7,F,Me,H,-]、[A274;G7,F,H,Me,-]、[A275;G7,Cl,F,H,-]、[A276;G7,Cl,H,F,-]、[A277;G7,Cl,Cl,H,-]、[A278;G7,Cl,H,Cl,-]、[A279;G7,Cl,Me,H,-]、[A280;G7,Cl,H,Me,-]、[A281;G7,Me,F,H,-]、[A282;G7,Me,H,F,-]、[A283;G7,Me,Cl,H,-]、[A284;G7,Me,H,Cl,-]、[A285;G7,Me,Me,H,-]、[A286;G7,Me,H,Me,-]、[A287;G7,H,F,F,-]、[A288;G7,H,Cl,F,-]、[A289;G7,H,Me,F,-]、[A290;G7,H,F,Cl,-]、[A291;G7,H,Cl,Cl,-]、[A292;G7,H,Me,Cl,-]、[A293;G7,H,F,Me,-]、[A294;G7,H,Cl,Me,-]、[A295;G7,H,Me,Me,-]、[A296;G8,H,H,H,-]、[A297;G8,F,H,H,-]、[A298;G8,H,F,H,-]、[A299;G8,H,H,F,-]、[A300;G8,Cl,H,H,-]、[A301;G8,H,Cl,H,-]、[A302;G8,H,H,Cl,-]、[A303;G8,Me,H,H,-]、[A304;G8,H,Me,H,-]、[A305;G8,H,H,Me,-]、[A306;G8,F,F,H,-]、[A307;G8,F,H,F,-]、[A308;G8,F,Cl,H,-]、[A309;G8,F,H,Cl,-]、[A310;G8,F,Me,H,-]、[A311;G8,F,H,Me,-]、[A312;G8,Cl,F,H,-]、[A313;G8,Cl,H,F,-]、[A314;G8,Cl,Cl,H,-]、[A315;G8,Cl,H,Cl,-]、[A316;G8,Cl,Me,H,-]、[A317;G8,Cl,H,Me,-]、[A318;G8,Me,F,H,-]、[A319;G8,Me,H,F,-]、[A320;G8,Me,Cl,H,-]、[A321;G8,Me,H,Cl,-]、[A322;G8,Me,Me,H,-]、[A323;G8,Me,H,Me,-]、[A324;G8,H,F,F,-]、[A325;G8,H,Cl,F,-]、[A326;G8,H,Me,F,-]、[A327;G8,H,F,Cl,-]、[A328;G8,H,Cl,Cl,-]、[A329;G8,H,Me,Cl,-]、[A330;G8,H,F,Me,-]、[A331;G8,H,Cl,Me,-]、[A332;G8,H,Me,Me,-]、[A333;G9,H,H,H,-]、[A334;G9,F,H,H,-]、[A335;G9,H,F,H,-]、[A336;G9,H,H,F,-]、[A337;G9,Cl,H,H,-]、[A338;G9,H,Cl,H,-]、[A339;G9,H,H,Cl,-]、[A340;G9,Me,H,H,-]、[A341;G9,H,Me,H,-]、[A342;G9,H,H,Me,-]、[A343;G9,F,F,H,-]、[A344;G9,F,H,F,-]、[A345;G9,F,Cl,H,-]、[A346;G9,F,H,Cl,-]、[A347;G9,F,Me,H,-]、[A348;G9,F,H,Me,-]、[A349;G9,Cl,F,H,-]、[A350;G9,Cl,H,F,-]、[A351;G9,Cl,Cl,H,-]、[A352;G9,Cl,H,Cl,-]、[A353;G9,Cl,Me,H,-]、[A354;G9,Cl,H,Me,-]、[A355;G9,Me,F,H,-]、[A356;G9,Me,H,F,-]、[A357;G9,Me,Cl,H,-]、[A358;G9,Me,H,Cl,-]、[A359;G9,Me,Me,H,-]、[A360;G9,Me,H,Me,-]、[A361;G9,H,F,F,-]、[A362;G9,H,Cl,F,-]、[A363;G9,H,Me,F,-]、[A364;G9,H,F,Cl,-]、[A365;G9,H,Cl,Cl,-]、[A366;G9,H,Me,Cl,-]、[A367;G9,H,F,Me,-]、[A368;G9,H,Cl,Me,-]、[A369;G9,H,Me,Me,-]、[A370;G10,H,H,H,-]、[A371;G10,F,H,H,-]、[A372;G10,H,F,H,-]、[A373;G10,H,H,F,-]、[A374;G10,Cl,H,H,-]、[A375;G10,H,Cl,H,-]、[A376;G10,H,H,Cl,-]、[A377;G10,Me,H,H,-]、[A378;G10,H,Me,H,-]、[A379;G10,H,H,Me,-]、[A380;G10,F,F,H,-]、[A381;G10,F,H,F,-]、[A382;G10,F,Cl,H,-]、[A383;G10,F,H,Cl,-]、[A384;G10,F,Me,H,-]、[A385;G10,F,H,Me,-]、[A386;G10,Cl,F,H,-]、[A387;G10,Cl,H,F,-]、[A388;G10,Cl,Cl,H,-]、[A389;G10,Cl,H,Cl,-]、[A390;G10,Cl,Me,H,-]、[A391;G10,Cl,H,Me,-]、[A392;G10,Me,F,H,-]、[A393;G10,Me,H,F,-]、[A394;G10,Me,Cl,H,-]、[A395;G10,Me,H,Cl,-]、[A396;G10,Me,Me,H,-]、[A397;G10,Me,H,Me,-]、[A398;G10,H,F,F,-]、[A399;G10,H,Cl,F,-]、[A400;G10,H,Me,F,-]、[A401;G10,H,F,Cl,-]、[A402;G10,H,Cl,Cl,-]、[A403;G10,H,Me,Cl,-]、[A404;G10,H,F,Me,-]、[A405;G10,H,Cl,Me,-]、[A406;G10,H,Me,Me,-]、[A407;G11,H,H,H,-]、[A408;G11,F,H,H,-]、[A409;G11,H,F,H,-]、[A410;G11,H,H,F,-]、[A411;G11,Cl,H,H,-]、[A412;G11,H,Cl,H,-]、[A413;G11,H,H,Cl,-]、[A414;G11,Me,H,H,-]、[A415;G11,H,Me,H,-]、[A416;G11,H,H,Me,-]、[A417;G11,F,F,H,-]、[A418;G11,F,H,F,-]、[A419;G11,F,Cl,H,-]、[A420;G11,F,H,Cl,-]、[A421;G11,F,Me,H,-]、[A422;G11,F,H,Me,-]、[A423;G11,Cl,F,H,-]、[A424;G11,Cl,H,F,-]、[A425;G11,Cl,Cl,H,-]、[A426;G11,Cl,H,Cl,-]、[A427;G11,Cl,Me,H,-]、[A428;G11,Cl,H,Me,-]、[A429;G11,Me,F,H,-]、[A430;G11,Me,H,F,-]、[A431;G11,Me,Cl,H,-]、[A432;G11,Me,H,Cl,-]、[A433;G11,Me,Me,H,-]、[A434;G11,Me,H,Me,-]、[A435;G11,H,F,F,-]、[A436;G11,H,Cl,F,-]、[A437;G11,H,Me,F,-]、[A438;G11,H,F,Cl,-]、[A439;G11,H,Cl,Cl,-]、[A440;G11,H,Me,Cl,-]、[A441;G11,H,F,Me,-]、[A442;G11,H,Cl,Me,-]、[A443;G11,H,Me,Me,-]、[A444;G12,H,H,H,-]、[A445;G12,F,H,H,-]、[A446;G12,H,F,H,-]、[A447;G12,H,H,F,-]、[A448;G12,Cl,H,H,-]、[A449;G12,H,Cl,H,-]、[A450;G12,H,H,Cl,-]、[A451;G12,Me,H,H,-]、[A452;G12,H,Me,H,-]、[A453;G12,H,H,Me,-]、[A454;G12,F,F,H,-]、[A455;G12,F,H,F,-]、[A456;G12,F,Cl,H,-]、[A457;G12,F,H,Cl,-]、[A458;G12,F,Me,H,-]、[A459;G12,F,H,Me,-]、[A460;G12,Cl,F,H,-]、[A461;G12,Cl,H,F,-]、[A462;G12,Cl,Cl,H,-]、[A463;G12,Cl,H,Cl,-]、[A464;G12,Cl,Me,H,-]、[A465;G12,Cl,H,Me,-]、[A466;G12,Me,F,H,-]、[A467;G12,Me,H,F,-]、[A468;G12,Me,Cl,H,-]、[A469;G12,Me,H,Cl,-]、[A470;G12,Me,Me,H,-]、[A471;G12,Me,H,Me,-]、[A472;G12,H,F,F,-]、[A473;G12,H,Cl,F,-]、[A474;G12,H,Me,F,-]、[A475;G12,H,F,Cl,-]、[A476;G12,H,Cl,Cl,-]、[A477;G12,H,Me,Cl,-]、[A478;G12,H,F,Me,-]、[A479;G12,H,Cl,Me,-]、[A480;G12,H,Me,Me,-]、[A481;G13,H,H,H,-]、[A482;G13,F,H,H,-]、[A483;G13,H,F,H,-]、[A484;G13,H,H,F,-]、[A485;G13,Cl,H,H,-]、[A486;G13,H,Cl,H,-]、[A487;G13,H,H,Cl,-]、[A488;G13,Me,H,H,-]、[A489;G13,H,Me,H,-]、[A490;G13,H,H,Me,-]、[A491;G13,F,F,H,-]、[A492;G13,F,H,F,-]、[A493;G13,F,Cl,H,-]、[A494;G13,F,H,Cl,-]、[A495;G13,F,Me,H,-]、[A496;G13,F,H,Me,-]、[A497;G13,Cl,F,H,-]、[A498;G13,Cl,H,F,-]、[A499;G13,Cl,Cl,H,-]、[A500;G13,Cl,H,Cl,-]、[A501;G13,Cl,Me,H,-]、[A502;G13,Cl,H,Me,-]、[A503;G13,Me,F,H,-]、[A504;G13,Me,H,F,-]、[A505;G13,Me,Cl,H,-]、[A506;G13,Me,H,Cl,-]、[A507;G13,Me,Me, H,-]、[A508;G13,Me,H,Me,-]、[A509;G13,H,F,F,-]、[A510;G13,H,Cl,F,-]、[A511;G13,H,Me,F,-]、[A512;G13,H,F,Cl,-]、[A513;G13,H,Cl,Cl,-]、[A514;G13,H,Me,Cl,-]、[A515;G13,H,F,Me,-]、[A516;G13,H,Cl,Me,-]、[A517;G13,H,Me,Me,-]、[A518;G14,Me,H,H,-]、[A519;G14,Me,F,H,-]、[A520;G14,Me,H,F,-]、[A521;G14,Me,Cl,H,-]、[A522;G14,Me,H,Cl,-]、[A523;G14,Me,Me,H,-]、[A524;G14,Me,H,Me,-]、[A525;G14,Me,F,F,-]、[A526;G14,Me,F,Cl,-]、[A527;G14,Me,F,Me,-]、[A528;G14,Me,Cl,F,-]、[A529;G14,Me,Cl,Cl,-]、[A530;G14,Me,Cl,Me,-]、[A531;G14,Me,Me,F,-]、[A532;G14,Me,Me,Cl,-]、[A533;G14,Me,Me,Me,-]、[A534;G15,Me,H,H,-]、[A535;G15,Me,F,H,-]、[A536;G15,Me,H,F,-]、[A537;G15,Me,Cl,H,-]、[A538;G15,Me,H,Cl,-]、[A539;G15,Me,Me,H,-]、[A540;G15,Me,H,Me,-]、[A541;G15,Me,F,F,-]、[A542;G15,Me,F,Cl,-]、[A543;G15,Me,F,Me,-]、[A544;G15,Me,Cl,F,-]、[A545;G15,Me,Cl,Cl,-]、[A546;G15,Me,Cl,Me,-]、[A547;G15,Me,Me,F,-]、[A548;G15,Me,Me,Cl,-]、[A549;G15,Me,Me,Me,-]、[A550;G16,Me,H,H,-]、[A551;G16,Me,F,H,-]、[A552;G16,Me,H,F,-]、[A553;G16,Me,Cl,H,-]、[A554;G16,Me,H,Cl,-]、[A555;G16,Me,Me,H,-]、[A556;G16,Me,H,Me,-]、[A557;G16,Me,F,F,-]、[A558;G16,Me,F,Cl,-]、[A559;G16,Me,F,Me,-]、[A560;G16,Me,Cl,F,-]、[A561;G16,Me,Cl,Cl,-]、[A562;G16,Me,Cl,Me,-]、[A563;G16,Me,Me,F,-]、[A564;G16,Me,Me,Cl,-]、[A565;G16,Me,Me,Me,-]、[A566;G17,Me,H,H,-]、[A567;G17,Me,F,H,-]、[A568;G17,Me,H,F,-]、[A569;G17,Me,Cl,H,-]、[A570;G17,Me,H,Cl,-]、[A571;G17,Me,Me,H,-]、[A572;G17,Me,H,Me,-]、[A573;G17,Me,F,F,-]、[A574;G17,Me,F,Cl,-]、[A575;G17,Me,F,Me,-]、[A576;G17,Me,Cl,F,-]、[A577;G17,Me,Cl,Cl,-]、[A578;G17,Me,Cl,Me,-]、[A579;G17,Me,Me,F,-]、[A580;G17,Me,Me,Cl,-]、[A581;G17,Me,Me,Me,-]、[A582;G18,Me,H,H,-]、[A583;G18,Me,F,H,-]、[A584;G18,Me,H,F,-]、[A585;G18,Me,Cl,H,-]、[A586;G18,Me,H,Cl,-]、[A587;G18,Me,Me,H,-]、[A588;G18,Me,H,Me,-]、[A589;G18,Me,F,F,-]、[A590;G18,Me,F,Cl,-]、[A591;G18,Me,F,Me,-]、[A592;G18,Me,Cl,F,-]、[A593;G18,Me,Cl,Cl,-]、[A594;G18,Me,Cl,Me,-]、[A595;G18,Me,Me,F,-]、[A596;G18,Me,Me,Cl,-]、[A597;G18,Me,Me,Me,-]、[A598;G19,H,H,-,-]、[A599;G19,F,H,-,-]、[A600;G19,H,F,-,-]、[A601;G19,Cl,H,-,-]、[A602;G19,H,Cl,-,-]、[A603;G19,Me,H,-,-]、[A604;G19,H,Me,-,-]、[A605;G19,F,F,-,-]、[A606;G19,F,Cl,-,-]、[A607;G19,F,Me,-,-]、[A608;G19,Cl,F,-,-]、[A609;G19,Cl,Cl,-,-]、[A610;G19,Cl,Me,-,-]、[A611;G19,Me,F,-,-]、[A612;G19,Me,Cl,-,-]、[A613;G19,Me,Me,-,-]、[A614;G20,H,H,-,-]、[A615;G20,F,H,-,-]、[A616;G20,H,F,-,-]、[A617;G20,Cl,H,-,-]、[A618;G20,H,Cl,-,-]、[A619;G20,Me,H,-,-]、[A620;G20,H,Me,-,-]、[A621;G20,F,F,-,-]、[A622;G20,F,Cl,-,-]、[A623;G20,F,Me,-,-]、[A624;G20,Cl,F,-,-]、[A625;G20,Cl,Cl,-,-]、[A626;G20,Cl,Me,-,-]、[A627;G20,Me,F,-,-]、[A628;G20,Me,Cl,-,-]、[A629;G20,Me,Me,-,-]、[A630;G21,H,H,-,-]、[A631;G21,F,H,-,-]、[A632;G21,H,F,-,-]、[A633;G21,Cl,H,-,-]、[A634;G21,H,Cl,-,-]、[A635;G21,Me,H,-,-]、[A636;G21,H,Me,-,-]、[A637;G21,F,F,-,-]、[A638;G21,F,Cl,-,-]、[A639;G21,F,Me,-,-]、[A640;G21,Cl,F,-,-]、[A641;G21,Cl,Cl,-,-]、[A642;G21,Cl,Me,-,-]、[A643;G21,Me,F,-,-]、[A644;G21,Me,Cl,-,-]、[A645;G21,Me,Me,-,-]、[A646;G22,H,H,-,-]、[A647;G22,F,H,-,-]、[A648;G22,H,F,-,-]、[A649;G22,Cl,H,-,-]、[A650;G22,H,Cl,-,-]、[A651;G22,Me,H,-,-]、[A652;G22,H,Me,-,-]、[A653;G22,F,F,-,-]、[A654;G22,F,Cl,-,-]、[A655;G22,F,Me,-,-]、[A656;G22,Cl,F,-,-]、[A657;G22,Cl,Cl,-,-]、[A658;G22,Cl,Me,-,-]、[A659;G22,Me,F,-,-]、[A660;G22,Me,Cl,-,-]、[A661;G22,Me,Me,-,-]、[A662;G23,H,H,-,-]、[A663;G23,F,H,-,-]、[A664;G23,H,F,-,-]、[A665;G23,Cl,H,-,-]、[A666;G23,H,Cl,-,-]、[A667;G23,Me,H,-,-]、[A668;G23,H,Me,-,-]、[A669;G23,F,F,-,-]、[A670;G23,F,Cl,-,-]、[A671;G23,F,Me,-,-]、[A672;G23,Cl,F,-,-]、[A673;G23,Cl,Cl,-,-]、[A674;G23,Cl,Me,-,-]、[A675;G23,Me,F,-,-]、[A676;G23,Me,Cl,-,-]、[A677;G23,Me,Me,-,-]、[A678;G24,H,H,-,-]、[A679;G24,F,H,-,-]、[A680;G24,H,F,-,-]、[A681;G24,Cl,H,-,-]、[A682;G24,H,Cl,-,-]、[A683;G24,Me,H,-,-]、[A684;G24,H,Me,-,-]、[A685;G24,F,F,-,-]、[A686;G24,F,Cl,-,-]、[A687;G24,F,Me,-,-]、[A688;G24,Cl,F,-,-]、[A689;G24,Cl,Cl,-,-]、[A690;G24,Cl,Me,-,-]、[A691;G24,Me,F,-,-]、[A692;G24,Me,Cl,-,-]、[A693;G24,Me,Me,-,-]、[A694;G25,H,H,-,-]、[A695;G25,F,H,-,-]、[A696;G25,H,F,-,-]、[A697;G25,Cl,H,-,-]、[A698;G25,H,Cl,-,-]、[A699;G25,Me,H,-,-]、[A700;G25,H,Me,-,-]、[A701;G25,F,F,-,-]、[A702;G25,F,Cl,-,-]、[A703;G25,F,Me,-,-]、[A704;G25,Cl,F,-,-]、[A705;G25,Cl,Cl,-,-]、[A706;G25,Cl,Me,-,-]、[A707;G25,Me,F,-,-]、[A708;G25,Me,Cl,-,-]、[A709;G25,Me,Me,-,-]、[A710;G26,H,H,-,-]、[A711;G26,F,H,-,-]、[A712;G26,H,F,-,-]、[A713;G26,Cl,H,-,-]、[A714;G26,H,Cl,-,-]、[A715;G26,Me,H,-,-]、[A716;G26,H,Me,-,-]、[A717;G26,F,F,-,-]、[A718;G26,F,Cl,-,-]、[A719;G26,F,Me,-,-]、[A720;G26,Cl,F,-,-]、[A721;G26,Cl,Cl,-,-]、[A722;G26,Cl,Me,-,-]、[A723;G26,Me,F,-,-]、[A724;G26,Me,Cl,-,-]、[A725;G26,Me,Me,-,-]、[A726;G27,H,H,-,-]、[A727;G27,F,H,-,-]、[A728;G27,H,F,-,-]、[A729;G27,Cl,H,-,-]、[A730;G27,H,Cl,-,-]、[A731;G27,Me,H,-,-]、[A732;G27,H,Me,-,-]、[A733;G27,F,F,-,-]、[A734;G27,F,Cl,-,-]、[A735;G27,F,Me,-,-]、[A736;G27,Cl,F,-,-]、[A737;G27,Cl,Cl,-,-]、[A738;G27,Cl,Me,-,-]、[A739;G27,Me,F,-,-]、[A740;G27,Me,Cl,-,-]、[A741;G27,Me,Me,-,-]、[A742;G28,H,H,-,-]、[A743;G28,F,H,-,-]、[A744;G28,H,F,-,-]、[A745;G28,Cl,H,-,-]、[A746;G28,H,Cl,-,-]、[A747;G28,Me,H,-,-]、[A748;G28,H,Me,-,-]、[A749;G28,F,F,-,-]、[A750;G28,F,Cl,-,-]、[A751;G28,F,Me,-,-]、[A752;G28,Cl,F,-,-]、[A753;G28,Cl,Cl,-,-]、[A754;G28,Cl,Me,-,-]、[A755;G28,Me,F,-,-]、[A756;G28,Me,Cl,-,-]、[A757;G28,Me,Me,-,-]、[A758;G29,H,H,-,-]、[A759;G29,F,H,-,-]、[A760;G29,H,F,-,-]、[A761;G29,Cl,H,-,-]、[A762;G29,H,Cl,-,-]、[A763;G29,Me,H,-,-]、[A764;G29,H,Me,-,-]、[A765;G29,F,F,-,-]、[A766;G29,F,Cl,-,-]、[A767;G29,F,Me,-,-]、[A768;G29,Cl,F,-,-]、[A769;G29,Cl,Cl,-,-]、[A770;G29,Cl,Me,-,-]、[A771;G29,Me,F,-,-]、[A772;G29,Me,Cl,-,-]、[A773;G29,Me,Me,-,-]、[A774;G30,H,H,-,-]、[A775;G30,F,H,-,-]、[A776;G30,H,F,-,-]、[A777;G30,Cl,H,-,-]、[A778;G30,H,Cl,-,-]、[A779;G30,Me,H,-,-]、[A780;G30,H,Me,-,-]、[A781;G30,F,F,-,-]、[A782;G30,F,Cl,-,-]、[A783;G30,F,Me,-,-]、[A784;G30,Cl,F,-,-]、[A785;G30,Cl,Cl,-,-]、[A786;G30,Cl,Me,-,-]、[A787;G30,Me,F,-,-]、[A788;G30,Me,Cl,-,-]、[A789;G30,Me,Me,-,-]、[A790;G31,H,-,-,-]、[A791;G31,F,-,-,-]、[A792;G31,Cl,-,-,-]、[A793;G31,Me,-,-,-]、[A794;G31,OMe,-,-,-]、[A795;G32,H,-,-,-]、[A796;G32,F,-,-,-]、[A797;G32,Cl,-,-,-]、[A798;G32,Me,-,-,-]、[A799;G32,OMe,-,-,-]、[A800;G33,H,-,-,-]、[A801;G33,F,-,-,-]、[A802;G33,Cl,-,-,-]、[A803;G33,Me,-,-,-]、[A804;G33,OMe,-,-,-]、[A805;G34,H,-,-,-]、[A806;G34,F,-,-,-]、[A807;G34,Cl,-,-,-]、[A808;G34,Me,-,-,-]、[A809;G34,OMe,-,-,-]、[A810;G35,H,-,-,-]、[A811;G35,F,-,-,-]、[A812;G35,Cl,-,-,-]、[A813;G35,Me,-,-,-]、[A814;G35,OMe,-,-,-]、[A815;G36,H,-,-,-]、[A816;G36,F,-,-,-]、[A817;G36,Cl,-,-,-]、[A818;G36,Me,-,-,-]、[A819;G36,OMe,-,-,-]、[A820;G37,H,H,H,-]、[A821;G37,F,H,H,-]、[A822;G37,H,F,H,-]、[A823;G37,H,H,F,-]、[A824;G37,Cl,H,H,-]、[A825;G37,H,Cl,H,-]、[A826;G37,H,H,Cl,-]、[A827;G37,Me,H,H,-]、[A828;G37,H,Me,H,-]、[A829;G37,H,H,Me,-]、[A830;G37,F,F,H,-]、[A831;G37,F,H,F,-]、[A832;G3...

Claims

1. Formula (I) [In the formula, n represents 1 or 2; R 1 represents a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group A, and any atom not bonded to Q among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocyclic ring as a spiro atom}, a 5- to 7-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from group B1 (provided that when Q is a group represented by Q6, , 1H-pyrazol-3-yl group) {among the atoms constituting the 5-7 membered aromatic heterocyclic group (when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded), any two adjacent atoms not bonded to Q may form another benzene ring, C4-C7 alicyclic hydrocarbon, 4-7 membered non-aromatic heterocycle, or 5-7 membered aromatic heterocycle containing the two adjacent atoms {the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4-7 membered non-aromatic heterocycle, and the 5-7 membered aromatic heterocycle may be substituted with one or more halogen atoms}}, or -C≡CR 13 Q represents a group represented by Q1, a group represented by Q2, a group represented by Q3, a group represented by Q4, a group represented by Q5, or a group represented by Q6, Z represents a C2-C6 chain hydrocarbon group, a methyl group substituted with one or more fluorine atoms, a C1-C2 alkyl group {the C1-C2 alkyl group is substituted with a methoxy group or an ethoxy group}, a C3-C8 alicyclic hydrocarbon group, a 3-8 membered non-aromatic heterocyclic group {the C3-C8 alicyclic hydrocarbon group and the 3-8 membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group C}, a 5-10 membered aromatic heterocyclic group optionally substituted with one or more substituents selected from group D, or NR 14 R 15 Q1, Q2, Q3, Q4, Q5, and Q6 are each a group represented by the following formula (# represents R 1 represents the bonding site with a sulfur atom), R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are the same or different and each represents a hydrogen atom or a fluorine atom; 1 is CR 12 or a nitrogen atom; X 2 is CR 16 or a nitrogen atom; X 3 is CR 17 or a nitrogen atom; X 4 is CR 18 or a nitrogen atom (provided that X 1 is CR 12 And X 2 is CR 16 And X 3 is CR 17 And X 4 is CR 18 (Except when 8 , R 9 , R 10 , R 11 , R 12 , R 16 , R 17 and R 18 R are the same or different and each represents a methyl group optionally substituted with one or more fluorine atoms, a halogen atom, or a hydrogen atom; 13 represents a C1-C6 chain hydrocarbon group which may be substituted with one or more substituents selected from group E, a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group A}, a phenyl group, or a 5- to 7-membered aromatic heterocyclic group {the phenyl group and the 5- to 7-membered aromatic heterocyclic group may be substituted with one or more substituents selected from group D}, R 14 and R 15 are the same or different and represent a C1-C6 alkyl group, a methyl group substituted with one or more fluorine atoms, or a C1-C2 alkyl group {the C1-C2 alkyl group is substituted with a methoxy group or an ethoxy group}. Group A: a group consisting of a C1-C6 chain hydrocarbon group, a C1-C6 alkoxy group {the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group may be substituted with one or more substituents selected from Group E}, a hydroxy group, a halogen atom, and a cyano group. Group B1: the group consisting of a C3-C10 alicyclic hydrocarbon group optionally substituted with one or more substituents selected from Group D, a methyl group optionally substituted with one or more substituents selected from Group F, a C2-C6 chain hydrocarbon group optionally substituted with one or more substituents selected from Group E, a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group {the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group and the C1-C6 alkylsulfonyl group are optionally substituted with one or more halogen atoms}, a hydroxy group, a halogen atom, and a cyano group. Group C: the group consisting of a C1-C6 chain hydrocarbon group, a C1-C6 alkoxy group (the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group may be substituted with one or more substituents selected from Group E}, an oxo group, a thioxo group, a hydroxy group, a halogen atom, and a cyano group. Group D: the group consisting of a C1-C6 chain hydrocarbon group, a C1-C6 alkoxy group (the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group may be substituted with one or more substituents selected from Group E}, a halogen atom, and a cyano group. Group E: the group consisting of a C1-C3 alkoxy group, a halogen atom, and a cyano group. Group F: the group consisting of a methoxy group, a chlorine atom, and a cyano group. A method for controlling plant diseases, which comprises treating a plant or soil in which a plant is grown with a compound represented by the formula (I) or an N-oxide thereof, or a salt thereof.

2. In claim 1, the compound represented by formula (I) or its N-oxide or a salt thereof is 1 is a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group may be substituted with one or more substituents selected from group A, and any atom constituting the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group that is not bonded to Q may form a C3-C7 alicyclic hydrocarbon or a 3- to 7-membered non-aromatic heterocycle as a spiro atom}, an optionally substituted 5- to 7-membered aromatic heterocyclic group (provided that, when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) {any two adjacent atoms not bonded to Q among the atoms constituting the 5- to 7-membered aromatic heterocyclic group (provided that, when Q is a group represented by Q6, 1H-pyrazol-3-yl group is excluded) may form another C4-C7 alicyclic hydrocarbon, 4- to 7-membered non-aromatic heterocycle, or 5- to 7-membered aromatic heterocycle containing the two adjacent atoms}, or -C≡CR 13 or an N-oxide thereof, or a salt thereof. Group B: the group consisting of a methyl group optionally substituted with one or more substituents selected from Group F, a C2-C6 chain hydrocarbon group optionally substituted with one or more substituents selected from Group E, a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group {the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group and the C1-C6 alkylsulfonyl group are optionally substituted with one or more halogen atoms}, a hydroxy group, a halogen atom, and a cyano group.

3. In claim 1, the compound represented by formula (I) or its N-oxide or salt thereof is represented by the formula (I), wherein Q is a group represented by Q1, a group represented by Q2, a group represented by Q5, or a group represented by Q6; 1 a C3-C10 alicyclic hydrocarbon group, a 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) {the C3-C10 alicyclic hydrocarbon group and the 3- to 10-membered non-aromatic heterocyclic group (provided that when Q is a group represented by Q2, a carbon atom constituting the 3- to 10-membered non-aromatic heterocyclic group is bonded to the group represented by Q2) are each independently selected from group A, and among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3-10 membered non-aromatic heterocyclic group (when Q is a group represented by Q2, a carbon atom constituting the 3-10 membered non-aromatic heterocyclic group is bonded to the group represented by Q2), any atom not bonded to Q may form a C3-C7 alicyclic hydrocarbon or a 3-7 membered non-aromatic heterocycle as a spiro atom); and a 5- to 7-membered aromatic heterocyclic group which may be bonded to the group represented by Q2 (provided that when Q is a group represented by Q6, excluding a 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2) {the 5- to 7-membered aromatic heterocyclic group (provided that when Q is a group represented by Q6, excluding a 1H-pyrazol-3-yl group, and when Q is a group represented by Q2, a carbon atom constituting the 5- to 7-membered aromatic heterocyclic group is bonded to the group represented by Q2); Any two adjacent atoms not bonded to Q among the atoms constituting the group bonded to the group shown in the formula (I) may form another benzene ring, a C4-C7 alicyclic hydrocarbon, a 4- to 7-membered non-aromatic heterocycle, or a 5- to 7-membered aromatic heterocycle containing the two adjacent atoms {the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4- to 7-membered non-aromatic heterocycle, and the 5- to 7-membered aromatic heterocycle may be substituted with one or more halogen atoms}, or -C≡CR 13 Z represents a C2-C6 chain hydrocarbon group, a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or more substituents selected from group D, or NR 14 R 15 And R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , R 11 , and R 12 is a hydrogen atom, and X 2 and X 4 is CH, X 3 is a nitrogen atom, R 13 is a C1-C6 chain hydrocarbon group or a phenyl group, R 14 and R 15 and are the same or different and are a C1-C6 alkyl group, an N-oxide thereof, or a salt thereof.

4. Formula (II) [In the formula, na represents 1 or 2; X 1a represents CH or a nitrogen atom; R 1a represents a C3-C10 alicyclic hydrocarbon group, a 3- to 7-membered non-aromatic heterocyclic group {the C3-C10 alicyclic hydrocarbon group and the 3- to 7-membered non-aromatic heterocyclic group are each selected from group A a and any atom not bonded to pyridine or pyrazine among the atoms constituting the C3-C10 alicyclic hydrocarbon group and the 3-7-membered non-aromatic heterocyclic group may form a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocycle as a spiro atom}, or a 5-7-membered aromatic heterocyclic group {the 5-7-membered aromatic heterocyclic group is a group selected from group B1 a among the atoms constituting the 5-7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another benzene ring, C4-C7 alicyclic hydrocarbon, 4-7-membered non-aromatic heterocycle, or 5-7-membered aromatic heterocycle containing the two adjacent atoms {the benzene ring, the C4-C7 alicyclic hydrocarbon, the 4-7-membered non-aromatic heterocycle, and the 5-7-membered aromatic heterocycle may be substituted with one or more halogen atoms}, Z a represents a C2-C6 chain hydrocarbon group, group C a a C3-C8 alicyclic hydrocarbon group optionally substituted by one or more substituents selected from the following, or a 5- to 10-membered aromatic heterocyclic group {the 5- to 10-membered aromatic heterocyclic group is selected from the group D a may be substituted with one or more substituents selected from the following. a C1-C6 chain hydrocarbon group, C1-C6 alkoxy group {the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group are each selected from group E a Group B1 is a group consisting of a hydroxy group, a halogen atom, and a cyano group, and may be substituted with one or more substituents selected from the following: a :Group D a a C3-C10 alicyclic hydrocarbon group optionally substituted with one or more substituents selected from group F a a methyl group which may be substituted with one or more substituents selected from group E a Group C consisting of a C2-C6 chain hydrocarbon group optionally substituted by one or more substituents selected from the above, a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group {the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group, and the C1-C6 alkylsulfonyl group may be substituted by one or more halogen atoms}, a hydroxy group, a halogen atom, and a cyano group. a C1-C6 chain hydrocarbon group, C1-C6 alkoxy group {the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group are each selected from group E a Group D consists of an oxo group, a thioxo group, a hydroxy group, a halogen atom, and a cyano group. a C1-C6 chain hydrocarbon group, C1-C6 alkoxy group {the C1-C6 chain hydrocarbon group and the C1-C6 alkoxy group are each selected from group E a Group E consists of a halogen atom and a cyano group, each of which may be substituted with one or more substituents selected from the group consisting of aryl, aryloxy ... a Group F: the group consisting of a C1-C3 alkoxy group, a halogen atom, and a cyano group. a : the group consisting of a methoxy group, a chlorine atom, and a cyano group; or an N-oxide thereof, or a salt thereof.

5. R 1a a 3- to 7-membered non-aromatic heterocyclic group {the 3- to 7-membered non-aromatic heterocyclic group is selected from group A a and any atom not bonded to pyridine or pyrazine among the atoms constituting the 3-7-membered non-aromatic heterocyclic group may form a C3-C7 alicyclic hydrocarbon or a 3-7-membered non-aromatic heterocycle as a spiro atom}, or a 5-7-membered aromatic heterocyclic group {the 5-7-membered aromatic heterocyclic group is a group selected from group B a and among the atoms constituting the 5-7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another C4-C7 alicyclic hydrocarbon, a 4-7-membered non-aromatic heterocycle, or a 5-7-membered aromatic heterocycle containing the adjacent two atoms, or an N-oxide thereof, or a salt thereof according to claim 4: a :Group F a a methyl group which may be substituted with one or more substituents selected from group E a the group consisting of a C2-C6 chain hydrocarbon group optionally substituted by one or more substituents selected from, a C1-C6 alkoxy group, a C1-C6 alkylsulfanyl group, a C1-C6 alkylsulfinyl group, a C1-C6 alkylsulfonyl group {the C1-C6 alkoxy group, the C1-C6 alkylsulfanyl group, the C1-C6 alkylsulfinyl group and the C1-C6 alkylsulfonyl group are optionally substituted by one or more halogen atoms}, a hydroxy group, a halogen atom, and a cyano group.

6. R 1a a C3-C10 alicyclic hydrocarbon group optionally substituted with one or more C1-C6 chain hydrocarbon groups, a 3- to 7-membered non-aromatic heterocyclic group {the 3- to 7-membered non-aromatic heterocyclic group is selected from the group A a 2, and any atom constituting the 3-7 membered non-aromatic heterocyclic group which is not bonded to pyridine or pyrazine may form a C3-C7 alicyclic hydrocarbon as a spiro atom}, or a 5-7 membered aromatic heterocyclic group {the 5-7 membered aromatic heterocyclic group is a group selected from group B2 a and among the atoms constituting the 5- to 7-membered aromatic heterocyclic group, any two adjacent atoms not bonded to pyridine or pyrazine may form another benzene ring or a C4-C7 alicyclic hydrocarbon containing the adjacent two atoms; Z a is a C2-C6 chain hydrocarbon group or a 5- to 10-membered aromatic heterocyclic group {the 5- to 10-membered aromatic heterocyclic group is selected from the group D a The compound according to claim 4, or an N-oxide thereof, or a salt thereof, which is a group A, a Group B2: A group consisting of C1-C3 alkyl groups and halogen atoms. a : The group consisting of C3-C6 alicyclic hydrocarbon groups, C1-C6 chain hydrocarbon groups, and halogen atoms.

7. A composition comprising a compound according to any one of claims 4 to 6, an N-oxide thereof, or a salt thereof, and an inert carrier.

8. A composition containing one or more components selected from the group consisting of group (a), group (b), group (c) and group (d), and the compound according to any one of claims 4 to 6 or its N-oxide or a salt thereof: Group (a): a group consisting of insecticidal active components, acaricidal active components and nematicidal active components; Group (b): fungicidal active components; Group (c): plant growth regulator components; Group (d): repellent components.

9. A method for controlling plant diseases, which comprises applying an effective amount of the compound or N-oxide or salt thereof according to any one of claims 4 to 6, or an effective amount of the composition according to claim 8 to a plant or the soil in which the plant is grown.

10. Use of the compound according to any one of claims 4 to 6, or an N-oxide thereof, or a salt thereof, or the composition according to claim 8, for controlling plant diseases.

11. A seed or vegetative reproductive organ bearing an effective amount of a compound or N-oxide or salt thereof according to any one of claims 4 to 6, or an effective amount of a composition according to claim 8.

Images